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-Abstract-
The anti-metabolite - 5-Fluorouracil (5-FU) -  is the most widely used chemotherapeutic 
drug. It exerts its anti cancer effect through incorporation into DNA and RNA. 
Characterisation of this drugs mode of action is crucial in the development of future 
therapies. There have been many DNA microarray experiments performed in order to 
gain such information. However, only two proteomic experiments have been performed 
to date that look at the effect of 5-FU treatment. Here the proteomic alterations induced 
by IC8o 5-FU treatment of normal and cancer cells of epithelial origin of the lung and 
breast are investigated. These cell lines include a lung adenocarcinoma (A549), a non 
small cell lung carcinoma cell line (DLKP), normal bronchial epithelial cell line 
(NHBE), a breast adenocarcinoma (MCF-7) and human mammary epithelial cells 
(HMEC). Phenotypes were characterised and 5-FU was found to induce and reduce 
invasion in various cell lines. Adherence was altered in one of the three cancer cell lines 
to the extracellular matrix proteins collagen type IV and fibronectin. Differential 
regulated proteins were quantified using 2  dimensional difference gel electrophoresis 
(2D-DIGE) and differentially regulated proteins were identified using matrix-assisted 
laser desorption/ionization time of flight mass spectrometry (MALDI-ToF MS). Data 
shows the NHBE showed a dose dependent response to 5-FU treatment. Proteins that 
were found regulated are discussed in terms of microtubule dynamics and future drug 
combinations, translation control and stress, cytosketetal dynamics and invasion, and 
inhibition of apoptosis.
5-Fluorouracil is being increasing replaced in clinical trials with 3rd generation 5-FU 
drugs such as capecitabine. Capecitabine is converted in the liver to 5-fluoro-5’-
deoxyuridine (55FdU) and this is converted to 5-FU by thymidine phosphorylase whose 
over expression is induced by radiotherapy. 5-FU is converted to 5-fluoro-2’- 
deoxyuridine in the cytoplasm. A comparison using 2D-DIGE between DLKP treated 5- 
FU and the fluoropyrimidines -  52FdU and 55FdU at ICgo cocentrations to determine 
similar proteomic alterations. Results demonstrated that the down regulation of 
Stathmin as a common fluoropyrimidine response. Furthermore this data may indicate a 
role for the use of vinca alkoloids or taxanes in combination with 5-FU.
Resistance to 5-FU is a major clinical problem as mediated predominantly by over 
expression of Thymidylate Synthetase. A variant of DLKP was generated by pulse 
selection with 55FdU and showed a ~4 fold resistance to 5-FU. Proteomic analysis 
using 2D-DIGE identified several proteins involved in uracil metabolism and oxidative 
metabolism differentially regulated between DLKP and DLKP-55.
DLKP is a heterogeneous cell line composed of at least three subpopulations. These 
subpopulations were isolated and were assigned the names DLKP-SQ, DLKP-I and 
DLKP-M. In this thesis data is presented demonstrating highly significant differences in 
motility and invasion between the clonal subpopulation. Analysis of proteomic 
alteration was carried out using 2D-DIGE on both the total cell lysate and the 
hydrophobic proteomes. Proteins were identified in the total cell lysates that suggest 
that DLKP-M is mesenchymal-like in nature as originally described and that the 
interconversion process observed between the clones is regulated at least by key 
proteins involved in protein metabolism. Analysis of the hydrophobic proteome found 
at least 300 proteins that correlated with motility/invasion and collagen synthesis. 
Identification of these proteins demonstrated increased association of microfilaments to
the cellular membranes a process important in cellular motility. Furthermore 3 poorly 
described proteins were identified that correlated with motility/invasion and collagen 
synthesis. In addition data generated by these experiments indicates that 
fluoropyrimidine treatment of DLKP does not result in the selection of one of the 
subpopulations of DLKP and that DLKP-55 is not a subpopulation of DLKP. Data also 
shows the presence of protein in the heterogeneous population that are not present or are 
over expressed in the clonal populations indicating cell-cell communication.
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1.0 Introduction
1.1 Fluorouracil
1.1.1 Development of the fluoropyrimidines and 5- 
Fluorouracil
In 1957 Heidelberger created the anti-metabolite group of 
drugs referred to as the fluoropyrimidines and is the first 
example of a rationally designed drug. The group of 
fluoropyrimidines include 5-Fluorouracil (5-FU)
{Heildelberger et al., 1957} and it has become the most commonly used 
chemotherapeutic drug used today {Longley et al., 2003}. The development of the 
fluoropyrimidines was based on the observation that rat hepatomas utilised far greater 
amounts of the pyrimidine - uracil {Rutman et al., 1954}. The molecular structure of 
5-FU can be seen in figure 1.1 and is essentially a uracil molecule with a fluorine 
atom substituted for a hydrogen atom in position 5, hence the name 5-Fluorouracil 
{Heidelberger et al., 1957}.
1.1.2 Clinical usage of 5-FU
In the 1980’s the most commonly dosage schedules with 5-FU were a monthly course 
with 5 daily doses given as intravenous bolus infusions of 400-600mg/ml , or of one 
bolus infusion at same concentration on a weekly basis. Dosage is generally limited 
by myelosuppression or mucositis. Alternatively a continuous infusion is employed 
intravenous infusion is used, a higher dosage is required of 1 0 0 0 - 2 0 0 0  mg/m /d to 
achieve a steady state concentration of l-5jaM of 5-FU in plasma where the steady 
state concentration can vary as much as 10 fold during treatment. This treatment 
regimes side effect is mucositis with minimal myelosupression. Continuous infusion 
was found to be superior over bolus infusion (Erlichman, C. et al. 1988}. The 5-FU 
half life in plasma is in the order of 10 to 20 minutes {Diasio, 1989}. 
Dihydropyrimidine dehydrogenase is responsible for catabolic degradation of 5-FU in 
the clinic and modem therapies include the use of Eniluracil, a dihydropyrimidine 
dehydrogenase inhibitor, and allows for the clinically lower dosage of 300mg/ml/d in 
combination with Eniluracil these trials failed and use of clinical trials is discontinued 
(Malet-Martino and Martino, 2000). Other dosage regimes in include combination 
with the salt of folinic acid called commercially as Leucovorin {Adjei et al. 2002}.
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Figure 1.1: Chemical 
structure o f 5-FU
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Second generation 5-FU prodrugs were developed with the intention for oral 
administration and include l-(2-tetrahydrofuryl)-5-fluorouracil (Tegafur or Futraful), 
5-fluoro-5’-deoxyuridine (doxifluridine or Furtulon®, abbrev. 55FdU) but caused 
intestinal toxicity, which lead to the generation of third generation drugs and include 
capecitabine (discussed later) and the dihydropyrimidine dehydrogenase inhibitory 
compounds Eniluracil used in combination with uracil and Futraful and S-l a 
combination of Futraful plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate 
(Malet-Martino and Martino, 2000).
1.1.3 5-Fluorouracil metabolism and method of action
Like most metabolites two pathways referred to as catabolism and anabolism process 
5-FU. The anabolic route gives rise to the active metabolites and the catabolic leads to 
5-FU degradation and elimination from the organism (Malet-Martino and Martino,
2000).
Anabolism
5-FU is processed by a series of enzymatic reactions that are normally utilised by 
uracil and its derivatives and thus results in 5-FU incorporation into RNA and DNA, 
and to the formation of 5-FU nucleotide sugars (Malet-Martino and Martino, 2000).
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Figure 1.2: Metabolism o f 5-FU results in the production o f its active metabolites; FdUMP, FdUTP 
and FUTP, that result in DNA and RNA damage. Enzymes are represented by red ovals; DPD 
dihydrodyrimidine dehydrogenase; UP (uracil phosphorylase; UK (uridine kinase); TP (thymidine 
phosphorylase); TK (thymidine kinase); RR (ribonucleotide reductase); OPRT (Orotate 
phosphoribosyl transferase).
Upon entry into the cells 5-FU is converted through a series of enzymatic reaction 
into fluorouridine monophosphate which is incorporated into RNA and can inhibit 
polyadenylation of RNA and prevent pseudouridine maturation preventing correct 
folding of tRNA. The anabolism of 5-FU is summarised in figure 1.2.
5-FU is also converted into fluorodeoxyuridine monophosphate (FdUMP) by a series 
of enzymatic steps. FdUMP irreversibly binds to thymidylate synthetase (TS). This 
inhibition prevents TS from replenishing the thymidine pool during DNA synthesis of
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the S-phase of the cell cycle. As a result other nucleotides are incorporated into DNA. 
The DNA excision repair mechanism excises these misincorporated bases from the 
DNA backbone. At this point there is little thymidine available for DNA synthesis 
(Malet-Martino and Martino., 2000). DNA synthesis is effectively stopped at
FdUMP may be further anabolized to the triphosphate, FdUTP, which serves as an
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alternative substrate for dTTP in DNA replication. Once incorporated into DNA, this 
is a substrate for the base repair enzyme, uracil glycosylase. If multiple analog 
residues are incorporated in close proximity, the attempts to remove them may result 
in DNA fragmentation (Ingraham et al., 1982). The ribonucleoside triphosphate of 5- 
fluorouracil, FUTP, may be incorporated into RNA, and affect the function of RNA 
transcripts (Longley et al., 2003).
1.1.4 Mode of action of 5-FU
The anabolism of 5-FU results in the production of the metabolic derivates - FdUMP, 
FdUTP and FUTP. These compounds are responsible for the cytotoxic effects induced 
by 5-FU. FdUMP irreversibly binds to TS causing its inactivation leading dTTP 
depletion causing stalling of DNA replication during S phase of the cell cycle. FdUTP 
is incorporated into DNA leading to uracil glycosylase excision, since dTTP is 
depleted this results in a series of nucleotide misincorporations, if  multiple FdUTP 
residues are incorporated in close proximity it may result in DNA fragmentation. 
FUTP is incorporated in to RNA and leads to RNA instability.
Clinically the mode of action of 5-FU is dependent upon administration regimen -  
bolus or continuous infusion. Studies have shown that bolus infusions predominantly 
cause RNA damage leading to cell death whereas continuous infusions lead to TS 
inhibition and DNA damage (Malet-Martino and Martino, 2000).
1.1.4 DNA damage and repair
How cells exactly detect DNA lesions caused by 5-FU mediated stalling of replication 
forks is poorly understood. However, both ATR and Chkl have a role in maintaining 
the potential functionality during stalled replication of DNA or stalled replication 
forks. It is thought that the proteins that respond first to DNA replication stresses are 
the DNA clamp loading proteins Rad 17 and the heterotrimeric clamp Rad9-Husl- 
Radl (9-1-1 complex). (Clamp proteins are DNA binding proteins essential for DNA 
repair) Rad 17 preferentially binds to nicked DNA and recruits the 9-1-1 complex 
which then enables ATR to recognize it substrates which leads to cell cycle arrest and 
to either DNA repair or apoptosis (Renton et al., 2003).
ATM and DNA-PK are serine/threonine kinases that represent a second set of DNA 
damage sensors, and their role in the detection of 5-FU induced DNA damage is
1 0
unclear (Sampath et al., 2003). Recent research found that MCF-7 cells exposed to 5- 
FU under conditions that induce p53 accumulation in the presence of the ATM 
inhibitor, caffeine, found that p53 failed to accumulate indicating the genotoxic 
response triggered by 5-FU is mediated by ATM recognition of DNA damage. 
However, the exact role of ATM, other than phosphorylation of p53 on serine 
residues is unknown (Renton et al., 2003). The involvement of DNA-PK or ATR 
signal transduction in response to 5-FU genotoxicity is unknown.
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1.1.5 RNA damage and RNA Decay
All RNA species snRNA, mRNA, tRNA and rRNA during transcription in the 
presence of FUTP will result in the incorporation of the fluorinated residues. The 
RNA molecules rRNA, tRNA and snRNA require the conversion of uracil into 
pseudouridine for maturation. If FUTP is incorporated in this location formation of 
pseudouridine is prevented and the RNA secondary structure and function is disrupted 
(Gu et al., 1999; Longley et al., 2003). Functionality of snRNA can be impaired when 
synthesised in the presence of FUTP (Lenz et al., 1994).
The nuclear RNA processing exosome, a complex of 10 exoribonucleases, plays an 
important role in rRNA processing as it is required for proper 3'-end processing of 
rRNA and for the degradation of abnormal pre-rRNA processing intermediates. RNA 
is surveyed by exosomes and they detect structurally abnormal mRNAs. There are 
few studies done to date that have investigated the role of fluorinated RNA and 
exosome surveillance. However microarray experiments on yeast treated with 5-FU 
suggest that 5-FU inhibits an exosome-dependent surveillance pathway that degrades 
polyadenylated precursor rRNAs (Fang, F. 2004).
Protein synthesis requires aminoacylation of amino acids to the elongating peptide by 
ribosomes attached to mRNA. In rat models aminoacylation rates vary depending on 
5-FU dose and amino acid and is a result of fluorinated tRNA (Vulimiri et al., 1993).
1.1.6 Catabolism
In vivo, approximately 80% of 5-FU is degraded by the catabolic pathway. The 
degradation of 5-FU is mediated through the alanine aspartate metabolic route. The 
first step of this process is governed by dihydropyrimidine dehydrogenase (DPD) and
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is the rate-limiting step in determining how much 5-FU is converted to 5,6-dihydro-5- 
fluorouracil and requires NADPH. 5,6-dihydro-5-fluorouracil is ftirther broke down 
by a series of enzymatic steps to form fluoracetate, 2-fluoro-3-hydrxypropanic acid, 
fluorine ion and a-fluoro-J3-alanine conjucated to bile acids (Malet-Martino and 
Martino, 2000).
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1.1.7 5-Fluorouracil clinical treatment
Fluorouracil is often used in combination with many drugs, which include 
Leucovorin, Methotrexate and interferons. The generation of second and third 
generation fluorouracil derivatives such as UFT, S-l and capecitabine that have been 
designed to lessen the burden on patients. These drugs produce a more targeted 
response when used in combination with radiation. Thus the use of 5-FU is being 
replaced with the next generation of 5-FU derivatives in clinical trials. However, 5- 
FU still remains the most commonly used chemotherapeutic today. 5-FU and second 
and third generation analogue drugs are used to treat colorectal, head and neck, 
gastric, cervical, kidney, basal skin, lung, pancreatic, and breast cancers (Malet- 
Martino M. and Martino R., 2000).
1.1.8 Global mRNA analysis 5-Fluorouracil treatments
Several microarray experiments have done on in vitro models investigating growth 
inhibition induced by 5-FU (Hemandez-Vargas, 2006; Troester, 2005).
Hernandez-Vargas et al. (2006) identified a list of genes that respond in a dose 
dependent manner in MCF-7 cells. Dose dependent regulation was observed; genes 
regulated in the IC50 48 hour dose include CCNG2, CCNB2, AURKA/STK15 and 
TNFRSF11B and in the IC80 48 hour dose regulation of SFN, BAK1, TP53I3/PIG3, 
BCL2 and APAF1 was observed. Genes that were not previously reported regulated 
in response to 5-FU induced DNA damage include BAK1, CCNG2, SFN and 
TP53I3/PIG3. A set of genes belonging to the E2F pathway were regulated by 5-FU 
treatment (Hemandez-Vargas, 2006). The E2F pathway involves the regulation of 
transcription through phosphorylation of Retinoblastoma binding proteins which 
interacts with Inhibitor of DNA binding proteins and promotes angiogenesis and 
invasion (Galbellini et al., 2006). Follow up promoter analysis of direct p53 DNA 
binding sites revealed the existence of novel p53 targets after 5-FU treatment and 
included inhibitors of DNA binding 1 (ID1) and 2 (ID2) and provides a mechanistic 
connection between p21, ID1 and ID2 overexpression and p53 regulation (Hemandez-
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Vargas, 2006). Work performed in our laboratory demonstrated that the halogenated 
pyrimidines induce a similar up-regulation of ID1, and ID2 and analysis of data 
established as well a functional link between p21 and the ID proteins (McMorrow, Ph. 
D. Thesis, 2004).
Troester et al. (2005) performed a thorough experiment comparing the response of 
two immortalised normal cell lines, and two breast cancer cell lines to exposure to 5- 
FU. A common normal cell line response, a common tumour cell line response and a 
cell-type (basal versus luminal) response were observed. The common1 overall 
expression pattern in the two luminal cell lines included well-characterized cell cycle 
regulators such as cyclin A2, cyclin Bl, cell division cycle 2, and many genes 
involved in specific phases of the cell cycle and include Ki-67, ribonucleotide 
reductase M2, polo-like kinase, and topoisomerase IIA. This cluster also included 
pituitary tumor-transforming 1 , a gene that is overexpressed in many cancers, is 
tumorigenic in vivo, and has been shown to bind p53. The gene product of 
serine/threonine kinase 6  (STK6 ) is also present and has cell-cycle-dependent 
expression, with maximum expression in G2-M; in addition, STK6  has been shown to 
bind chromosome 20 open reading frame 1, which is also repressed. Squalene
epoxidase was downregulated in the luminal cell lines and is a gene that was
differentially expressed between luminal and basal tumors in vivo. A large list of 
genes that include DNA-damage and stress response genes was up regulated in 
response to treatment in the luminal lines. The genes p21wafl and the DNA-damage 
response gene GADD45 were induced strongly in both lines. Also present were a 
number of genes involved in xenobiotic metabolism including carboyxlesterase 2 , 
epoxide hydrolase, and ferredoxin reductase (Troester et al,. 2005)
Differences between basal and luminal cell lines in response to 5-FU were identified
and among these genes was X-box binding protein 1 (XBP1), a gene whose
expression was previously shown to be highly expressed in luminal tumors in vivo. 
XBP1 is a transcription factor involved in mediating the unfolded protein response, 
which may represent a stress response that is more prominent in secretory luminal 
cells. HER2 also appeared to be induced more distinctly in luminal cells treated with 
5-FU (Troester et al,. 2005)
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Maxwell et al. (2003) performed a microarray experiment to identify genes that are 
transcriptionally activated by 5-FU treatment in the MCF-7 breast cancer cell line. Of 
2400 genes analyzed, 619 were up-regulated by >3-fold. Genes that were consistently 
found to be up-regulated were spermine/spermidine acetyl transferase (SSAT), 
annexin II, thymosin-13-10, chaperonin-10, and MAT-8 . The 5-FU-induced activation 
of MAT-8 , thymosin-B-10, and chaperonin-10 was abrogated by inactivation of p53 in 
MCF-7 cells, whereas induction of SSAT and annexin II was significantly reduced in 
the absence of p53. Basal expression levels of SSAT, annexin II, thymosin 13-10, and 
chaperonin-10 were increased and MAT- 8  expression dramatically increased in a 5- 
FU-resistant colorectal cancer cell line(H630-R10) compared with the parental H630 
cell line, suggesting these genes may be useful biomarkers of resistance {Maxwell et 
al., 2003}.
1.1.9 Global Protein expression analysis of 5-Fluororuacil treatment
There are only 2 proteomic studies published to date that have looked at the anti­
proliferative effect of 5-FU. Neither publication used the fluorescent Cy dye 
chemistry for protein detection and quantification and instead used silver staining 
techniques and colloidal commassie Blue staining to quantify protein expression 
trends. CCB lacks sensitivity and thus fewer proteins are detected while silver stained 
gels are sensitive they display poor linearity and gives poor statisitcs.
Chen et al. 2006 investigated the apoptotic effect of 5-FU on gastric cancer (MGC- 
803) cells and identified using MALDI-ToF MS a selection of proteins related to 
metabolism, oxidation, cytoskeleton and signal transduction.
Yim et al., (2006) treated HeLa cells with 5-FU and identified differentially regulated 
proteins using colloidal commassie blue stained 2DE gels. The results indicate that 5- 
FU engaged the mitochondrial apoptotic pathway involving cytosolic cytochrome c 
release and subsequent activation of caspase-9 and caspase-3 as well as the membrane 
death receptor-mediated apoptotic pathway involving activation of caspase- 8  with an 
Apo-l/CD95 (Fas)-dependent fashion. Yim et al. (2006) conclusion suggests that 5-
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FU suppresses the growth of cervical cancer cells not only by antiproliferative effect 
but also through antiviral regulation.
1.1.10 Environmental stress mechanisms
A cell encounters a wide variety of stresses and must be capable of dealing with these 
appropriately manner. There are a variety of stresses that impact a cell. These include 
genotoxins leading to DNA damage, hypoxia and various stresses that lead to 
incorrect folding of protein. These general stress conditions lead to activation of either 
genotoxic stress or endoplasmic reticulum stress. As demonstrated above 5-FU has 
impacted upon the expression of genes involved in both processes.
1.1.11 Genotoxic stress
As already stated ATM and probably ATR detect 5-FU induced DNA damage and 
can lead to accumulation of p53 in cells exposed to 5-FU due to stalled replication 
forks and possibly double strand breaks depending on the degree of 5-FU exposure. 
The DNA damage signal from double strand breaks replication stress is primarily 
recognized by ATM (ataxia telangiectasia mutated) or the ATR-ATRIP (ataxia- 
telangiectasia-and-RAD3-related-ATR-interacting-protein) complex, respectively. 
Chromatin structure changes can lead to the autophosphorylation-mediated activation 
of ATM, which is subsequently recruited to the double strand breaks. The site of 
damage contains the MRN complex (composed of RAD50, MRE11 (meiotic- 
recombination-11) and NBS1 (Nijmegen breakage syndrome-1)) and BRCA1 (breast- 
cancer-susceptibility protein-1). H2AX (histone-2A family, member X), 53BP1 (p53- 
binding protein-1), MDC1 (mediator of DNA-damage checkpoint protein-1) and 
SMC1 (structural maintenance of chromosomes-1) are phosphorylated by ATM, and 
are the key proteins that are involved in transducing a double strand break-induced 
signal. The ATR-ATRIP complex is recruited to the replication forks by the single­
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stranded DNA-RPA (replication protein A) complex. The RAD9-RAD1-HUS1 
complex and its loading factor RAD 17 facilitate recognition of the stalled fork. BLM 
(Bloom syndrome protein) and H2AX are phosphorylated in an ATR/CHK1- 
dependent manner in response to replication stress. CHK1 and CHK2, the respective 
targets of ATR and ATM, also phosphorylate the transducer proteins. The transducer 
proteins transmit the signal to effector proteins such as p53, which is phosphorylated 
at specific residues by ATM, ATR, CHK1 and CHK2. p53 is involved in cell-cycle 
arrest, DNA repair, apoptosis or senescence. p53 has roles that do not involve its 
transactivation functions during DNA repair — nucleotide-excision repair, base- 
excision repair, mismatch repair, non-homologous end-joining — and homologous 
recombination. The repair processes are also partially influenced by the 
transactivation function of p53 (Sengupta et al. 2005).
1.1.12 ER stress/Unfolded protein response
When eukaryotic cells encounter physiologically taxing conditions that impact on 
protein folding in the endoplasmic reticulum, a signal-transduction cascade is 
activated; this is termed the unfolded protein response (UPR). The UPR is a multi 
pronged response that is largely cytoprotective, but under conditions of prolonged 
stress apoptosis is induced. The UPR can be activated in tumours and is apparently 
due to their inadequate vascularization. This results in limited oxygen and nutrients, 
which interfere with the normal maturation of secretory-pathway proteins. Activation 
of the UPR might promote dormancy, aid tumour growth or protect the host by 
inducing apoptosis. in vitro activation of the UPR alters the sensitivity of tumour cells 
to chemotherapeutic agents. Several tentative observations have been made to 
implicate the UPR in tumour growth and resistance to treatments, more 
comprehensive in vivo studies are required to establish which components of the 
pathways are responsible for these undesirable out comes (Mori, 2004).
The mammalian UPR is an expansion of the basic yeast UPR. Two inositol-requiring 
gene 1 (Irel) homologues are expressed in mammalian cells: IREla and IREip. 
Activated IRE1 removes 26 bases from the XBP1 transcript through its endonuclease 
activity and allows the synthesis of a highly active transcription factor with a more 
potent transactivation domain than the one encoded by the unspliced form of XBP1. A 
transient inhibition of protein synthesis during the UPR, which is achieved by
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activation of PKR-like endoplasmic reticulum (ER) kinase (PERK) that 
phosphorylates the eukaryotic translation initiation factor-2a (eIF-2a). This leads to 
the loss of cyclin D1 from cells, causing a G1 arrest that prevents the propagation of 
cells experiencing ER stress. The block in translation specifically allows the 
activating transcription factor 4 (ATF4) to be synthesized and transactivate 
downstream genes, like GADD34, which is the regulatory subunit of the PP1 
phosphatase that acts on eIF-2a and reverses the translation arrest, and C/EBP- 
homologous protein (CHOP), which has been implicated in apoptosis. PERK is also 
required for NF-kB activation, which positively regulates anti-apoptotic proteins like 
BCL2 (important in inhibiting cytochrome c release from the mitochodria) during ER 
stress, so contributing to the balance between survival and death signals. The 
ATF6 a/ATF6 p transcription factors are synthesized as ER-localized transmembrane 
proteins, which are cleaved by the Golgi localized SIP and S2P proteases during 
activation of the UPR, liberating the cytosolic transcription-factor domain. ATF6  
induces XBP1 transcription, which is then spliced by the activated IRE1 endonuclease 
domain to produce a highly active transcription factor leading to the upregulation of 
ER chaperones such as ERdj3 and folding enzymes such as peptidylprolyl isomerase 
B (PPIase B). If ER stress conditions are not resolved, apoptotic pathways are 
initiated. Procaspase-12 in mice is localized to the cytosolic face of the ER membrane 
and is activated in response to ER stress by IRE 1-dependent mechanisms. In humans 
it is likely that capase 4 is activated and not caspases 12. Similar to the situation in 
yeast, BiP binds to the luminal domain of all three mammalian UPR transducers 
(IRE1, PERK and ATF6 ) and keeps them inactive in the absence of ER stress. The 
accumulation of unfolded proteins in the ER results in the release of BiP from the 
luminal domains of the transducers and the dimerization and activation of the kinases. 
In the case of ATF6 , the release of BiP from the luminal domain allows its transport 
to the Golgi, where the transcription-factor domain is liberated from the membrane 
and transported to the nucleus (Mori, 2004).
1.1.13 Genotoxic stress and ER stress
During ER stress the accumulation of p53 is prevented by Glycogen synthase kinase- 
3p (GSK3P). GSK3P was found to phosphorylate nuclear localized p53 at serine 315.
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This phosphorylation was found to relocalize p53 to cytoplasm and mediate its 
degradation. It is believed that ER stress can protect cells from apoptosis by 
preventing p53 accumulation (Qu et al. 2004). The exact mechanism is not defined.
1.1.14 HSPs and apoptosis
Reactive oxygen species (ROS) are produced during exposure to toxin including 5- 
FU. The main source of ROS in a cell is the mitochondria and are produced by by the 
occasional loss of an electron from the conversion of NAD(H) to NADPH in the 
mitochondria. Cellular stress place a high rewuirement on the metabolism and cause 
increased metabolism thus causing dangerously high levels of ROS and trigger 
apoptosis pathways (Chen et al., 2003; Scafer et al., 2006; Screeder et al., 2006).
Cell death signals induce the release of cytochrome c from the mitochondria that then 
binds to the APAF-1, inducing oligmerization and eventual recruitment of 
procaspase-9 and activation of the caspase cascade and cell death. HSPs have 
emerged recently that are known to regulate activation of apoptosis (Takayama et al. 
2003).
1.1.14.1 HSPB1 (Heat shock protein 27) in apoptosis
In unstressed cells HSPB1 (Heat shock protein 27) exists as a large oligiomeric unit of 
up to 800KDa usually comprising of 6  tetrameric subunits of HSPB1. During a stress 
response HSPB1 is phosphorylated on 3 known sites and are at serine residues 15, 78 
and 82. During stress MAPK is activated and phosphorylates MAPKAP 2 and 3 
which subsequently phosphorylates HSPB1. Protein Kinase C may also phosphorylate 
HSPB1. HSPB1, during stress, facilitates the repair and destruction of damaged 
proteins during stress. HSPB1 was shown to bind eIF4G under in vitro conditions and 
suggests it may inhibit translation initiation and other data indicates that HSPB1 may 
also stimulate the recovery of transcription and translation after heat shock 
{Concannon, C.G. 2003}. Over expression of HSP27 increases resistance to various 
forms of apoptopic signaling. One mechanism by which HSP27 can inhibit apoptosis 
is by the sequestering of cytochrome c in the cytoplasm preventing binding to APAF- 
1 thus preventing activation of the caspase cascade {Gorman et al. 2005}. HSPB1 has
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also been found to protect cells from reactive oxygen species produced during 
mitochondrial disfunction prior to induction of apoptosis. HSPB1 induces the 
increased expression of Glucose-6 -phosphate dehydrogenase which produces 
NADPH and modulates intercellular RADOX potential. Other roles for HSPB1 
indicate that the non-phosphorylated non-oligiomerised isoforms can contribute to F- 
actin stabilization while phosphorylated and oligiomerised isoforms do not interact 
with F-actin or actin (Concannon, 2003). See figure 1.4.
1.1.14.2 Other HSPs
HSP70 shows a similar mode of apoptosis inhibition and involves the sequestering of 
APAF-1 at the procaspase-9 binding site {Beere, et al. 2000}. HSP60 is bound to 
procaspase-3 in the mitochondrial matrix and is involved in its maturation. Under 
hypoxic stress these proteins are released into the cytosol and dissociate from each 
other (Concannonm 2003).
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Figure 1.4: Heat shock protein inhibition of apoptosome formation (Scafer et al., 
2006; Screeder et al., 2006)
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1.1.15 Translation initiation and elongation
Translational initiation begins by first the dissociation of the 80S ribosome into 40S 
and 60S subunits followed by forming the 43 S pre-initiation complex containing the 
40S ribosome subunit, elFl, elFlA, eIF3, eIF5, and the ternary complex composed of 
eIF2, Met-tRNAiMet and GTP. mRNAs bound with eIF4F and eIF4B at their 5'-end 
caps then join the 43 S pre-initiation complex followed by scanning along the mRNA 
for the physiological AUG translational initiation codon and forming the 48S pre­
initiation complex. Finally, with the release of elFs, the 60S subunit joins the 48S 
complex to form the 80S ribosome for elongation, completing the initiation steps for 
cap-dependent translation. In all these steps of initiation, eIF3 plays a central role. 
eIF3 is also important for cap-independent translational initiation, such as the internal 
ribosome entry site (IRES) mediated translation initiation of viral RNAs and by 
analogy of cellular mRNAs (Holcik and Sonenberg, 2005).
eIF3 is the most complex translational initiation factor with a molecular weight of 
about 550-700 kDa in mammalian cells consisting of thirteen putative subunits 
known as eIF3Sl-eIF3S13. The eIF3S5 (eIF3Se) has been identified as a negative 
oncogene where its down regulation has been associated with oncogenic 
transformation. The expression of eIF3e is reduced in 37% breast cancers and 31% 
non-small cell lung cancers. Furthermore the eIF35 plays an important role in 
recruiting eIF-4G (a component of eIF4F) to the translation initiation complex (Dong 
et ah, 2006).
1.1.16 5-FU and translation control
As stated previously 5-FU treatment was found to increase expression of the eIF2B 
protein, and decrease expression of the mRNA transcript of the protein eIF3 subunit 
3. The translation initiation factor eIF2B exchanges GDP for GTP on eIF-2a allowing 
for an additional amino acid to be added to growing peptide. The translation initiation 
factor eIF3 directly recruits the 40S ribosomal subunit into the translation initiation
22
complex and the eIF3 subunits have recently been shown to play important roles in 
regulating translation (LeFebvre et al., 2006).
1.1.17 5-FU and mRNA decay
The effect of FUTP (5-FU metabolic derivative) incorporation into mRNA to form 
fluorinated mRNA and investigation of translation efficiencies on a small set of 
mRNA’s revealed no change in translation efficiency (Glazier et al., 1981). However 
it is worth noting that bolus infusion of 5-FU induces cell death through incorporation 
of FUTP into mRNA. Although there is no direct evidence it is likely that fluorinated 
mRNA is repaired or destroyed by the cellular machinery and when in excess causes 
cell death.
1.1.18 Translation during stress
ER stress has been shown to phosphorylate eIF2a and inhibit translation initiation. 
Data discussed above would suggest that 5-FU treatments can cause ER stress as 
indicated by accumulation of the XBP-1 transcript a hallmark of ER stress. Thus in 
some instances 5-FU can lead to translation repression. Alternatively 5-FU treatment 
of Hela cells caused down regulation of eIF3 subunits 3 mRNA. This data may 
indicate reduced formation of translation initiation complexes.
During cellular stress conditions a cell needs to focus on dealing with the stress 
effector and as discussed previously there are different mechanisms that deal with the 
detection of cellular injury such as ER stress for dealing with protein damage and 
genotoxic response that deals with DNA lesions. During ER stress cells repress 
translation by phosphorylation of eIF2a and induction of XBP-1 transcript (Holcik 
and Sonenberg 2003. DNA damage or genotoxicity has been shown in general to 
cause the down regulation of RNA polymerase I and II and thus reduce the rate of 
ribosomal RNA and tRNA production (Schultz et al., 2003). Both mechanisms cause 
a down regulation of global translation initiation rates. Under such condition 
translation of proteins is believed to be regulated by a mechanism called internal 
ribosome entry sites (IRES) mediated translation. IRES translation is better under 
stood during ER stress but is still poorly described.
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1.1.19 Summary of 5-FU mode of action
The anti-metabolite 5-FU enters the cell and is metabolized to produce its active 
derivatives -  fluorodeoxyuridine triphosphate, fluorodeoxyuridine monophosphate 
and fluorouridine triphosphate. These products are incorporated into DNA and RNA 
where they exert their anti-neoplastic effects. RNA incorporation can lead to 
interference in RNA maturation and degradation. DNA incorporation can lead to 
accumulation of p53 through activation of ATR/ATM DNA repair mechanisms. 
Proteomic data and microarray data on 5-FU treatments show the following; 5-FU 
effects the expression of translation initiation factors, and causes differential 
regulation of genes involved in the E2F pathway (potentially inducing differentiation 
effects such as angiogenesis and metastasis). Normal and cancer cell lines were found 
to respond to 5-FU in different manners.
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1.2 Fluoropyrimidines
There are numerous fluoropyrimidines and here only 5-fluoro-2’deoxyuridine 
(52FdU) and 5-Fluoro-5’deoxyuridine (55FdU) are introduced. 52FdU is a metabolic 
derivative of 5-FU and as such should have a similar mode of action.
Capecitabine is a third generation 5-FU drug, developed from 55FdU a second 
generation 5-FU drug. 55FdU was designed for oral administration but caused 
unacceptable intestinal toxicity. Capecitabine is a further modified so that it is 
converted to 5’-deoxy-5-fluorocytidine (dFCR) by carboxylesterase in the liver thus 
avoiding intestinal toxicity. Cytdine deaminase in the liver or tumour converts dFCR 
to 55FdU. Thymidine deaminase converts 55FdU to 5-FU in the liver or tumour 
(Malet-Martino M. and Martino R., 2000). Radiotherapy works well with 55FdU as it 
promotes the increased expression of TP at the site of the tumour during therapy. 
Combination therapies with 55FdU or Capecitabine and radiation result in increased 
production of 5-FU localised to the tumour.
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1.3 Fluorouracil resistance
As already stated 5-FU is used in the treatment of Breast, Colon, and other cancers 
and development of resistance to 5-FU is a major obstacle to be overcome.
1.3.1 In vitro resistance to 5-FU
In vitro resistance to 5-FU has been linked to TS and TP over expression (Longley,
2003).
Shin et al. 2005 investigated resistance in a selection of colon cancer cell lines using a 
proteomics based approach and there findings show that ATP synthase down- 
regulation may not only be a bioenergetic signature of colorectal carcinomas but may 
also lead to cellular events responsible for 5-FU resistance. Yoo et al. (2004) using 
proteomics techniques to analyse 5-FU-resistant human colon cancer cells (resistant 
variant developed from SNU-769A) were found to overexpress metabotropic 
glutamate receptor 4 (mGluR4) and tentatively linked it to 5-FU resistance. PARK et 
al., (2002) identified 5 proteins differentially regulated between resistant and parental 
cell lines using proteomic silver stain based quantification. These proteins are 
HNRPK, transcription factor II, FLJ11122, Hook3 protein and TCP-1.
Wang et al. (2004) compared five 5-FU resistant cell lines to their five parental cell 
lines and identified 91 genes associated with 5-FU sensitivity. Key genes involved in 
5-FU activation were significantly down-regulated (thymidine kinase, orotate 
phosphoribosyltransferase, uridine monophosphate kinase, pyrimidine nucleoside 
phosphorylase) in resistant cells. Overexpression of thymidylate synthase and its 
adjacent gene, c-Yes, was detected in the resistant cell lines. The mRNA and protein 
overexpression of nuclear factor _B (NF_B) p65 and related anti-apoptotic c-Flip 
gene was detected in resistant cells. The 5-FU- resistant cell lines also showed high 
NF_B DNA-binding activity. Cotransfection of NF_B p50 and p65 cDNA induced 5- 
FU resistance in MCF-7 cells. Both NF_B- and 5-FU-induced resistant cell lines 
manifested reduced expression of genes governing Gl-S and S-phase transition. 
Expression of genes involved in DNA replication was also down regulated in resistant 
cell lines. These findings were consistent with the slower growth rate, higher 
proportion of Gl, and lower proportion of S-phase cells in the resistant cell lines. This 
phenotype may protect resistant cells from cell death induced by incorporation of 5- 
FU derivatives into DNA chains, thus allowing time to repair 5-FU -induced damage 
(Wang et al. 2004).
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Expression levels of SSAT, annexin II, thymosin fl-10, and chaperonin-10 were 
increased and MAT- 8  expression increased in a 5-FU-resistant colorectal cancer cell 
line (H630-R10) compared with the parental H630 cell line, suggesting these genes 
maybe useful biomarkers of resistance {Maxwell etal., 2003}.
Research by Klampfer et al. (2005) indicate that Ras mutations promote apoptosis in 
response to 5-FU treatment and imply that tumors with Ras mutations and/or reduced 
expression of gelsolin may show enhanced apoptosis in response to 5-FU also in vivo.
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1.3.2 Clinical (in vivo) resistance to 5-FU
High TS expression has consistently been shown to cause resistance to 5-FU 
(Longley, 2003). Thymidine phosphorylase however has shown conflicting data 
between preclinical and clinical data, however this data may be explained by the fact 
that TP is also an angiogenic endothelial growth factor and high TP expression in 
colorectal cancer has been correlated with poor prognosis. Dihydropyrimidine 
dehydrogenase (DPD) mRNA expression in colorectal tumours has been linked to 5- 
FU resistance and this correlation presumably leads to higher levels of 
Dihydropyrimidine dehydrogenase and thus higher rates of 5-FU degradation 
(Longley, D.B. 2003). Salonga et al. (2000) showed that responsiveness to 5-FU was 
dependent on the independent expression of Dihydropyrimidine dehydrogenase, TS 
and TP and measurement of all three markers accurately predicted the responsiveness 
to 5-FU based chemotherapy.
1.3.3 Thymidylate synthetase
Thymidylate synthase (TS) is an E2F1-regulated enzyme that is essential for DNA 
synthesis and repair. TS protein and mRNA levels are elevated in many human 
cancers, and high TS levels have been correlated with poor prognosis in patients with 
colorectal, breast, cervical, bladder, kidney, and non-small cell lung cancers (Rathman 
et al. 2004).
TS is regulated at both transcriptional and post-transcriptional levels and functions as 
a RNA binding protein. The translation of human TS mRNA is regulated by its own 
protein product via a negative autoregulatory mechanism whereby the binding of TS
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protein to at least two distinct sequences on its own TS mRNA results in translational 
repression. TS is also capable of interacting with several other cellular mRNAs 
including the mRNA of the transcription factors p53 and c-Myc (Xi et al. 2006). An 
acute increase in TS expression after 5-FU treatment is often observed and is 
regulated at the translational level (Xi et al. 2006). Long-term resistance to 5-FU is 
related to transcriptional activation and gene amplification of TS (Xi et al. 2006). Xi 
et al. (2006) conducted experimentations to determine proteins regulated by TS at a 
post-transcriptional level during 5-FU exposure. Microarray profiling of His Tagged 
TS immunoprecipitated from polysomes fractions was investigated to identify mRNA 
that was regulated at a post-transcriptional level by TS. These include SPRR1A, 
RRM2, KRT6 A, B, C, SPRR1B, GPIBB, CDKNIA, SEII, KRT17, PLAU, DDB2, 
SFN (Xi et al. 2006).
A recent report suggested that TS may also function as an oncogene as transfection 
with the gene transformed NIH3T3 cells {Rahman et al., 2004}
As mentioned the mode of action of 5-FU is the irreversible binding and inhibition of 
its activity leading to DNA lesions. Interestingly other halogen pyrimidine 
metabolites have not been reported to irreversibly bind to TS.
1.3.4 5-Fluorouracil as differentiating agents
As discussed previously 5-FU has been shown to impact upon various cellular stresses 
and potentially causes the regulation of gene expression at the transcriptional and 
post-transcriptional levels. The role of 5-FU in modulating TS expression has been 
shown not only to assist in DNA repair but also have additional roles in post- 
transcriptional regulation of proteins involved in differentiation such as KRT6 A and 
KRT17 (Xi et al. 2006). 5-FU has also been shown to increase expression of TP also 
known as platelet derived growth factor and plays a role in promoting angiogenesis 
(Griffin et al., 2002).
28
1.3.5 5-Fluorouracil and the cellular microenvironment
As explained previously 5-FU has been shown to impact upon a wide variety of 
cellular processes with in the cell, here the literature is explored to investigate the role 
in which 5-FU has on the cellular phenomenon such as adherence and invasion.
Integrin as Pi is expressed on activated endothelial cells and plays a critical role in 
tumor angiogenesis. A novel integrin as Pi antagonist, ATN-161, was assessed in 
combination with 5-FU to determine if it would inhibit angiogenesis and growth of 
liver métastasés in a murine model. Targeting integrin as Pi in combination with 5- 
FU infusion reduced liver métastasés formation and improved survival in this colon 
cancer model when compared to 5-FU alone. The enhancement of antineoplastic 
activity from the combination of anti-angiogenic therapy and chemotherapy may be a 
promising approach for treating metastatic colorectal cancer {Stoeltzing et al., 2003}. 
This data demonstrated the role of integrin as Pi in promoting cell survival and 
metastasis during 5-FU treatment.
RhoB is a small GTPase important in promoting cellular motility. Jiang et al. (2004) 
demonstrated that Ras/PI3K/Akt pathway inhibited RhoB induction and inhibited 
tumor survival, transformation, invasion, and metastasis. Treatment with 5-FU was 
also found induce RhoB expression. This data suggests that 5-FU treatment may have 
a modulating effect on invasion (Jiang et al. 2004).
Induction of apoptosis in fludarabine (5-FU analogue) treated human leukaemia cells 
was prevented by integrin-mediated adhesion to ECM on the basis of upregulation of 
Bcl-2-like proteins in parallel to downregulation of proapoptotic proteins such as Bax 
or Bim (Helhgans et al., 2006)
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1.4 The cell line DLKP and its subpopulations
Previous work in our laboratory established the cell line DLKP. It was histologically 
diagnosed as a ‘poorly differentiated squamous carcinoma’ or Non-Small cell Lung 
Carcinoma (NSCLC) and is of lung epithelial origin (McBride et al., 1998}. NSCLC 
are characterized by a remarkable degree of cellular heterogeneity. The present 
studies indicate that practically all NSCLC samples yield, together with a fraction of 
diploid cells, one or more than one aneuploid subpopulations (Teodori et al., 1983). 
DLKP contains three morphologically distinct subpopulations. Three clonal 
populations were isolated from this cell line that displayed the morphology of these 
morphologically distinct populations, and DNA fingerprinting established that they 
were derived from the parental population. Based on there morphologies two clones 
were designated DLKP-M (mesenchymal-like) and DLKP-SQ (squamous-like) and as 
these two population were observed to interconvert with the third population and was 
designated DLKP-I (intermediate). DLKP-SQ and DLKP-M do not interconvert with 
each other. The heterogeneous population of DLKP is composed of -70% DLKP-SQ, 
-25% DLKP-I and -5% DLKP-M. The growth characteristics of DLKP and its 
subpopulations were investigated and were found to have distinct growth curves 
under various culture conditions and DLKP-M was found to have a significantly 
lower growth rate of all the subpopulations. The attachment properties of this cell line 
were assessed with the ECM proteins collagen type IV, fibronectin and laminin. It 
was observed that the four cell lines displayed a high affinity to collagen type IV 
compared to other cell lines and that DLKP-M displayed higher initial attachment to 
fibronectin. The presence of tight junctions was found to be absent (assessed by 
electrical resistance) and therefore DLKP and its subpopulations are unpolarised 
epithelial cells. Marker expression determined that the DLKP clones did not express 
cytokeratins although it was observed that in DLKP a few cells (<1%) stained positive 
with a pan-cytokeratin antibody (detects cytokeratins 1 , 4 - 6 ,  8 ,10, 13 18 and 19). 
These 4 cell lines were found to be positive for Vimentin, Desmin and neurofilaments 
amongst other protein however no specific protein markers of each population were 
identified (McBride et al., 1998).
1.4.1 Epithelial-Mesenchymal transition
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Epithelial and mesenchymal cells differ from each other in various functional and 
phenotypic characteristics. Epithelial cells form layers of cells that are adjoined by 
specialized membrane structures, such as tight junctions, adherens junctions, 
desmosomes and gap junctions. In addition, epithelial cells have apical-basolateral 
polarization, which manifests itself through the localized distribution of adhesion 
molecules such as cadherins and certain integrins, the organization of cell-cell 
junctions as a lateral belt, the polarized organization of the actin cytoskeleton, and the 
presence of a basal lamina at the basal surface. Epithelial cells are motile and can 
move away from their nearest neighbours, while remaining within the epithelial layer. 
Mesenchymal cells do not form an organized cell layer, nor do they have the same 
apical-basolateral organization and polarization of the cell-surface molecules and the 
actin cytoskeleton as epithelial cells. They contact neighbouring mesenchymal cells 
only in a focal manner, and are not typically associated with a basal lamina. In 
culture, mesenchymal cells have a spindle-shaped, fibroblast-like morphology, 
whereas epithelial cells grow as clusters of cells that maintain complete cell-cell 
adhesion with neighbouring epithelial cells. Cultured mesenchymal cells tend be 
highly motile, but this is not necessarily the case in vivo. Indeed, there is plasticity in 
the way that mesenchymal cells migrate — they might migrate together as chains, or 
as individual cells that exhibit either cyclic extension-adhesion-retraction 
translocation or amoeboid-type crawling (Thiery, 2006}.
Epithelial cells can convert into mesenchymal cells through a process known as the 
epithelial-mesenchymal transition. The term epithelial-mesenchymal transition 
describes a series of events during which epithelial cells lose many of their epithelial 
characteristics and take on properties that are typical of mesenchymal cells, which 
require complex changes in cell architecture and behaviour). The transition from 
epithelial- to mesenchymal-cell characteristics encompasses a spectrum of inter- and 
intracellular changes, not all of which are always seen during epithelial-mesenchymal 
transition. Epithelial-mesenchymal transition does not therefore necessarily refer to a 
lineage switch. The precise spectrum of changes that occur during epithelial- 
mesenchymal transition is probably determined by the integration of extracellular 
signals the cell receives, although this is still unclear. The reverse process, known as 
mesenchymal-epithelial transition has also been reported (Thiery, 2006}.
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Mesenchyme tissue (cells, matrix and soluble factors) influence the morphogenesis, 
proliferation and differentiation of a variety of embryonic epithelia, e.g. in the tooth, 
skin, mammary and salivary glands. Mesenchyme derivatives also 'maintain' adult 
epithelia, e.g. the local proliferation rate and cytokeratin composition of oral mucosa. 
Abnormalities in such epithelial-mesenchymal interactions lead to a variety of 
pathologies such as premalignant lesions, e.g. leukoplakia, tumours and psoriasis 
(Sharpe, 1988). Stromagenesis is a host reaction of connective tissue that, when 
induced in cancer, produces a progressive and permissive mesenchymal 
microenvironment, thereby supporting tumour progression. The stromal 
microenvironment is complex and comprises several cell types, including fibroblasts, 
the primary producers of the non-cellular glycoprotein scaffolds known as 
extracellular matrices. The events that support tumour progression during 
stromagenesis are for the most part unknown due to the lack of suitable, 
physiologically relevant, experimental model systems (Amatangelo, 2005).
A homologue of the tumour suppressor p53, p63, is critical for the development and 
maintenance of squamous epithelia. p63 is specifically expressed in the basal layers of 
stratified epithelial tissues and is considered a specific marker for cells of this type. 
The role of p63 in tumorigenesis remains poorly defined. Numerous studies have 
highlighted the oncogenic potential of the predominant p63 isoform DeltaNp63 alpha; 
however, data suggest that other p63 proteins can act as tumor suppressors or alter the 
metastatic potential of tumors. DeltaNp63 alpha can act as a transcriptional repressor, 
but the link between the transcriptional functions of p63 and its biological role is still 
unclear. Disruption of p63, using siRNA, in squamous cell lines resulted in down- 
regulation of transcripts specifically expressed in squamous tissues and a significant 
alteration of keratinocyte differentiation. Disruption of p63 led to up-regulation of 
markers of nonepithelial tissues (mesenchyme and neural tissue) in both primary and 
immortalized squamous cells. Many of these up-regulated genes are associated with 
increased capacity for invasion and metastasis in tumors. Loss of p63 expression 
caused a shift toward mesenchymal morphology and an increase in motility in 
primary keratinocytes and squamous cell lines. This suggests that loss of endogenous 
p63 expression results in up-regulation of genes associated with invasion and 
metastasis, and predisposes to a loss of epithelial and acquisition of mesenchymal 
characteristics. These findings have implications for the role of p63 in both 
development and tumorigenesis {Barbieri, 2006}.
32
Throughout the entire process of cancer aetiology, progression and metastasis, the 
microenvironment of the local host tissue can be an active participant. Invasion occurs 
within a tumour-host microecology, where stroma and tumour cells exchange 
enzymes and cytokines that modify the local extracellular matrix, stimulate migration, 
and promote proliferation and survival. A new class of cancer therapies that targets 
this pathological communication interface between tumour cells and host cells is 
currently under development {Liotta, 2001}.
Recently, a view of the tumour as a functional tissue interconnected with the 
microenvironment has recently been described. For many years, the stroma has been 
studied in the context of the malignant lesion, and only rarely has its role been 
considered before carcinogenic lesions appear. Recent studies have provided evidence 
that stromal cells and their products can cause the transformation of adjacent cells 
through transient signalling that leads to the disruption of homeostatic regulation, 
including control of tissue architecture, adhesion, cell death, and proliferation. It is 
now well established that tumor progression requires a continually evolving network 
of interactions between neoplastic cells and extracellular matrix. A relevant step of 
this process is the remodeling of microenvironment which surrounds tumors leading 
to the release of ECM-associated growth factors which can then stimulate tumor 
and/or endothelial cells. Finally, tumor cells reorganizing the extracellular matrix to 
facilitate communications and escape the homeostatic control exerted by the 
microenvironment modify response to cytotoxic treatments (Pupa, 2002}.
Integrin-mediated cell adhesions provide dynamic, bidirectional links between the 
extracellular matrix and the cytoskeleton. Besides having central roles in cell 
migration and morphogenesis, focal adhesions and related structures convey 
information across the cell membrane, to regulate extracellular-matrix assembly, cell 
proliferation, differentiation, and death. (Geiger, 2001}
1.4.2 Cell Matrix interactions
Adherence proteins regulate migration, invasion and ECM remodelling and assembly. 
These adherence proteins include members of the integrin and syndecan family.
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1.4.3 Integrins
As cancer cells become metastatic and as endothelial cells become angiogenic, they 
develop altered affinity and avidity for their ECM and is mediated by alterations in 
the expression of integrins, release of proteases that remodel the ECM and the 
deposition of new ECM molecules. These activate signaling cascades that regulate 
gene expression, cytoskeletal organization, cell adhesion and (more importantly in 
terms of cancer) cell survival. Cellular invasion and migration are governed at both 
the extracellular and intracellular levels by several factors that include ECM 
composition, adjacent cells, and the presence of soluble and insoluble gradients
(Hood, J.D. 2002; Anderson et al., 2006). .................
During migration, cells project lamellipodia that attach to the ECM whilst 
simultaneously breaking existing ECM contacts at their trailing edge allowing the cell 
to pull itself forward. Extension of lamellipodia is induced by actin polymerization. 
Retraction of the cell edge is dependent on fracturing the cell-ECM linkage in highly 
adhesive environments or by simple dissociation of integrins (the cellular receptors 
for ECM molecules). Integrins are glycoproteins that form heterodimeric receptors for 
ECM molecules. The integrin family can form at least 25 distinct pairings of the 18 a- 
subunits and 8  fJ-subunits. Each a|3 pairing is specific for a unique set of ligands. 
Integrins relay molecular cues regarding the cellular environment and through signal 
transduction that influences cell shape, survival, proliferation, gene transcription and 
migration. Upon binging to ligand, integrins cluster into focal contacts that contain 
different actin-associated proteins, such as a-actinin, vinculin, tensin and paxillin, 
which form a link between the focal contact and the cytoskeleton.. Integrin binding to 
ligands in the extracellular matrix (ECM) activates focal adhesion kinase (FAK), 
which binds and activates multiple signalling proteins. FAK autophosphorylation at 
tyrosine 925 causes it to bind growth-factor-receptor-bound protein 2 (GRB2) and 
activate another small G protein, RAS. FAK activation also promotes SRC-dependent 
phosphorylation of SHC, leading to GRB2 recruitment and RAS activation. Activated 
RAS recruits RAF to the cytoplasmic membrane, where it can be activated by protein 
kinases such as SRC, thereby leading to mitogen-activated protein kinase kinase 
(MEK) and extracellular-signal-regulated kinase (ERK) activation. Once activated by 
FAK or SHC, RAS can activate phosphatidylinositol 3-kinase (PI3K) and RAF.
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Activated SRC can also phosphorylate CRK-associated substrate (CAS), enabling it 
to bind CRK and dedicator of cytokinesis 180 (DOCK-180), leading to RAC 
activation. Activated RAC, in conjunction with activated CDC42, can regulate 
numerous biochemical pathways, including activation of p21-activated kinase (PAK). 
PAK affects numerous pathways, and also activates RAF’s kinase activity. MEK, 
once activated by RAS and RAF, can phosphorylate and activate ERK. ERK 
activation leads to transcriptional activity, alterations in integrin affinity for ligand, 
and myosin-light-chain kinase (MLCK) activity. Independent of FAK activation,
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Figure 1.4: Integrin signalling regulates actin dynamics and transcription
signaling molecules such as SHC and PKC are also activated by integrin adhesion 
events. Activating these molecules can also eventually lead to RAS and RAF 
activation, along with the alterations in the cytoskeleton that are necessary for the 
migratory phenotype (Hood, J.D. 2002; Anderson et al., 2006).
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1.4.4 Rho family members and actin dynamics
Most of the functional information on Rho-family proteins has come from studies of 
Rho A, Racl and Cdc42. All share common growth-promoting and anti-apoptotic 
functions, as well as regulation of gene expression, through activation of signaling 
molecules such as serum response factor, NF-kB, the stress-activated protein kinases 
and cyclin Dl. All three promote actin cytoskeleton reorganization, but have distinct 
effects on cell shape and movement (see figure 1.5). RhoA promotes actin-myosin 
contractility and, thereby, the formation of stress fibers and focal adhesions, regulating 
cell shape, attachment and motility. Racl promotes actin polymerization and the 
formation of lamellipodia, which are curtain-like extensions that consist of thin 
protrusive actin sheets at the leading edge of migrating cells. Cdc42 causes formation 
of filopodia, which are thin, finger-like cytoplasmic extensions that contain tight actin 
bundles and might be involved in the recognition of the extracellular environment 
(Weenerberg et al., 2004).
1.4.5 Integrin and proteases
Integrins are involved in regulating proteolytic enzymes that degrade the basement 
membrane (the initial barrier to surrounding tissue). The basement membrane forms a 
non-cellular scaffold for cells and is made up of a complex mix of ECM proteins, 
including laminins, collagens and proteoglycans. Cancer cells produce, activate and 
release several types of proteases that specifically cleave ECM molecules. Two 
members of the matrix metalloproteinase (MMP) family, MMP-2 (gelatinase A) and 
MMP-9 (gelatinase B) have the highest activity against type IV collagen, which is the 
main constituent of the basement membrane {Hood, J.D. 2002}. Other proteases 
involved in ECM remodeling include the cysteine proteases (Cathepsin B) and 
aspartic proteases (Cathepsin D) (Pupa et al 2002).
1.4.6 Syndecans
3 7
The syndecan family are transmembrane proteoglycans expressed on adherent cells. 
The family of four proteins (sdc-1, -2, -3, -4) participate in cell-matrix adhesion, the 
regulation of growth factors (FGFs, VEGF, HGF) binding and signaling. The 
syndecans are composed of an extracellular domain (contains heparan sulfate and 
chondroitin sulfate glycosaminoglycan chains), a transmembrane region and a short 
cytoplasmic domain. The cytoplasmic domain attaches activated protein kinase C 
alpha, phosphatidyl-inositol-4,5-bisphosphate, syntenin, beta-catenin and many others 
molecules and is important in focal contacts. Syndecans bind numerous ligands 
present in extracellular matrix and include growth factors, enzymes, and ECMs such 
as fibronectin and laminin. They form connections with actin cytoskeleton in focal 
contacts. The changes in syndecan expression influence cell adhesion and migration, 
structure of focal contacts and cytoskeleton and participate in cell differentiation and 
tissue regeneration {Brzoska, 2005}. Syndecan-2 have been shown to participate in 
focal adherence and induce regulation of rho stimulating actin nucleation (Irie et al.
2004).
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1.4.7 Cytoskeletal alteration during migration
The cytoskeleton of eukaryotic cells is composed of actin microfilaments, 
microtubules, and intermediate filaments. An important property of actin is its ability 
to produce movement. Microfilament assembly at the cell membrane protrudes the 
membrane forward producing the ruffling membranes in actively moving cells. 
Microfilaments can also play a passive structural role by providing the internal 
stiffening rods in microvilli, maintaining cell shape, and anchoring cytoskeletal 
proteins.
1.4.7.1 Assembly of Actin Filaments
Actin polymerization is a condensation reaction. The main features of this process are 
first a slow initial association to an actin dimer that is more likely to rapidly dissociate 
to monomers than to assemble, secondly the formation of a stable actin trimer that 
represents the nucleus of polymerization, a state where actin assembly is more likely 
than is disassembly and thirdly the elongation phase during which actin monomers are 
rapidly assembled.
1.4.7.2 The Arp2/3 Complex
The Arp2/3 complex is a stable complex of seven-subunits — two actin-related 
proteins (Arp2 and Arp3) and five additional novel proteins (p40, p35, p i9, pi 8 , and 
p i4). ARP2/3 activity requires binding to activated WASP protein which contains two 
actin-profilin binding domain. Thus ARP2/3 complex is important in the stimulation 
of actin nucleation (Anton et al., 2006). The principal function of Arp2/3 is to create 
branch points by nucleating the assembly of filaments near ruffling membranes, a 
process that needs ATP. Arp2/3 is also considered to be a cross-linking protein, and 
some authors believe it can cap the pointed (depolymerizing) ends of actin filaments, 
although this is still controversial (dos Remedios et al. 2003}.
1.4.7.3 Elongation and Annealing of F-actin
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Elongation involves association and dissociation of monomers from the filament and 
can occur at either end of the filament. However, association predominantly occurs at 
the barbed end and dissociation at the pointed end. An ATP binding site is required 
for the extension of actin filament by hydrolysis producing actin filaments (F-actin) 
containing ADP. During depolymerization of ADP-actin subunits in F-actin rapidly 
exchange their bound ADP for ATP in solution and is accelerated by profilin. Due to 
the cycling nature of actin elongation and polymerisation the process is referred to as 
"treadmilling" (dos Remedios et al. 2003; des Marais et al., 2005).
Actin Binding proteins (ABP) present in vivo regulate different aspects of the 
assembly/disassembly process. These include filament stabilizers (e.g., tropomyosin), 
capping proteins (e.g., CapZ, tropomodulin), ABPs that promote branching (e.g., 
Arp2/3), and ABPs that sequester G-actin and thus maintain a pool of monomers in 
solution (e.g., thymosin (54, profilin) (dos Remedios et al. 2003; des Marais et al., 
2005).
Actin filament lengths are affected by fragmentation and annealing. Fragmentation 
can arise from thermal motion in vitro, but in vivo much of this will be constrained by 
the other contents of the cytoplasm. Annealing occurs when an existing filament binds 
to the appropriate end of a second filament. Arp2/3 is believed to create branch points 
in actin microfilaments by "capturing" existing filaments (dos Remedios et al. 2003; 
des Marais et al., 2005).
1.4.7.4 ADF/Cofilin
The actin depolymerizing factors ADF/cofilin family of proteins are ubiquitously 
expressed in all eukaryotic cells and are relatively small (15-19 kDa) proteins that 
exist in multiple isoforms. Their main functions include the rapid recycling of actin 
monomers associated with membrane ruffling and with cytokinesis. Different genes 
encode for ADF and cofilin, but although it is common to regard them as 
synonymous, they are distinctly different (dos Remedios et al. 2003; des Marais et al.,
2005).
Cofilin accelerates the dissociation of monomers from the pointed ends of filaments. 
Phosphorylation of cofilin dissociates it from ADP-actin. Cofilin cycles through
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phosphorylation and déphosphorylation in order to allow it to function in its 
depolymerising role during actin threadmilling (dos Remedios et al. 2003; des Marais 
et al., 2005).
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1.4.7.5 Profìlin
Profilin promotes the exchange of ADP for ATP that facilitates the addition of 
profilin-ATP-actin at the barbed end of F-actin and thus is important in F-actin 
elongation (dos Remedios et al. 2003; des Marais et al., 2005).
1.4.7.6 Gelsolin Superfamily
Gelsolin is part of a superfamily of ABPs expressed in all eukaryotes. The grouping 
includes gelsolin, villin, adseverin, CapG, flil, and severin. Unlike coflin and profilin, 
an isoform of intracellular gelsolin can circulate in plasma where it severs and caps 
actin filaments released into the circulation. Gelsolin is an important ABP because of 
its high affinity for actin filaments. Binding of gelsolin initiates the severing, but 
while binding to filaments is rapid, its severing action is slow. Gelsolin is also 
involved in capping and is calcium dependent (dos Remedios et al. 2003; des Marais 
et al., 2005).
After severing, gelsolin remains attached to the barbed end of the filament as a cap, 
thereby preventing the reannealing of actin fragments. Capping prevents rapid growth 
at the barbed ends while disassembly proceeds unchecked at the pointed ends, 
resulting in the rapid disassembly until equilibrium is established between capped 
filaments and free gelsolin. Dissociation (uncapping) of gelsolin from these filaments 
generates numerous polymerization-competent ends that seed the rapid assembly of 
new filaments. Thus the cytoskeleton can be rapidly rebuilt in a new direction and cell 
movement can be redirected (dos Remedios et al. 2003; des Marais et al., 2005).
1.4.7.7 CapZ, a barbed-end capping protein
The reported biological roles of CapZ include nucléation of actin assembly, capture of 
pre-existing filaments, regulation of actin assembly at the barbed ends of filaments, 
elimination of annealing at the barbed ends of filaments. CapZ does not affect the rate
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of fragmentation of actin filaments and does not bind to their pointed ends (Sept D et 
al 1999; dos Remedios et al. 2003; des Marais et al., 2005).
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1.5 Aims of thesis
Previous work performed in the NICB found that the halogenated pyrimidine, 
Bromodeoxyuridine (BrdU), was capable of inducing markers of epithelial 
differentiation in the poorly differentiated cell line DLKP {McBride,S. et al. 1999}. 
Specifically, the up-regulation of Keratins 8, 18 and 19 were observed and 
investigation of mRNA and proteins expression levels indicated regulation at a post- 
transcriptional level (McBride et al., 1999; Meleady et al., 2001; Walsh et al., 2003}.
Further research with other halogen pyrimidines (Fluoro-, chloro-, and iodo- 
pyrimidines) was found to induce similar effects (O’ Sullivan F, Thesis, 1999; 
McMorrow J, Thesis, 2004). Of these fluoropyrimidines investigated the 
chemotherapeutic, 5-Fluorouracil (5-FU), was found to induce expression of keratin 8 
and 18 and was regulated at a post-transcriptional level (O’ Sullivan F, Ph.D. Thesis, 
1999; McMorrow J, Ph.D. Thesis, 2004).
As regulation of keratin 8 and 18 was observed to occur at a post transcriptional level 
by halogenated pyrimidine treatment investigation of alterations induced by 5-FU was 
to be carried out at a proteomic level in order to investigate possible mechanisms of 
translation control and identify proteins differentially regulated that may be controlled 
at a post-transcriptional level.
Transfection of the simple epithelial markers keratin 8 and 18 were found to induce 
invasion and its expression is found to correlate with invasion (Chu et al. 1996). Work 
performed in our laboratory demonstrated that pulse selection of many cell lines to 
chemotherapeutic drugs including 5-FU often induced a more invasive phenotype 
(Liang Ph. D. Thesis, 2002). Thus 5-FU has been shown to induce an increase in 
invasion and it may be linked to increased expression of keratin markers associated 
with increased invasion. To assess if 5-FU treatments could alter the invasive status of 
various cell lines invasive status the degree of invasion was assessed post 5-FU 
treatment. Proteomic data was performed on these cell lines in order to characterise 
potential mechanisms induced by 5-FU treatment that lead to increased or decreased
1.5.1 5-Fluorouracil treatments and proteomic analysis
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invasion post 5-FU treatment. Normal cell lines were included in this experiment. A 
characteristic of epithelial is an invasive phenotype (Barbieri et al., 2006; Liotta et al., 
2001). The normal cell lines human mammary epithelial cells (HMEC) and normal 
human bronchial epithelial (NHBE) cells are used in these experiments. NHBE cells 
require retinoic acid to induce epithelial differentiation and would be expected to 
induce invasion (Lotan, 2003). To assess the role of 5-FU as a promoter of markers of 
epithelial differentiation and invasion these cells were cultured with out retinoic acid, i
1.5.2 Fluoropyrimidine treatments and proteomic analysis
As previously mentioned work performed in our laboratory found that the 
fluoropyrimidines are capable of inducing a differentiation effect in DLKP (O’ 
Sullivan F, Ph.D. Thesis, 1999; McMorrow J, Ph.D. Thesis, 2004). Further 
characterisation of this phenomenon is to be investigated at a proteomic level to 
further characterise the effect of these drug and to determine a common mode of 
action between these drugs. Adherence profiles were determined after 7 days 
treatment with the fluoropyrimidines and analysis of differential protein expression 
was investigated.
1.5.3 Development of a 5-FU resistant cell line and proteomic analysis
Understanding resistance to 5-FU and comparison to 5-FU treatments is important in 
the understanding of how cancer cell may develop resistance. Development of 
resistant variants of DLKP and A549 by pulse selection with the fluoropyrimidine 
drugs in order to develop a stable 5-FU resistant variant of DLKP or A549. Resistant 
variants developed were then characterised at a proteomic level to determine possible 
resistance mechanisms.
1.5.4 Further characterisation of invasion and motility rates in DLKP and its 
subpopulations and characterisation of total and membrane proteomes
The heterogeneous cell line DLKP is composed of at least three morphologically 
distinct populations and these have been designated DLKP-SQ, DLKP-I and DLKP-
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M (McBride et al., 1998). Investigation of these cell lines determined that the -SQ and 
-M populations interconverted with the -I population (McBride et al., 1998). 
Investigation of adherence profiles indicated that DLKP-M adhered more readily to 
fibronectin and had a slower growth rate when compared to the other populations 
(McBride et al., 1998). No distinct protein markers of these populations could be 
determined (McBride et al., 1998). Invasion and motility rates are to be determined 
using DLKP and clones of the same passage as described by McBride, S. 1998. 
Investigation of the interconversion between these populations is investigated using 
two dimensional difference gel electrophoresis (2D-DIGE) analysis of total Cell lysate 
proteome and hydrophobic proteomes.
Comparison DLKP clonal 2D-DIGE experiment and DLKP treated with 5-FU in 
combination with invasion assays results would allow for identification of protein 
trends that parallel invasion trends and this would help identify proteins potentially 
involved in progression of invasion. This data may also show if 5-FU treatment 
caused the selection of subpopulation or induced specific alterations associated with 
5-FU treatment.
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1.5.5 Summary of Aims
5-FU treatments of cancer and normal cells in vitro
> Determination of phenotypic changes (invasion, and adherence to ECM 
proteins) in cancer and normal cells of the lung post 5-FU exposure
> Proteomic analysis of these cell lines after 7 days exposure to 5-FU at an ICgo 
drug concentration
> Identification of potential mechanisms important during 5-FU treatment that 
contribute to differentiation, inhibition of growth, prevention of apoptosis, and 
progression of invasion.
Fluoropyrimidine treatments of DLKP in vitro
> Proteomic analysis of DLKP after 7 days exposure to the fluoropyrimidines at 
an ICgo concentration and determination of common markers of 
fluoropyrimidine treatment
Development of a 5-FU drug resistant variant
> Pulse selection of DLKP and A549 with the fluoropyrimidine drugs to develop 
a 5-FU stably resistant variant
> Identification and characterisation of a stable 5-FU resistant variant
> Proteomic analysis of variants versus Parental cell lines
> Assess if an overlap exists between fluoropyrimidine treatments and cell lines 
pulse selected by the fluoropyrimidines
Characterisation of DLKP and its subpopulations
> Investigation of motility and invasion rates of DLKP and its subpopulations
>• Total cell lysate and hydrophobic proteome analysis of DLKP and its 
subpopulations
> Identification of clonal markers
> Identification of proteins involved in invasion
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2.0 Materials and Methods
2.1 Ultrapure water
Ultrapure water (UHP) was used in the preparation of all media and solutions. This 
water was purified to a standard of 12-18 mil/cm resistance by a reverse osmosis 
system (Millipore Milll-RO 10 Plus, Elgastat UHP).
2.2 Glassware
The solutions used in the various stages of cell culture were stored in sterile glass 
bottles. All sterile bottles and other glassware required for cell culture related 
applications were prepared as follows: glassware and lids were soaked in a 2% RBS- 
25 (AGB Scientific) for 1 hour. After this time, they were cleansed and washed in an 
industrial dishwasher, using Neodisher detergent and rinsed twice with UHP. The 
resulting materials were sterilised by autoclaving.
2.3 Sterilisation Procedures
All thermostable solutions, water and glassware were sterilised by autoclaving at 
121 °C for 20 minutes at 15 p.s.i.. Thermolabile solutions were filtered through 0.22 
□m sterile filters (Millipore, Millex-GV SLGV025BS). Larger volumes (up to 10
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litres) of thermolabile solutions were filter sterilised through a micro-culture bell filter 
(Gelman, 12158).
2.4 Preparation of cell culture media
| M . , •
Media for the routine culture of cancer cells was prepared by Joe Carey (technician) 
Basal media used during cell culture was prepared as follows: 10X media was added 
to sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine-N-(2- 
ethanesulfonic acid) and NaHC03 as required and adjusted to pH 7.45-7.55 using 
sterile 1.5 N NaOH or 1.5 N HC1. The media was then filtered through sterile 0.22|im 
bell filters (Gelman, 12158) and stored in sterile 500ml bottles at 4°C. Sterility as 
described in section 2.5.5.
Basal media were stored at 4°C for up to three months. The HEPES buffer was 
prepared by dissolving 23.8g of HEPES in 80ml UHP water and this solution was 
then sterilised by autoclaving. Then 5ml sterile 5N NaOH was added to give a final 
volume of 100ml. NaHC03 was prepared by dissolving 7.5g in 100ml UHP water 
followed by autoclaving. Complete media was then prepared as follows: supplements 
of 2mM L-glutamine (Gibco, 11140-0350) for all basal media and 1ml 100X non- 
essential amino acids (Gibco, 11140-035) and lOOmM sodium pyruvate (Gibco, 
11360-035) were added to MEM. Other basal media were supplied by sigma. 
Components were added as described in Table 2.1. Complete media was stored at 
4°C for a maximum of one week, complete normal cell media was stored for upto 1 
month.
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Bronchial Epithelial Medium (BEGM®) and Mammary Epithelial Cell Medium 
(MEGM®) required for culture of normal cells was supplied by Cambrex. This media 
supplied as a kit and includes supplementary growth factors, cytokines and antibiotics 
and were stored at -20°C. BEGM was prepared by addition of the following 
supplements under aseptic techniques. These supplements are
Table 2.1: Additional components in media.
Cell Line Culture Medium
A549 ATCC Media (Sigma), 5% FCS
DLKP ATCC Media (Sigma), 5% FCS
DLKP-SQ ATCC Media (Sigma), 5% FCS
DLKP-I ATCC Media (Sigma), 5% FCS
DLKP-M ATCC Media (Sigma), 5% FCS
DLKP-55 ATCC Media (Sigma), 5% FCS
MCF-7 DMEM Media (Sigma), 5% FCS
NHBE BEGM basal media, plus Bovine pituitary extract (2ml), Epithelial 
Growth factor (0.5ml), Insulin (0.5ml), hydrocortisone (0.5ml), 
transferrin (0.5mD. and without Retinoic acid and GA-1000
(Antibiotic mixture). Concentrations not specified by supplier
HMEC MEGM basal media, plus Bovine pituitary extract (2ml), Epithelial 
Growth factor (0.5ml), Insulin (0.5ml), hydrocortisone (0.5ml), 
transferin ('0.5ml'). and without GA-1000 (Antibiotic mixture). 
Concentrations not specified by supplier
2.5 Cells and Cell Culture
All cell culture work was carried out in a class II laminar air-flow cabinet (Nuaire 
Biological Laminar Air-Flow Cabinet). All experiments involving cytotoxic 
compounds were conducted in a cytogard laminar air-flow cabinet (Gelman Sciences, 
CG series). Before and after use the laminar air-flow cabinet was cleaned with 70%
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industrial methylated spirits (IMS). Any items brought into the cabinet were also 
cleaned with IMS. At any time, only one cell line was used in the laminar air-flow 
cabinet and upon completion of work with any given cell line the laminar air-flow 
cabinet was allowed to clear for at least 15 minutes so as to eliminate any possibility 
of cross-contamination between the various cell lines. The cabinet was cleaned 
weekly with industrial disinfectants (Virkon or TEGO) and these disinfectants were 
alternated every month. Details pertaining to the cell lines used for the experiments 
detailed in this thesis are provided in Table 2.5.1. All cells were incubated at 37°C 
and where required, in an atmosphere of 5% C02. Cells were fed with fresh media or 
subcultured (see Section 2.5.1) every 2-3 days in order to maintain active cell growth. 
All of the cell lines listed in Table 2.2 are anchorage-dependent cell lines.
Table 2.2: Addition cell line information.
Cell line Source Cell type
A549 NICB Lung Adenocarcinoma
DLKP NICB Non-Small Cell Lung carcinoma
DLKP-SQ NICB Non-Small Cell Lung carcinoma,
DLKP-I NICB Non-Small Cell Lung carcinoma
DLKP-M NICB Non-Small Cell Lung carcinoma,
DLKP-55 NICB Non-Small Cell Lung carcinoma variant
MCF-7 NICB Breast Adenocarcinoma
NHBE Cambrex Bronchial epithelial cells
HMEC Cambrex Mammary epithelial cells
2.5.1 Subculturing of cell lines
Subculturing o f cancer cell lines
The waste cell culture medium was removed from the tissue culture flask and 
discarded into a sterile bottle. The flask was then rinsed out with 1ml of 
trypsin/EDTA solution (0.25% trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, 
E9884) solution in PBS (Oxoid, BRI4a)) to ensure the removal of any residual media.
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5ml of trypsin was then added to the flask, which was then incubated at 37°C for 
approximately 5 minutes, until all of the cells detached from the inside surface of the 
flask. The trypsin was deactivated by adding an equal volume of complete media to 
the flask. The cell suspension was removed from the flask and placed in a sterile 
universal container (Sterilin, 128a) and centrifuged at lOOOrpm for 5 minutes. The 
supernatant was then discarded from the universal and the pellet was suspended in 
complete medium. A cell count was performed and an aliquot of cells was used to re­
seed a flask at the required density.
Subculturing o f Normal cell lines
Normal cell lines were subcultured in the following manner using the subculture 
reagent kit supplied by Cambrex (CC-5034). Cells were rinsed with 5 ml of room 
temperature Clonetics HEPES Buffered Saline Solution. The HEPES Buffered Saline 
Solution was allowed to evaporate from the flask. The cells were covered with 2 ml of 
room temperature Trypsin/EDTA. The cell layer was examined microscopically. The 
trypsinisation process was allowed to continue until approximately 90% of the cells 
had rounded up and takes about 2-6 minutes, depending on the cell type. At this point, 
the flask was rapped against the palm of hand to release the majority of the cells from 
the culture surface. If only a few cells detached, trypsinisation was allowed to 
continue for a further 30 seconds, and flask was given a further rap with the palm of 
the hand. This process was repeated until the majority of cells had detached. The 
trypsin in the flask was immediately nuetralised by addition of 4 ml of room 
temperature Trypsin Neutralizing Solution.
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2.5.2 Cell counting
Cells were trypsinised, pelleted and resuspended in media. The suspension was 
incubated for 3 minutes at room temperature. A IOjj.1 aliquot of the mixture was then 
applied to the chamber of a glass coverslip enclosed haemocytometer. Cells in the 16 
squares of the four grids of the chamber were counted. The average cell numbers per 
16 squares were multiplied by a factor of 104 and the relevant dilution factor to 
determine the number of cells per ml in the original cell suspension
2.5.3 Cryopreservation of cells
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in Section 2.5.2. Cell pellets were resuspended in a suitable volume of 
serum. An equal volume of a 10 % DMSO/serum solution was added drop wise to the 
cell suspension. A total volume of 1ml of this suspension (which should contain 
approximately 7x106 cells) was then placed in cryovials (Greiner, 122278). These 
vials were then placed in a polystyrene rack in the -20°C freezer for 1 hour and then 
subsequently placed in a -80°C freezer for at least 4 hours to overnight. Subsequently 
vials were removed from the -80°C freezer and transferred to the liquid Nitrogen 
phase of the liquid nitrogen tank for storage (- 196°C).
2.5.4 Thawing of cryopreserved cells
A volume of 5ml of fresh growth medium was added to a sterile universal. The 
cryopreserved cells were removed from the liquid nitrogen and thawed by using
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gentle pipetting action on the frozen cell suspension in the cryovial. The cells were 
removed from the cryovial and transferred to the aliquoted media. The resulting cell 
suspension was centrifuged at 1,000 rpm for 5 minutes. The supernatant was removed 
and the pellet resuspended in fresh culture medium. Thawed cells were counted as 
described in section 2.5.2 and then divided amongst 25cm2 flasks at 5xl04 per flask 
and allowed to attach overnight. The following day, flasks were refed with fresh
media to remove any non-viable cells. The same process was used for both normal
, 1
and cancer cell lines.
2.5.5 Monitoring of sterility of cell culture solutions
Sterility testing was performed in the case of all cell culture media and cell culture 
related solutions. Samples of prepared basal media were inoculated on to Colombia 
blood agar plates (Oxoid, CM331), Thioglycollate broths (Oxoid, CM 173) and 
Sabauraud dextrose (Oxoid, CM217) and incubating the plates at 37°C and 25°C. 
These tests facilitated the detection of bacteria, fungus and yeast contamination. 
Complete cell culture media were sterility tested at least four days prior to use, using 
Columbia blood agar.
2.6 Mycoplasma analysis o f cell lines
Cell lines were tested for possible mycoplasma contamination by Mr. Michael Henry. 
The protocol used is detailed in the following Sections 2.6.1.
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2.6.1 Indirect staining procedure for Mycoplasma analysis
Mycoplasma negative NRK (Normal rat kidney fibroblast) cells were used as an 
indicator cells for this analysis. The cells were incubated with a sample volume of 
supernatant from the cell lines in question and then examined for Mycoplasma 
contamination. A fluorescent Hoechst stain was used in this analysis. The stain binds 
specifically to DNA and so stains the nucleus of the cell in addition to any 
Mycoplasma present. Mycoplasma infection was indicated by fluorescent bodies in 
the cytoplasm of the NRK cells.
2.7 In vitro toxicity assays
2.7.1 Miniaturised in vitro toxicity assay
Cells in the exponential phase of growth were harvested by trypsinisation as described 
in section 2.5.1. Cell suspensions containing 1 x 104 cells per ml were prepared in 
cell culture medium. Volumes of lOOfal/well of these cell suspensions were added to 
96-well plates (Costar, 3599) using a multichannel pipette. Cells were then incubated 
for 24 hours at 37°C in an atmosphere containing 5% CO2. Cytotoxic drug dilutions 
were prepared at 2X their final concentration in cell culture medium. Volumes of the 
drug dilutions (100^1) were then added to each well using a multichannel pipette. 
Cells were incubated for a further 7-8 days at 37°C and 5% C02 until the control 
wells had reached approximately 80-90% confluency. Following the incubation
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period of 7-8 days, media was removed from the plates. Each well on the plate was 
washed twice with 100|xl PBS. This was then removed and 100^1 of freshly prepared 
phosphatase substrate (lOmM p-nitrophenol phosphate (Sigma 104-0) in 0.1M sodium 
acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH 5.5) was added to each 
well. The plates were then incubated in the dark at 37°C for 2 hours. The enzymatic 
reaction was stopped by the addition of 50pl of 1M NaOH. The plate was read in a 
dual beam plate reader at 405nm with a reference wavelength of 620nm. Assessment 
of cell survival in the presence of drug was determined by the acid phosphatase assay 
(section 2.7.3). The concentration of drug which caused 50% inhibition of cell growth 
(IC50 of the drug) was determined from a plot of the % survival (relative to the 
control cells - 0|iM drug) versus cytotoxic drug concentration.
2.7.2 Fluoropyrimidine treatments for the determination of approximate IC80 
value; an in vitro compound toxicity assay
Exponentially growing cells were harvested as described in section 2.5.1. A total of 
5x104 cells were seeded into each of ten 25cm2 flasks and were further cultured for 
two days at 37°C in an atmosphere containing 5%CC>2 in 5ml of media. On days 2, 4 
and 6 media was replaced with fluoropyrimidine-supplemented media at 37°C and in 
control flasks (untreated) media was replaced with media heated to 37°C. By day 9 
cells were harvested as described in section 2.5.1 to determine the degree of growth 
inhibition.
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2.7.3 Fluoropyrimidine ICso treatment cel! culture and post treatment cell 
culture
A total of 5 x 105 cells were seeded into 175cm2 flasks and cultures for 2 days in 
25ml of media. Media was replaced with media supplemented with fluoropyrimidine 
drug at ICgo concentration determined as described in section 2.7.2, and confirmed by 
counting. Cells were cultured for a further 7 days were media was replaced with 
media supplemented freshly fluoropyrimidine after 2 and 4 days exposure.
For culturing of cells post 5-FU exposure, cells were trypsinised and seeded in to 
fresh 25cm2 flasks at a concentration 5xl04 cells in 5ml of media per flask and were 
fed every 2 days.
2.8 Safe handling of cytotoxic drugs
Cytotoxic drugs were handled with extreme caution at all times in the laboratory, due 
to their inherent danger. Disposable nitrile gloves (Medical Supply Company Ltd) 
were worn at all times and all work was carried out in cytotoxic cabinets (Gelman 
Sciences, CG series). All drugs were stored in a safety cabinet at room temperature or 
in designated areas at 4°C or -20°C. The storage and means of disposal of the 
cytotoxic drugs used in this work are outlined in Table 2.3.
Cytotoxic Agent Storage Disposal
Adriamycin 4°C in dark Incineration
Taxol Room temperature in dark Incineration
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5-FU -20oC in dark Incineration
55FdU -20oC in dark Incineration
52FdU -20oC in dark Incineration
Table 2.3 Storage and disposal details for chemotherapeutic agents (drug disposal 
carried out by Dr. Robert O Connor).
2.9 Pulse selection process with fluoropyrimidines
The cell lines DLKP and A549 were grown to 50% confluency in 75cm2 flasks. The 
cells were then exposed to a low level concentration of 5-FU, 52FdU and 55FdU for 4 
hour pulses, and this was gradually ramped in increments of 10-20(J,M in a series of 
10 pulses. Ramping was determined by failure to induce cell death or growth 
inhibition. Cells culture between pulse selections were then grown in drug-free media 
for at least 1 week, refeeding every 2-3 days between pulses and pulsing 
recommenced when cells reached 50% confluency and were seen to be proliferating.
2.10 Western blotting
2.10.1 Whole cell protein extraction
Media was removed and cells were trypsinised as described in section 2.5.1. Cells 
were washed twice with ice cold PBS. All procedures from this point forward were 
performed on ice. Cells were resuspended in 100-200^1 of NP-40 lysis buffer and 
incubated on ice for 60 minutes (see tables 2.4 and 2.5).
60
Table 2.4: below provides the details of the lysis buffer. Immediately before use, lO i^l
of the 100X stocks listed in table 2.4 were added to 1ml of lysis buffer.
Addition required per 500ml stock Final concentration
425ml UHP water -
25ml 1M Tris-HCl (pH 7.5) 50mM Tris-HCl (pH 7.5)
15ml 5M NaCl 150 mM NaCl
2.5ml NP-40 0.5% NP-40
Table 2.5: NP-40 lysis buffer
100X stock Preparation instructions
lOOmM Na3 V04 1.83gNa3 V04 in 100ml UHP
lOOmMDTT 154mg in 10ml UHP
lOOmM PMSF 174mg in 10ml 100% ethanol
100X Protease inhibitors 2.5 mg/ml leupeptin, 2.5 mg/ml aprotinin, 
15 mg/ml benzamidine and 1 mg/ml 
trypsin inhibitor in UHP water
Cells were sonicated with 10 pulses lasting 0.5 seconds at 50% power. Lysed cells 
were transferred to an eppendorf and pelleted at 13,000 r.p.m for 10 minutes. 
Supernatant was removed and protein concentration quantified as detailed in section 
2.10.2. Samples were then stored in aliquots at -80°C.
2.10.2 Protein Quantification
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 
5000006) as follows. A 2mg/ml bovine serum albumin (BSA) solution (Sigma, 
A9543) was prepared freshly in lysis buffer. A protein standard curve (0, 0.2, 0.4, 
0.6, 0.8 and l.Omg/ml) was prepared from the BSA stock with dilutions made in lysis 
buffer. The Bio-Rad reagent was diluted 1:5 in UHP water and filtered through 
Whatman paper before use. A 20(j.l volume of protein standard dilution or sample
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(diluted 1:20) was added to 0.98ml of diluted dye reagent and the mixture vortexed. 
After 5 minutes incubation, absorbance was assessed at 570nm. The concentration of 
the protein samples was determined from the plot of the absorbance at 570nm versus 
concentration of the protein standard.
2.10.3 SDS-PAGE
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). The stacking and resolving gels were prepared as 
illustrated in table 2.10.4.1. Gels were cast using the Atto rig system. It consists of 
two glass plates, one square and the other notched with two fixed 1.5mm spacers. A 
rubber seal is placed around the spacers and across the base of the notched plate. The 
other plate is placed on top of this and two clamps are placed on either side to create a 
tightly sealed mould for the pouring of polyacrylamide gels. The resolving gel is 
poured into the gel mould and allowed to set while covered with methanol. Once set 
the methanol is decanted and the gel is rinsed with UHP and subsequently stacking 
gel is poured. A comb was placed into the stacking gel after pouring in order to create 
wells for sample loading (maximum sample loading volume of 15-20/xl).
Table 2.6: Preparation protocol for SDS-PAGE gels (2 x 0.75mm gels).
Components 7.5% Resolving Gel 12% Resolving Gel 5%Stacking Gel
Acrylamide stock 3.8ml 6.0ml 0.8ml
UHP water 8.0ml 6.0ml 3.6ml
1.875 M Tris-HCl 
pH 8.8
3.0ml 3.0ml
1.25 M Tris-HCl 
pH 6.8
“ - 0.5ml
10% SDS 150|O.L 150|xL 50nL
10% NH4- 
persulfate
60fiL 50|o.L 17|xL
TEMED 9\iL 7.5|J,L 9|J,L
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The acrylamide stock in Table 2.6 consists of a 30% (29:1) ratio of acrylamide:bis- 
acrylamide (Sigma, A2792). The molecular weight markers (Biorad, C3437) and 
protein samples were heated to 95°C for 5 minutes. After heating, equal
amounts of protein (10-30fag) were added in to each well. The gels were run at 250V 
and 45mA until the bromophenol blue dye front was found to have reached the end of 
the gel, at which time sufficient resolution of the molecular weight markers was 
achieved. i
2.10.4 Western Blotting
Once electrophoresis had been completed, the SDS-PAGE gel was equilibrated in 
transfer buffer (25mM Tris (Sigma, T8404), 192mM glycine (Sigma, G7126), pH 8.3- 
8.5) for approximately 30 minutes. Six sheets of Whatman 3mm filter paper were 
soaked in freshly prepared transfer buffer. These were then placed on the cathode 
plate of a semi-dry blotting apparatus (Bio-rad). Air pockets were then removed from 
between the filter paper. Nitrocellulose membrane (GE Healthcare, RPN 303D), 
which had been equilibriated in the same transfer buffer, was placed over the filter 
paper on the cathode plate. Air pockets were once again removed. The gels were then 
aligned on to the membrane. Six additional sheets of transfer buffer soaked filter 
paper were placed on top of the gel and all air pockets removed. The proteins were 
transferred from the gel to the membrane at a constant current of 34mA 30-60 
minutes, until all colour markers had transferred.
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Following protein transfer, the membranes were blocked for 2 hours using 5% milk 
powder (Cadburys; Marvel skimmed milk) in PBS at 4°C. Membranes were treated 
with primary antibody in PBS/0.5% tween/5% milk powder overnight at 4oC under 
gentle agitation. Primary antibody was removed after this period and the membranes 
rinsed 3 times with PBS containing 0.5% Tween 20 (Sigma P1379) for a total of 30 
minutes. Secondary antibody (1 in 1,000 dilution of anti-mouse IgG peroxidase 
conjugate (Dako) in PBS, 1 in 2,000 dilution of anti-rabbit IgG (Dako) in PBS or, 1 
in 1,000 dilution of anti-rat IgG (Dako, P0450) in PBS) was added for 1.5 hour at 
room temperature. The membranes were washed thoroughly in PBS containing 0.5% 
Tween for 15 minutes.
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Primary Antibody 
Antigen
Specie
s
Conditions Supplier
HSPA5 Mouse 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
BD
TP53 Mouse 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
Oncogene
KRT8 Mouse 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
Sigma
KRT18 Mouse 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
Sigma
Sdc-2 Rabbit 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
Zymed
pi integrin Mouse 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
BD 1 1 1
alintegrin Rabbit 1/500 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
Chemicon
a5 integrin Rabbit 1/500 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
Chemicon
TS Mouse 1/500 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
ABCAM
GAPDH Mouse 1/10000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
ABCAM
GAPDH Rabbit 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
ABCAM
Gelsolin Mouse 1/1000 dilution, O/N, 5% 
Marvel/0.5% tween/PBS-A
ABCAM
Table 2.7 List of Primary antibodies, species, conditions, supplier.
2.10.5 Enhanced chemiluminescence (ECL) detection
Immunoblots were developed using an Enhanced Chemiluminescence kit (GE 
Healthcare, RPN2109) which facilitated the detection of bound peroxidase-conjugated 
secondary antibody.
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Following the final washing nitrocellulose membranes were dipped in 1:1 mixture of 
ECL reagents to ensure even coverage and were covered with an acetate sheet in a 
rolling action to ensure exclusion of air pockets. The membrane was then exposed to 
chemiluminescent film (Roche) for various times (from 10 seconds to 10 minutes 
depending on the signal). The exposed chemiluminescent film was developed for 3 
minutes in developer (Kodak, LX-24). The film was then washed in water for 15 
seconds and transferred to a fixative (Kodak, FX-40) for 5 minutes. The film was 
then washed with water for 5-10 minutes and left to dry at room temperature.
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2.11 Extracellular Matrix A dherence Assays
2.11.1 Reconstitution of ECM Proteins
Adhesion assays were performed using the method of Torimura et al. (1999). 
Collagen type IV (Sigma C-5533), fibronectin (Sigma F-2006) and laminin (Sigma L- 
2020) were reconstituted in PBS to a stock concentration of 500 (4,g/ml. Stocks were 
aliquoted into sterile eppendorfs. Fibronectin and collagen stocks were stored at - 
20°C, while laminin stocks were stored at -80°C. Matrigel (Sigma E-1270) was 
aliquoted and stored at -20°C until use. Matrigel undergoes thermally activated 
polymerisation when brought to 20-40°C to form a reconstituted basement membrane.
2.11.2 Coating of Plates
Each of the ECM proteins, collagen, fibronectin and laminin, was diluted to 25(j,g/ml 
while matrigel was diluted to lmg/ml with PBS. 250|xl aliquots were placed into 
wells of a 24-well plate. The plates were gently tapped to ensure that the base of each 
well was completely covered with solution. The plates were then incubated overnight 
at 4°C. The ECM solutions were then removed from the wells and the wells rinsed 
twice with sterile PBS. 0.5ml of a sterile 0.1% BSA/PBS solution was dispensed into 
each well to reduce non-specific binding. The plates were incubated at 37°C for 20 
minutes and then rinsed twice again with PBS.
2.11.3 Adhesion Assay
Cells were set up in 75 cm2 flasks and then harvested and resuspended in serum-free 
HAM’s F12 medium. The cells were then plated at a concentration of 2.5 x 104 cells 
per well in triplicate and incubated at 37°C for 15, 30 and 60 minutes. A blank 
control was included for each ECM protein and contained no cells. After each the 
specified elapsed time, the cell suspension was removed, non-adhered cells were
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removed by rinsing with PBS. Subsequently 250^1 of freshly prepared phosphatase 
substrate (lOmM p-nitrophenol phosphate (Sigma 104-0) in 0.1M sodium acetate 
(Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH 5.5) was added to each well. 
The plates were then incubated in the dark at 37°C for 2 hours. The enzymatic 
reaction was stopped by the addition of 1 0 0 (0.1 of 1M NaOH. 100|j.l aliquots were
transferred to a 96-well plate and read in a dual beam plate reader at 405nm with a
■:tr i ........ . *
reference wavelength of 620nm.
l i n > 0  » I • 1 f i
2.12 Invasion Assays
Invasion assay was performed using pre-cast Matrigel invasion chambers supplied by 
BD Biocoat™ Matrigel™ Invasion Chambers (BD Biosciences 354480) and invasion 
assays were performed as described by manufacturer. Briefly, Matrigel coated 
Boyden invasion chambers were reconstituted by addition of 500 (¿1 of DMEM into 
the boyden invasion chamber sits in a well of 24 well plate containing 750|j.L of 
DMEM media. The chamber was subsequently incubated for at least 2 hours at 37°C 
to ensure complete rehydration of matrigel. Cells to be analysed were harvested by 
trypsinisation and counted as described in sections 2.5.1 and 2.5.2, respectively. Cell 
pellets were resuspended and 1x10s cells were prepared in 500fil media per cell line. 
The DMEM media was removed from invasion chambers and wells and 750^1 of 
complete media was added to the well and cell suspension was added to Boyden 
chamber. Cells were incubated at 37°C for 24 and 48 hours depending on cell lines 
degree of invasiveness. After this time period, the inner side of the insert was wiped 
with a wet cotton bud (Johnson and Johnson) while the outer side of the insert was
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stained with 0.25% crystal violet for 10 minutes and then rinsed and allowed to dry. 
The inserts were then viewed under the microscope. The numbers of invasive cells 
were counted using a microscope equipped with a raticule. A total of 5 raticule fields 
were counted per biological replicate at 1 Ox magnification and the average number of 
cells for this area was determined. No FCS gradients or chemoattractants were used to 
stimulate invasion. The non-invasive cell line MCF-7 and highly invasive cell line 
A549 were used as a negative and positive invasion controls.
2.13 Motility Assay
Motility assays were carried out by the addition of 100fj.l of media containing 1x105 
cells into a non-coated boyden invasion chamber (BD biosciences 351154) and were 
incubated for 48 hours at 37°C. bumber of motile cells were quantified at described in 
section 2.14.
2.14 Proteomics
2.14.1 Chemicals
The N-hydroxy succinimidyl ester-derivatives of the cyanine dyes Cy2, Cy3, and 
Cy5, immobilised pH gradient strips and Ampholytes were purchased from GE 
Healthcare. Urea and iodoacetamide were bought from Fluka Chemical Corp 
(Milwaukee, WI). All other reagents were supplied by sigma.
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2.14.2 Protein Preparation for 2D-elctrophoresis
2.14.2.1 Total cell lysate Proteome Preparation
Cells for 2D analysis were removed from adherent culture by trypsinisation. Trypsin 
was neutralized by addition of media, and cells were subsequently washed twice in 
cold PBS and twice with cold sucrose-tris (lOmM sucrose, lOOmM Tris, pH 8 ) buffer. 
Cells were lysed using a buffer containing (4% (w/v) CHAPS, 7M urea, 2M Thiourea, 
10 mM Tris-HCl, 5mM Magnesium Acetate pH 8.5 plus DNase) at concentration of 3 
x 107 cells per ml. Cells were passed through a 18 gauge syringe until solution 
become homogenous and non-viscous and was incubated at room temperature for 1 
hour. Insoluble material was removed by centrifugation at 14,000 rpm for 20 min at 
10°C. Protein concentration was determined using the Bradford protein assay kit 
(Biorad).
2.14.2.2 Membrane fractionation
The fractionation process for the isolation of hydrophobic proteins from the cell lines 
DLKP and its subpopulations was carried out using ReadyPrep™ Protein Extraction 
Kit (Membrane I) (Biorad). Samples were prepared as previously described in section
2.5.3 and were lysed in a solution containing 2% precondensed Triton X-l 14 in TBS 
(150mM NaCl, lOmM Tris-HCl, pH 7.6) and was incubated for 15 minutes in ice. 
Samples were centrifuged at 10,000 x g for 10 minutes and the supernatant was 
collected and incubated at 37°C. The cloudy solution obtained was centrifuged at 
1000 x g for 10 minutes. This caused the formation of two liquid phases. The lower 
liquid phase was collected and is enriched in hydrophobic proteins. Proteins were 
precipitated using cold acetone. The fractionation process follows Santoni et al., 
(2000) protocol for the extraction of membrane proteins. Dr. Andrew Dowd carried 
out this fractionation process.
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2.14.3 Cy Dye labelling for 2D-DIGE
Cell lysates prepared as described in section 2.17 were labelled with N-hydroxy 
succinimidyl ester-derivatives of the cyanine dyes Cy2, Cy3, and Cy5 as follows. 
Typically, samples yielded 2-10 ng/|iL protein and 50 fig of protein from total cell 
lysate or 25 ng of protein from membrane fractionation was minimally labelled with 
l|iL  solution containing 200 pmol of either Cy3 or Cy5 per 50|j,g of protein for 
comparison on the same 2D gel. Labelling reactions were performed on ice in the 
dark for 30 mins and then quenched with a 1 (j,L of lOmM free lysine per 200pmol of 
Cy Dye for 10 mins on ice. A pool of all samples was also prepared and labelled with 
Cy2 to be used as a standard on all gels to aid image matching and cross-gel statistical 
analysis. The Cy3 and Cy5 labelling reactions (50 |ig of each) from each lysate were 
mixed and run on the same gels with an equal amount (50 (ig) of Cy2-labeled 
standard (Alban et al., 2003). In each 2D-DIGE experiment a total of 3 biological 
replicates were used for each group. Each biological replicate was run as technical 
duplicates.
2.14.4 2D-electrophoresis and imaging of 2D-DIGE gels
Immobilized 18cm linear pH gradient (IPG) strips, pH 4-7, were rehydrated in 
rehydration buffer (7M urea, 2M Thiourea, 4% CHAPS, 0.5% IPG Buffer, 50 mM 
DTT) overnight, according to the manufacturers guidelines. Isoelectric focusing was 
performed using an IPGphor apparatus (GE Healthcare) for a total of 48 kV/h at 
20°C, 50 mA. Strips were equilibrated for 20 mins in 50 mM Tris-HCl, pH 8 .8 , 6  M 
urea, 30% (v/v) glycerol, 1% (w/v) SDS containing 65 mM DTT and then for 20 mins 
in the same buffer containing 240 mM iodoacetamide. Equilibrated IPG strips were
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transferred onto 18 cm x 20 cm 12.5% uniform polyacrylamide gels poured between 
low fluorescence glass plates. Strips were overlaid with 0.5% (w/v) low melting point 
agarose in 2x running buffer containing bromphenol blue. Gels were run using the 
Ettan Dalt 6  or Ettan Dalt 12 (GE Healthcare) at 2.5 W/gel for 30 mins then 100 W in 
total at 10°C until the dye front had run off the bottom of the gels. All the images 
were collected on a Typhoon 9400 Variable Mode Imager (GE Healthcare).
2.14.5 Statistical analysis and image processing of 2D-DIGE gels
Images collected of 2D-DIGE gels were were examined in Image Quant Tool Box
(GE Healthcare) to ensure images were not saturated. Subsequently images were 
cropped to remove area of gel that does not contain protein spots and cropping area 
was aligned with a reference protein spot for consistant cropping between gels. 
Statistics and quantification of protein expression were carried out using Biological 
Variation Analysis (BVA) a component of Decyder software (GE Healthcare). Images 
were manually inspected to ensure accurate spot matching between gels. Generation 
of protein pick lists for identification using MALDI-ToF MS were determined using 
filters are described per experiment in section 3.0.
2.14.6 Preparation of plates for spot picking
Low fluorescent plates were polished with lint free wipes soaked in methanol and 
allowed to dry at room temperature for 10 minutes. During this time the Bind-Silane 
solution was prepared and is composed of the components listed in table 2.8. A 
volume of 1.5ml of this solution was pipetted onto one side of each low fluorescent 
plate using a Pasteur pipette. The solution was spread over each plate using a fresh 
lint free swab. Plates were placed in a rack and covered with a sheet of aluminium foil
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to prevent dust particules adhering to surface of plates and were allowed to dry for at 
least 90 minutes. Plates were again polished with methanol and allowed to dry for 10 
minutes. Low fluorescent plates were placed together with its accompanying spacer 
plate with the bind-silane surface in contact with the spacers on the spacer plate. 
Plates were then placed in the DALT 6  or DALT 12 as described in section 2.19. For 
preparative gels protein samples were prepared as described in section 2.19. A total of 
300fxg of protein was loaded on to each preparative gel. Loading of protein samples 
onto IEF strips was the same as with loading of labelled proteins described in section 
2.19 with one exception. No 2X running buffer was added to protein solutions prior to 
addition to IEF strips.
Table 2.8: Components of Bind Silane solution
Reagent Quantity
Ethanol 8  ml
Glacial Acetic acid 2 0 0  nl
Bind-silane 1 0  Hi
double distilled H20 1 . 8  ml
Total volume ~ 1 0 ml (enough for 6  gels)
2.14.7 Colloidal staining of 2D-Gels, imaging, and spot matching to BVA
Preparative 2D gels prepared as described in section 2.21 were removed from the
DALT 6  or DALT 12. The spacer plates were removed from the plate/Gel sandwich 
using wedging action with a “wonder wedge” (GE healthcare). The spacer plate was 
removed for cleaning later. The polyacryamide gel fixed to the low fluorescent plate 
was allowed to fix in a solution of 7% glacial acetic acid, 40% methanol for at least 
60 minutes in a plastic container under agitation. Brilliant Blue G-Colloidal 
concentrate (Sigma B2025) was diluted in UHP water at ratio of 1:4 to give a final 
volume of 11 and was mixed by inversion of bottle. Immediately before staining the
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colloidals were activated by addition of 100ml of methanol to 400ml of diluted 
solution. This solution was mixed with severe agitation for 30 seconds as it is 
important in order to activate colloidals. The fixing solution was removed from gel 
and activated colloidal solution waspoured onto gel. Gels were allowed to stain for 1- 
4 hours under vigorous agitation. Staining was complete when gel appears dark blue 
and highly abundant protein spots are clearly visible. Decant colloidal staining 
solution into 1L Duran bottle. Gel and container were quickly rinsed with UHP water 
to remove as much colloidal staining solution as possible. Destaining solution 
composed of 10% acetic acid, 25% methanol and 65% UHP water (v/v) was poured 
onto gel in container and was agitated for 30 seconds. The gel was rinsed with 25% 
methanol and allowed to destain in 25% methanol for up to 24 hours. Residual 
colloidal precipitate was removed by wiping swab soaked in 25% methanol. 
Destaining was stopped as soon as gel background became clear. Two reference 
marker stickers were placed on the back of the plate and the plate was scanned using 
Lab Scan software. The image was imported into Image Master and spots were 
detected. Location of reference markers was assigned (IR1 for left reference marker 
and IR2 for right reference marker). Using a printed image of the master gel from the 
BVA experiment were the locations of pick proteins are indicated the locations of 
proteins colloidal gels that were found to be of interest were selected for robotic 
picking. See section 2.26 for robotic picking of spots.
2.14.8 Synthesis of Ruthenium (II) tris bathophenanthroline Bisulphonate 
(RuPBS)
The fluorescent dye RuPBS was synthesised as described by Rabilloud et al.t (2001 
and 2000). For the synthesis of RuPBS 0.5 g of potassium pentachloro aquo ruthenate
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(26.9% Ru) was dissolved in 50 ml boiling water and kept under reflux, resulting in a 
deep red-brown solution. Three molar equivalents of 1 ,10-phenthroline monohydrate, 
were added and the refluxing continued for 20 min. The solution turned to a deep 
greenish brown. Meanwhile, a reducing solution containing 12 mM of sodium 
hydroxide and 8  mM of phosphinic acid (Fluka) in 10 ml water was prepared. This 
solution was then added to the refluxing mixture and refluxing was continued for 
another 20 min. The solution turned to a deep orange-brown. After cooling, the pH 
was adjusted to 7 with sodium hydroxide and the volume was adjusted to 65 ml with 
water. This gives a 20 mM stock solution, which can be stored in the fridge for 
several months. RuPBS was synthesized with the assistance of Mr. Gavin Sewell 
(Chemistry).
2.14.9 RuPBS staining of 2D gels, imaging, and spot matching to BVA
Preparative 2D gels prepared as described in section 2.21 were removed from DALT
6  or DALT 12. The spacer plate was removed from plate/Gel sandwich using wedging 
action with a “wonder wedge” (GE healthcare). The spacer plate was removed for 
cleaning later. The polyacryamide gel fixed to the low fluorescent plate was allowed 
to fix in a solution of 7% glacial acetic acid, 40% methanol for at least 60 minutes in a 
plastic container under agitation. Staining solution of 123ml of 0.2M acetic acid, 27ml 
of 0.2M sodium acetate, 120ml ethanol, 120ml Glycerol, 3ml Tween and the volume 
was adjusted to 600ml by the addition of UHP water. A volume of 15fj,l of RuPBS 
stock was added to this solution and the mixture was inverted several times to aid 
mixing. The fixing solution was removed and staining solution was poured on to the 
gel and allowed to stain for 4 hours or overnight under gentle agitation. The 
destaining solution was composed of 123ml of 0.2M acetic acid, 17ml of 0.2M
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sodium acetate, and 1 2 0 ml of ethanol, the volume was adjusted to 600ml by the 
addition of UHP water. Destaining was performed using 2 washes with the destaining 
solution for 4 hours each or 4 hours and an overnight destain. Two reference markers 
were placed on the back of the low fluorescence plates and gels were scanned at 
excitation wavelength of 488nm and emission wavelength of 605nm using the 
Typhoon 9400 scanner. Images were imported into Image Quant and cropped 
appropriately. A single gel DIA file was created for the detection of spots and 
reference marker locations were assigned. Spot map was exported and imported into 
the BVA file created for the DIGE experiment for which the preparative gel was part 
of. Matching mode was selected in the BVA experiment file and landmark mode was 
activated. Obvious highly abundant spots present in distinct protein patterns were 
matched manually in this mode. The software was then instructed to match image to 
experiment using these landmarks. Pick spots were displayed in match mode gel 
images by alteration of image preferences. Matching of these proteins spots between 
DIGE images prep gel images were checked individually and proteins that were 
matched incorrectly were corrected. Where the correct spot could not be found the 
spot was left unmatched. Pick list was then exported to Spotter. See section 2.26 for 
spot picking.
2.14.10 Pro-Q diamond staining of 2D gels, imaging, and spot matching to
BVA
Preparation and running of 2D gels is the same as described in section 2.24 with the 
following additional step. Peppermint stick (Molecular Probes) phosphoprotein ladder 
was prepared by the 1:4 parts dilution in 2x running buffer and was subsequently 
boiled for 5 minutes. A piece of filter paper of dimensions lcm+/-0.5 x 3cm was cut. 
A volume of 5(il diluted ladder was added to filter paper and using a forceps was
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placed next to IEF strip on top of gel. Agarose solution was applied and second 
dimension separation was completed as described in section 2.21. After completion of 
2D electrophoresis the spacer plate was removed from the plate/Gel sandwich using 
wedging action with a “wonder wedge”. The spacer plate was removed for cleaning 
later. Gels were fixed with two 30 minute fixation steps with a solution of 40% 
methanol, 10% acetic acid made to a volume of 500ml using UHP water. Gels were 
washed three times with 500ml UHP and stained for 2-hours in 400ml of Pro-Q® 
Diamond phosphoprotein gel stain (Molecular Probes) solution. Gels were then 
destained with three 30 minute washes with Pro-Q diamond Destain Solution. Gels 
were washed in two 5 minute washes with UHP water to rehydrate gels and were 
scanned with the typhoon 9400 scanner at excitation wavelength of 532nm and 
emission wavelength of 560nm. Gel destaining was confirmed by analysis of phospho 
protein ladder. Properly destained gels display only two phospho protein bands in the 
Peppermint stick phosphoprotein ladder. The image was appropriately saved and the 
gel was counter stained with RuPBS as described in section 2.24. (The phospho­
protein specific stain, Pro-Q diamond, is reported by manufacturer to be compatible 
with mass spectrometry techniques used for the identification of proteins. Thus such 
gels can be used as preparative gels and were found to give superior spectra to other 
techniques). Both fluorescent images were cropped using image quant, and a double 
image DIA file was created. Images were processed and imported into BVA as 
described in section 2.24. The RuPBS stained gel image was matched to BVA as 
described in section 2.24. Spots that appeared on picklist that appeared on both Pro-Q 
diamond stained gels and RuBPS stained gels were marked as phosphorylated.
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2.14.11 Spot picking of protein spot gel plugs from 2D-Gels
Preparative gels stained as described in sections 2.21, 2.22 and 2.23 were placed in
plate holder on the Ettan spot picker robot (GE Healthcare). Plates were positioned so 
that reference markers would appear between the two white strips on plate holder. The 
plate was secured in position by positioning of clamps on edges of plates and 
tightening of screws. The solution inlet pipe was removed form the 70% methanol and 
placed in UHP water. The robot was powered up and the syringe was primed 10 times 
to replace methanol with UHP water. The pick lists generated were imported into spot 
picker software and the robot was instructed to automatically detect the reference 
markers. Upon detection of reference markers the instrument instructs the user to 
insert an appropriate number of microtitre plates in to robot. Once this done a file 
directory is created which allows tracking of spots when transferred to the Digester 
robot and Spotter robot (GE Healthcare). Upon completion of gel picking gels can be 
scanned with relevant process to ensure picking was done accurately. Microtitre plates 
containing gel plugs were sealed with foil wrapping and were stored at 4°C until they 
were ready for digestion.
2.14.12 Destaining of gel plugs and protein digestion
Plates ready for digestion were placed in appropriate positions in Robot digester. The
files corresponding to microtitre plates placed in robot that were created in the spot 
picker robot were uploaded into robot. The UHP water surrounding gel plugs was 
removed, and destained for three 20 minute washes with 70% methanol 0.1% TFA. 
Gel plugs were dehydrated by 2 washes with 50% acetonitrile. They were allowed to 
aspirate for 1 hour. After 30 minutes of aspiration the Trypsin Gold, Mass 
Spectromoetry Grade (Promega V5280) was prepared. The trypsin was reconstituted 
by addition of 2 0 0 (4.1 of acetic acid buffer supplied by manufacturer. The solution was 
allowed to stand for 5minutes. Subsequently, 1.4ml of 40mM Ammonium
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Bicarbonate, 10% Acetonotrile in MS grade water is added to this 200(J,1 of activated 
trypsin to give a final concentration of lOug/ml. This solution is vortexed and 
dispensed equally amongst the 8  disposible plastic trypsin tubes (GE Healthcare). 
These tubes containing the trypsin are then placed in the robot in the appropriate 
position. Once at least 60 minutes of aspiration of gel plugs is complete and trypsin is 
prepared the robot was instructed to dispense 1 0 |j,l ot trypsin solution on top of each 
gel plug. The Microtitre plates were then wrapped in foil and incubated at 37°C
t ) \ v' 11; , . * ' i
overnight.
The following day the microtitre plates were removed from incubator and are placed 
in digester robot as previously described. An equal number of microtitre plates were 
prepared, labelled, and placed in appropriate extraction positions in robot. The robot 
was instructed to transfer piptides to the clean microtitre plates. This process involved
20 minute incubation at room temperature in 60j j .1 of 50% acetonitrile, 0.1%TFA and 
49.9% MS grade water, which is transferred in to extraction plate, followed by a 
second extraction cycle of 70(j.l of same solution for 20 minutes, which was transfered 
into same well as before. Upon transfer of protein digests to fresh microtitre plate the 
plates were placed in a speedvac for 60 minutes in order to desiccate peptide. Once 
solvent was observed to have vaporised completely plates were transferred to the ettan 
robot spotter.
4.14.13 Identification of differentially expressed proteins using MALDI- 
ToF Mass spectrometry
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2.14.13.1 Preparation of MALDI-ToF slides
MALDI-ToF slides were prepared by scrubbing with detergent, rinsing with UHP 
water, submerged in ethanol in a beaker and sonicated for two 30 minute intervals in a 
sonicator bath where ethanol was replaced between sonications. Slides were stored 
submerged in ethanol in a 50ml universal. Immediately prior to use slides were placed 
on to lint free tissue and allowed to aspirate until dry, and were subsequently inserted 
into MALDI-ToF trays using a forceps. Powder free gloves were worn at all times to 
maintain clean slides.
2.14.13.2 Mass spectrum analysis
Proteins digests (prepared as described in section 2.25) were spotted on to MALDI- 
ToF slides using sandwich technique. The sandwich technique involves the spotting 
of each slide with 0.3fjl of 7.5mg/ml CHCA in the spotting solution (composed of 
50% acetonitrile, 0.5% TFA and 49.5% MS grade water) and was allowed to aspirate 
for 10 minutes. Peptides created as described in section 2.26 were resuspended in 3/j.I 
of spotting solution and 0.3 |al was spotted on top of dried CHCA on MALDI-ToF 
slide. Immediately after this addition 0.3|xl of CHCA solution was added to and mixed 
peptide solution. This was allowed to aspirate for a further 10 minutes before insertion 
into the MALDI-ToF MS (GE Healthcare). A vacuum of 1.98x1 O'9 pa was pulled and 
the spotted peptide-CHCA mix was hit by a laser causing peptide ionisation. The 
conditions are so that each peptide is singly charged upon ionisation. The peptides 
being singly charged were attracted to the opposite end of the time of flight tube. 
Since the charge is one on each peptide the mass of the peptide can be determined by 
the time it takes for the peptide to reach the detector at the other end of the tube. A
typical peptide peak generated by this process is shown in figure 2.1. A peptide peak 
appears as a series of peaks differing by one mass unit and atomic isotopes of carbon, 
hydrogen and nitrogen create this phenomenon, however, carbon isotopes 
predominantly cause this. This information is vital during mass spectrometry as it 
allows the user to distinguish between peaks created by peptides and those created by 
non-peptides such as matrix or chemical contaminants.
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However, before proteins can be identified it is important to calibrate the Mass
spectrometer in order to assure accurate mass detection. To do this a mixture of 4 
peptides of known mass (referred to as Pep 4 mix (Lose Biolabs)) were used to 
calibrate the instrument. Their masses are listed below in table 2.9. Peptides between 
800 and 2500 mass units are predominantly used for identification and thus during 
calibration peptides of the Pep 4 mix that occur in this region are used for calibration 
purposes and are indicated in table 2.9.
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Table 2.9: The table lists the components of Pep 4 mix and masses. The peptides used 
to calibrate the instrument are indicated.
Peptide Name Mass Used for calibration
Angiotensin 2 1046.542 Yes
Nuerotensin 1672.918 Yes
ACTH fragment 18-39 2456.199 Yes
Insulin B chain oxidized 3494.651 No
Displayed in figure 2.2 is a typical mass spectrum generated by Pep 4 mix used for 
calibration. Automatic calibrations were checked to ensure the software had detected 
the correct peaks.
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Figure 2.2: A mass spectrum generated by Pep 4 mix used for initial calibration o f the MALDI- 
Tofmass spectrometer.
This calibration is saved as system calibration and is used to accurately measure the 
peptides measured in subsequent spectra generated on same slide.
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For each spectra generated a total of 358 individual spectra are collected, the intensity 
of each spectra are combined together by addition to create an accumulation spectra. 
A total of 3 accumulated spectra were created for each spotted peptide-CHCA mix. 
Calibration can be lost with progression of analysis, to further ensure accuracy of 
mass spectra the use of internal calibration was used to enhance mass accuracy. 
Trypsin eventually digests itself during the tryptic digestion process and this creates 
several peptide peaks that can be used to calibrate individual spectra. Figure 2.3 
demonstrates the most common trypsin peaks that may occur in a given mass 
spectrum. There are three commonn trypsin peaks that result from trypsin self 
digestion but they may not occur in every spectra and their occurrence depends upon 
the amount of protein being digested, the abundance of ionisable peptides and the 
degree of digestion. These products have a m/z of 854.564, 1046.509 and 2211.104
The software automatically searches and identifies trypsin peaks but these can often
83
be missed or incorrectly identified and thus it is important to inspect each spectra’s 
calibration.
Once calibration is completed to satisfaction processing of spectrum for protein 
identification can commence. The software automatically detects and processes the 
peaks and gives an expectation score for the protein being correctly identified. A 
spectrum resulting from digestion of the protein BiP/GRP78 is presented in figure 2.4. 
An expectation score of less than 0.01 is the cut off for protein identification. It is 
important to inspect a spectrum at this point as the software can miss peaks and they 
may need to be manually imputed. The criteria for peak detection is as follows; 
Algorithm centroid, Mass range 800-3500m/z, mono isotopic cut-off 3000m/z mass 
tolerance 0.2m/z and Average peak 1 m/z. Average peaks are peaks that display 
peptide pattern but are poorly resolved and the average of all those peaks are used to 
determine
The laser intensity and the laser target location can be adjusted by user. Adjustment of 
these paramenters is generally unnesseccary as the software automatically searches 
and adjusts laser intensity to create the optimal conditions for accurate mass specta 
accumulation. However on occasion under certain circumstances these parameters 
need to be manually controlled. Such instances occur when a spectrum contains far 
too many peaks which the software can confuse with the background, more often than 
not is fails to collect a spectrum and the mass spectra accumulation needs to be 
controlled manually. Digestion of low molecular weight proteins results in a mixture 
of 5-20 peptides. On occasion one or two peptides ionise more readily than the others 
and can generate peaks with high intensities. The software reduces the laser intensity 
and thus appearance of other peaks is often missed. In such occasions mass spectrums
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collected are manually controlled. Laser intensity in increased until a low level 
background is observed. Spectrum accumulation is then allowed to continue.
ft
Figure 2.4: A mass spectrum generated by tryptic digestion of BiP/GRP78. Black 
numbers above each peak indicates locations of peptide peaks in the amino acid 
sequence of the protein BiP.
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Protein identification using MALDI-ToF MS results in the identification of a protein 
with a gene index accession number. “Gene index accession number” for proteins 
were converted to “gene symbol” using DAVID database ID conversion tool 
(http://niaid.abcc.ncifcrf.gov/). Not all gene index accession numbers can be 
converted in this way as some identifications refer to proteins that may be poorly 
annotated or simple not updated in the database. In such instances the protein name 
was inputted into swissprot database fhttp://www. expas v. ore/sprat/) and the human 
protein reference database (www.hprd.org) and the gene symbol was found. In other 
instances where the protein could not be found in either of the above databases the 
protein sequence was blasted on the NCBI database using the protein blast tool. 
Proteins that were found to be 100% identical were used to identify the gene symbol. 
Such proteins names appear as unknown and the gene symbol found by protein 
blasting is adjacent to MALDI-ToF identification.
Lists of Gene symbols were imported into Pathway assist. Direct interactions and 
common pathways were identified using this software. Phosphorylation data was 
obtained from the human protein reference database. Enzyme location in metabolic 
pathways sources from the KEGG website
(www.genome.ad.jp/kegg/metabolism.html).
2.14.13.3 Bioinfomatic processing of Proteomic data
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2.15 Statistical Analysis
Significance of data presented in section 3.0 was determined using 2 tailed T-tests 
with 2  unpaired samples with unequal variance.
T-tests were performed on invasion and toxicity assays in order to determine if data 
was significant
A t-test > 0.05 was deemed not significant 
A t-test < 0.05 was deemed significant
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3.0 Results
3.1 Analysis o f 5-FU treatments
The fluoropyrimidine antimetabolite drug 5-FU is used in the treatment of a wide 
variety of cancers. It exerts its effect through inhibition of TS activity and inhibition 
of de novo synthesis of DNA and incorporation of fluoropyrimidine derivatives into 
RNA and DNA. These result in the inhibition of cell growth and the eventual 
induction of apoptosis. Understanding how cells respond at a proteomics level is 
poorly described in the literature and thus identifying molecular mechanisms induced 
by growth inhibition is key to understanding the mechanisms induced which 
contribute to cell survival and possible altered phenotypes. To assess this 5-FU 
treatment of the lung adenocarcinoma, A549, the NSCLC, DLKP, the lung normal 
bronchial epithelial cell line NHBE, the breast adenocarcinoma, MCF-7, and the 
normal mammary epithelial cell line, HMEC, were assessed to determine the drug 
concentration of 5-FU that would induce an inhibition of growth by at least 80% over 
a 7 day period. Using this drug concentration drug resistance and invasion rates were 
assessed post 5-FU treatment. Protein was prepared at day 7 of the 5-FU treatment 
from each cell line in biological triplicates and an exponentially growing untreated 
control was collected simultaneously. Protein preps were then prepared for the 
purposes of expression profiling using Cy dye labelling of protein preps and separated 
using 2D electrophoresis a process referred to as two dimensional difference gel 
electrophoresis (2D-DIGE).
89
3.1.1 Growth inhibition induced by 5-FU
In order to assess the anti-proliferative effect of 5-FU it was necessary to determine 
the concentration at which 5-FU induces an inhibition of growth. An exposure time of 
7 days was selected as it was found to induce differentiation effects in DLKP and 
A549 with similar drugs. The treatment regime involved the replacement of media 
with drug supplemented media every 2-3 days. For experimental consistency 5-FU 
supplemented media was replaced on days 2, and 4 of treatment regime (see section 
2.7.3). Figures 3.1.1 -  5 demonstrate that the concentration of 10|iM inhibited the 
growth of 5-FU by approximately 80-90%. The normal cell experiments included the 
additional concentration of 30|xM 5-FU as cells appeared to be as healthy 
microscopically as those exposed to 10(jM for 7 days and yielded similar cell 
numbers. In addition the pharmakokinetics of normal cells is different to that of 
cancer cells. Specifically cancer cells in vivo generally require a higher amount of 
uracil than normal tissue {Rutman, et al„ 1954}and thus 5-FU influx rates would be 
expected to be higher in cancer than normal cells. However, this may not be evident in 
vitro as cells are allowed to grow exponentially and there requirement for uracil may 
be equivalent. Figures 3.1.1-5 show that indeed inhibition of growth is comparable 
between cell lines and suggests that 5-FU consumption rates are related to 
proliferation and not disease status.
Growth post 5-FU exposure (10|xM for 7 days) was assessed in order to determine if 
cancer cell lines become senescent or apoptopic. Figures 3.1.6-8 demonstrates that all 
cell lines display an initial decrease followed by a gradual increase in cell number. 
A549 displays the quickest recovery. All cancer cell lines appear to increase cell 
number by day 7. Normal cell lines were not assessed. Normal cell lines can only be 
cultured for 2 0  doublings and cell division beyond this time point is not guaranteed. 
Proteomic analysis requires a large amount of cell to generate a sufficient protein 
mass for 2D-DIGE and protein identification. In light of these difficulties invasion 
was only assessed at day 7 of 5-FU treatment.
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Figure 3.1.1: Number of cells harvested after exposing A549 cells for 7 days at 
various 5-FU concentrations. The concentration of IO^ iM induces an inhibition of 
growth.
Inhibition of cell growth is inhibited by 90% in A549 by treatment with 10^M over a 
7 day treatment with 5-FU. The growth inhibition curve enters a plateau at IOjiM and 
would suggest inhibition of cell growth in the majority of cells per flask. A 
concentration of 3-4|j,M 5-FU induces a growth inhibition by 50%.
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Figure 3.1.2: Number of cells harvested after exposing DLKP cells for 7 days at 
various 5-FU concentrations. The concentration of 10|iM induces an inhibition of 
growth.
Inhibition of cell growth is inhibited by 80% in DLKP by treatment with 10(xM over a
7 day treatment with 5-FU. The growth inhibition curve enters a plateau at 10(iM and 
would suggest inhibition of cell growth in the majority of cells per flask. DLKP 
appears to have a higher tolerance to 5-FU than A549. A concentration of 6-7|^M 
induces a 50% growth inhibition in DLKP an approximate 2 fold increase in tolerance 
to 5-FU in DLKP over A549.
92
120
110
□ ----------------------- 1------------------------1------------------------» 1 1 » »
0 5 10 15 20 25 30 35
5-FU concentration (mlcrsM)
Figure 3.1.3: Number of cells harvested after exposing NHBE cells for 7 days at 
various 5-FU concentrations. The concentration of 10|iM induces an inhibition of 
growth.
Inhibition of cell growth is inhibited by 80% in NHBE by treatment with IOjiM 5-FU 
over a 7 day treatment. The growth inhibition curve enters a plateau at lO^M and 
would suggest inhibition of cell growth in the majority of cells per flask. Curve would 
indicate that 5|aM 5-FU induces a 50% inhibition of growth suggesting NHBE to be 
slightly more tolerant than A549 but less tolerant than DLKP to 5-FU treatment. 
NHBE appears to be similarily tolerant to 5-FU as DLKP and shows a higher 
tolerance to 5-FU than A549. However it should be noted that this graph contains 
limited data points due to limited supply of NHBE cells.
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Figure 3.1.4: Number of cells harvested after exposing MCF-7 cells for 7 days at 
various 5-FU concentrations. The concentration of lOpM induces an inhibition of 
growth.
Inhibition of cell growth is inhibited by 90% in MCF-7 by treatment with 10^M over 
a 7 day treatment with 5-FU. The growth inhibition curve enters a plateau at 10|iM 
and would suggest inhibition of cell growth in the majority of cells per flask. Growth 
inhibition of 50% is induced by 2-3|xM 5-FU and would suggest that MCF-7 is least 
tolerant to 5-FU of all cell lines.
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Figure 3.1.5: Number of cells harvested after exposing HMEC cells for 7 days at 
various 5-FU concentrations. The concentration of 10|xM induces an inhibition of 
growth.
Inhibition of cell growth is inhibited by 80% and 90% in HMEC by treatment with 10 
and 30 jiM, respectively, over a 7 day treatment regime. The growth inhibition curve 
enters a plateau at IOjiM and would suggest inhibition of cell growth in the majority 
of cells per flask. A concentration of 5|xM 5-FU induced growth inhibition by 50% 
and would suggest that HMEC is more tolerant to 5-FU than MCF-7. However it 
should be noted that this graph contains limited data points due to limited supply of 
HMEC cells.
95
0 1  2 3 4  6 6  7 8 9  10 11
Days paat 5-FU treatment
Figure 3.1.6: Growth curves of A549 and A549 post 5-FU treatment over a 10-day 
period (Gridiine factor 50000).
A549 appears to begin proliferating 6  days post 5-FU treatment. Thus toxicity assays 
may be set up after this time point in order to determine alterations in drug resistance.
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Figure 3.1.7: Growth curves of DLKP and DLKP post 5-FU treatment over a 10 day 
period (Gridiine factor 50000).
DLKP appears to begin proliferating 6  days post 5-FU treatment. Thus toxicity assays 
may be set up after this time point in order to determine alterations in drug resistance.
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Figure 3.1.8: Growth curves of MCF-7 and MCF-7 post 5-FU treatment over a 10 day 
period (Gridiine factor 50000).
MCF-7 appears to begin proliferating 6  days post 5-FU treatment. Thus toxicity 
assays may be set up after this time point in order to determine alterations in drug 
resistance.
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Summary of growth curves during and post 5-FU treatment
Growth was inhibited between 80-90% in all cell lines by the concentration of 10|iM. 
The normal cell lines of the breast and lung displayed higher tolerance in general 
when compared to the adenocarcinomas of the breast and lung. Due to this the 30jxM 
treatment of normal cell lines was included in the proteomic analysis and invasion 
analysis post treatment where available in order to investigate the effect of similar 
toxicity. This would allow a comparison between between normal and cancer cells at 
similar toxicities. All cancer cell displayed recovery of cell growth at 7 days post 
treatment.
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3.1.2 Altered adherence by 5-FU
Previous work performed using the other halogenated pyrimidines modulated the 
adherence profiles in DLKP and A549 to the ECM proteins collagen type IV, 
fibronectin and laminin (O’ Callaghan, M., unpublished). Specifically BrdU was 
found to induce increased adherence in DLKP and A549 to these substrates and this 
found to induced by the post-transcriptional upregulation of (X2 and Pi integrin 
subunits (Meleady, M., et al., 2001). Figures 3.1.9-11 shows that 5-FU effected the 
adherence profile in only A549. Specifically it induced increased adherence to 
collagen type IV and Laminin. Normal cells were not analysised due to the limited 
number of cells.
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Figure 3.1.9: Adherence profile in A549 and A549 after 7 days exposure to 5-FU to 
the extracellular matrix proteins collagen type IV, Fibronectin and Laminin over a 
time period of 15, 30 and 60 minutes.
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Figure 3.1.10: Adherence profile in DLKP and DLKP after 7 days exposure to 5-FU 
to the extracellular matrix proteins collagen type IV, Fibronectin and Laminin over a 
time period of 15, 30 and 60 minutes.
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Figure 3.1.11: Adherence profile in MCF-7 and MCF-7 after 7 days exposure to 5-FU 
to the extracellular matrix proteins collagen type IV, Fibronectin and Laminin over a 
time period of 15,30 and 60 minutes.
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3.1.2 Altered drug resistance to 5-FU, 55FdU, Adr and BrdU post 5-FU 
exposure in the cell lines A549, DLKP and MCF-7.
In vitro experiments have demonstrated that exposure to 5-FU results in the short­
term sensitisation to 5-FU (). In order to assess if 5-FU sensitisation occurs in this 
model, drug resistance was assessed up to 21 days post 5-FU exposure. The data in 
presented in table 3.1.1 and shows that A549 displays a resistance to 
halogenpyrimidines and a slight sensitisation to Adr by 7 days post treatment, by day 
14 there is no significant differences in drug treatment and by day 2 1  post treatment 
there appears to be a significant resistance to Adr. DLKP shows a general 
sensitisation and may be a result of low proliferation rates at this time point as can be 
seen from figure 3.1.7, by 21 days post treatment DLKP displays a significant 
resistance to the fluoropyrimidines. MCF-7 shows a sensitisation to 5-FU but not to 
Adr which suggests that sensitisation is due to a drug specific mechanism. Normal 
cells were not assessed to due limited number of cells and due to associated problems 
of high doublings in normal cell lines.
In summary A549 shows a transient resistance to the fluoropyrimidines which is lost 
after 7 days post treatment, DLKP appear to show resistance to the fluoropyrimidines
21 days post treatment and MCF-7 shows a sensitisation to fluorouracil 14 days post 
treatment but has not been determined to be transient/stable. The fold changes are 
small al may not be significant.
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Table 3.1.1: Drug resistance profiles in A549, DLKP and MCF-7 at specific time 
points post 5-FU exposure to chemotherapeutic and anti-metabolite drugs 5-FU,
55FdU, Adr and BrdU.
Cell line Days post Fold resistance to
comparison treatment 5-FU 55FdU Adr BrdU
A549 5-FU 
treated/A549 7 1.220 2.000 0.741 2.016
t-test 1.1x1 O'2 3x1 O'4 2.1 x10'3 1 x10'2
A549 5-FU 
treated/A549 14 0.966 1.348 1.070 0.831
t-test* 0.8 2.8 E-1 0.41 0.42
A549 5-FU 
treated/A549 21 0.987 1.512 1.400 1.024. .
t-test 0.4 0.72 1.6 x10"3 6.3 x10"3
DLKP 5-FU 
treated/DLKP 7 0.554 0.332 0.580 0.383
t-test* 7.1 x1 O'3 1.3x1 O'3 3.2 x10'3 9.2 x10‘3
DLKP 5-FU 
treated/DLKP 14 1.237 1.690 1.088 1.592
t-test 0.17 0.37 0.51 0.41
DLKP 5-FU 
treated/DLKP 21 1.389 1.887 1.033 0.987
t-test 5.1 x10'3 1.1 x10"3 0.1 0.63
MCF-7 5-FU 
treated/MCF-7 14
0.528 1.293
t-test 5.5 x10'5 1.6x10^
't-test is performed on samples compared in above line and consists of 3 biological
replicates.
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3.1.3 Altered invasion post 5-FU exposure
Invasion assays were performed as described in materials and methods section 2.14. 
Assays were performed on untreated parental cells compared simultaneously to 5-F.U 
treated cells at 0 and 7 days post 5-FU treatment. Invasion assays were performed 
over 24 and 48 hour incubation times. Normal cell lines (NHBE and HMEC) were 
only assessed at 0 days post treatment due to limited supply of cells. Data can be seen 
in figures 3.1.12 to 3.1.16.
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Figure 3.1.12 Invasion assays performed on A549 and A549 post 5-FU treatment, (a) 
Average number of invading cells per field in A549 and A549 at specified time points 
post 5-FU treatment. Representative images of (b) untreated A549 invaded cells after 
24 hours invasion assays compared to (c) simultaneous 24 hour invasion assay on 
A549 cells 0 days post treatment. Representative image of (d) untreated A549 invaded 
cells after 48 hours invasion assays compared to (e) simultaneous 48 hour invasion 
assay on A549 cells 0 days post treatment.
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Figure 3.1.13 Invasion assays performed on DLKP and DLKP post 5-FU treatment, 
(a) A bar chart summarising the invasion trends between DLKP and DLKP at 
specified time points post 5-FU treatment. Representative images of (b) untreated 
DLKP invaded cells after 24 hours invasion assays compared to (c) simultaneous 24 
hour invasion assay on A549 cells 0 days post treatment.
(a),
20
10
Ceil line DLKP DLKP 5-FU treated DLKP DLKP 5-FU treated
Incubation time 24 hours 24 hours 24 hours 24 hours
Experimental Untreated control for 0 days post 0 days post treatment Untreated control for 7 days post 7 days post treatment
conditions treatment samples treatment samples
Figure 3.1.14 Invasion assays performed on NHBE and NHBE post 5-FU treatment, 
(a) Average number of invading cells per field in NHBE and NHBE at specified time 
points post 5-FU treatment. Representative images of (b) untreated NHBE invaded 
cells after 48 hours invasion assays compared to (c) simultaneous 48 hour invasion 
assay on NHBE cells 0 days post treatment.
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Figure 3.1.15 Invasion assays performed on MCF-7 and MCF-7 post 5-FU treatment, 
(a) Average number of invading cells per field in MCF-7 and MCF-7 at specified time 
points post 5-FU treatment. Representative images of (b) untreated MCF-7 invaded 
cells after 24 hours invasion assays compared to (c) simultaneous 24 hour invasion 
assay on MCF-7 cells 0 days post treatment. Representative image of (d) untreated 
MCF-7 invaded cells after 72 hours invasion assays compared to (e) simultaneous 72 
hour invasion assay on MCF-7 cells 0 days post treatment.
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Figure 3.1.16 (a) Bar chart demonstrating apparent altered invasion rates in A549 
post 5-FU exposure, (b) image of invaded cells from HMEC after 48 hour incubation,
(c) image of invasive cells from HMEC 0 days post 5-FU exposure after 24 hour 
incubation time, (d) image of invaded cells from HMEC after 48 hour incubation,
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Summary of invasion assays
Table 3.1.2: summary of invasion trends with t-test performed on each analysis
showing data to be highly significant
Cell line comparison Incubation time Experimental
conditions
Fold change in number 
of invading cells
T-test score 
(p value =)
A549 10nM 5-FU 
treated / A549 
N=3
24 hours 0 days post 
treatment
-21
(n=3)
4.2xl0'16
A549 lOpM 5-FU 
treated / A549 
N=3
48 hours 0 days post 
treatment
-2.1
(n=3)
2x1 O'11
A549 10[iM 5-FU 
treated / A549 
N=3
24 hours 7 days post 
treatment
-3.4
(n=3)
1.3xl0'14
DLKP IOjiM 5-FU 
treated / DLKP 
N=3
24 hours 0 days post 
treatment
5.4
(n=3)
3.5xl0's
DLKP lOfiM 5-FU 
treated / DLKP
N=3
24 hours 7 days post 
treatment
6.3
(n=3)
3.9xlO"1J
NHBE lO^M 5-FU 
treated / NHBE 
N=3
48 hours 0 days post 
treatment
Apparent induction of 
invasive phenotype 
(n=3)
0*
MCF-7 lOfiM 5-FU 
treated / MCF-7 
N=3
48 hours 0 days post 
treatment
Apparent induction of 
invasive phenotype 
fn=3)
0*
MCF-7 10|aM 5-FU 
treated / MCF-7 
N=3
24 hours 0 days post 
treatment
1
(n=3)
0*
MCF-7 10^M 5-FU 
treated / MCF-7 
N=3
72 hours 7 days post 
treatment
Apparent induction of 
invasive phenotype 
(n=3)
0*
HMEC IOjiM 5-FU 
treated / HMEC 
N=3
48 hours 0 days post 
treatment
Apparent loss of 
invasive phenotype 
(n=3)
0*
HMEC 30^M 5-FU 
treated/HMEC 
N=3
48 hours 0 days post 
treatment
Apparent loss of 
invasive phenotype 
(n=3)
0*
*This data showec a change from the base line Cand thus T-test can not be performed
on this data but would indicate a 100% confidence in result or a p value of 0.
Invasion assays data presented in figures 3.1.12-16 indicate that MCF-7 and NHBE 
become invasive as a result of exposure to 5-FU. DLKP invasion rate increases 5 to 6 
fold as a result of exposure to 5-FU while HMEC and A549 display apparent 
decreases of invasion rates.
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3.1.4 Investigation of adherence related proteins.
Integrin are important membrane proteins and play a role in communicating to cell its 
extracellular environment and interactions with the cell and its extracellular 
environment. Integrins cluster together to form focal contacts and stimulate signal 
transduction through recruitment of the focal adherence kinase (FAK) and 
autophosphorylation which can lead to activation of ERK, MAPK, Src and regulation 
of G-proteins such as rho which play important roles in cell migration.
Syndecans play important roles in cell contractility and are important in 
stromatogenesis and tissue repair. Regulation of actin dynamics is poorly described by 
the syndecans but they are involved in regulating of proteins such as rho -  a GTPase 
responsible for regulating actin dynamics (Irie, et al., 2004).
Specifically the integrin subunits Pi, 012, and as and syndecan 2 were investigated.
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Figure 3.1.17: Western Blot for the presence of the integrin subunit (*2 in DLKP and
DLKP treated with the fluorouracil for 4 and 7 days (lOjag of protein per lane).
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Figure 3.1.18: Western Blot for the presence of the integrin subunit ct.2 in A549 and
A549 treated with 5-fluorouracil for 4 and 7 days (10(j.g of protein per lane).
Figure 3.1.19: Western Blot for the presence of the integrin subunit as in DLKP and
DLKP treated with the fluorouracil for 4 and 7 days (lO^g of protein per lane).
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Figure 3.1.20: Western Blot for the presence of the integrin subunit as in A549 and
A549 treated with 5-fluorouracil for 4 and 7 days (lOjig of protein per lane).
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Figure 3.1.21: Western Blot for the presence of the integrin subunit Pi in DLKP and 
DLKP treated with the fluorouracil for 4 and 7 days (10|o,g of protein per lane).
Figure 3.1.22: Western Blot for the presence of the integrin subunit Pi in A549 and 
A549 treated with the fluorouracil for 4 and 7 days (10|j,g of protein per lane).
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Figure 3.1.23: Western Blot for the presence of adherence related protein syndecan-2 
in A549 and A549 treated with 5-fluorouracil for 4 and 7 days (10|xg of protein per 
lane).
Figure 3.1.24: Western Blot for the presence of adherence related protein syndecan-2
in DLKP and DLKP treated with 5-fluorouracil for 4 and 7 days (10fJ.g of protein per
Investigation of the integrin subunits Pi, 0 .2 , and as and syndecan-2 reveal an up 
regulation of the integrin subunits Pi, 0 .2 , and a 5 and a down regulation of syndecan-2 
in DLKP treated with 5-FU, while in A549 treated with 5-FU the integrin subunits Pi, 
and as, and syndecan-2 are up regulated while the integrin subunit a 2 is down 
regulated.
The integrin subunits Pi forms a dimer with 0 .2 , and a5 integrin subunits. The 
formation of a dimer allows selective binding to ECM proteins and allow binding of 
actin filaments via connecting proteins. The formation of integrin dimers contribute to 
various signal transduction cascades that can inhibit apoptosis, promote motility and 
the secretion of matrix metaloproteases involved in invasion. Further more integrin 
signalling in combination with growth factor signalling is required for progression 
from G1 to S phase of the cell cycle (Damsky et al. 2002). Syndecan-2 forms a trimer 
with Pias integrin dimer and promotes binding to Fibronectin, its increased expression 
was found to reduce invasion (Kusano et al. 2004). Thus the alterations observed in 
Pias integrin dimer in combination with sydecan-2 are important for the regulation of 
the altered invasion rates. Further more increased expression of syndecan-2 in 
combination with Pias integrin was found to promote stress fiber formation and 
adherence to fibronectin (Kusano et al. 2000). Thus this expression trend would 
explain the increased adherence to the the ECM proteins collagen type IV and 
fibronectin and decreased invasion rate observed in A549 treated with 5-FU and the 
increased invasion rates observed in DLKP. It is likey that 5-FU induces stress fiber 
formation in A549 but not in DLKP and that signalling from the Pias integrin dimer 
promotes motility in DLKP.
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Figure 3.1.25: Western Blot for the presence o f endogenous control GAPDH in 
DLKP and DLKP treated with fluorouracil for 4 and 7 days (lOjig of protein per 
lane).
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Figure 3.1.26: Western Blot for the presence of endogenous control GAPDH in A549
and A549 treated with the fluorouracil for 4 and 7 days (lO^ig of protein per lane).
Figure 3.1.27: Western Blot for the presence of endogenous control GAPDH in
MCF-7 and MCF-7 treated with the fluorouracil for 4 and 7 days (10p,g of protein per
3.1.5 Investigation of p53 expression
The tumour suppression protein p53 is induced by DNA lesions or genotoxic stress as 
described in section 1.0. The accumulation of p53 suggests detection of DNA lesions, 
cell cycle arrest and may suggest p53 mediated transcription.
Figures 3.1.28: Expression of p53 in A549 after 4 and 7 days exposure to 5-FU
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Figures 3.1.29: Expression of p53 in DLKP after 4 and 7 days exposure to 5-FU
Figures 3.1.31: Expression of p53 in NHBE after 7 days exposure to IOjiM 5-FU
Figures 3.1.30: Expression of p53 in MCF-7 after 4 and 7 days exposure to 5-FU
Figures 3.1.31: Expression of p53 in HMEC after 7 days exposure to 10^M 5-FU
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The accumulation of p53 was observed in all cell lines with the exception of NHBE. 
The accumulation of p53 suggests incorporation of 5-FU derivates into DNA, the 
formation of DNA lesions and activation of ATR/ATM pathway leading to 
phosphorylation of p53 and localisation to the nucleus. In NHBE p53 was not 
observed to increase and suggests that the normal cell line NHBE is tolerant to 5-FU 
even though its growth rate was inhibited by 80% at both 10 and 30p,M. However due 
to limited sample p53 expression was not assessed in NHBE treated with 30{J,M 5-FU.
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3.1.6 Investigation of the epithelial markers Keratin 8 and 18
The intermediate filament proteins Keratin 8 and 18 were generally found to 
accumulate as a result of halogenated pyrimidine treatment in DLKP and A549 
(McMorrow J, Ph.D. thesis, 2004, O’ Sullivan F, Ph.D. thesis 1999). Keratin 8/18 pair 
are hallmarks of simple epithelial cells (Gilbert et al. 2004). Thus this data would 
suggest that the halogenated pyrimidines promote epithelial differentiation. Further 
more Keratin 8 and 18 been shown to promote invasion although the exact role in 
invasion is not clear it is believed to induce alteration in cytoskeletal architecture 
through the induction of integrin expression and resulting signal transductions (Chu et 
al. 1996).
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Figures 3.1.32: Expression of Keratin 8 in A549 after 4 and 7 days exposure to 5-FU
Figures 3.1.33: Expression of Keratin 8 in DLKP after 4 and 7 days exposure to 5-FU
Figures 3.1.34: Expression in of Keratin 8 MCF-7 after 4 and 7 days exposure to 5-
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Figures 3.1.35: Expression of keratin 18 in A549 after 4 and 7 days exposure to 5-FU
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Figures 3.1.36: Expression of keratin 18 in DLKP after 7 days exposure to 5-FU
Figures 3.1.37: Expression of Keratin 18 in MCF-7 after 4 and 7 days exposure to 5- 
FU
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The simple epithelial markers keratin8/18 were found to accumulate in DLKP and 
MCF-7 while in A549 they were found to decrease. The expression of keratin 8/18 
correlates with altered invasion in DLKP, MCF-7and A549 and this data supports a 
role for keratins in the 5-FU regulation of invasion.
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Table 3.1.3: Summary of western blots on the cell lines A549, DLKP, NHBE, MCF-7 
and HMEC treated with 5-FU investigating expression of adherence related proteins -  
integrins and sdc-2-, actin organisation regulating protein -  Rho-, intermediate
filament proteins keratin 8 and 18, and the genotoxicity re ated protein p53.
Protein A549 DLKP NHBE MCF-7 HMEC
a2 integrin Î 1 ? ? ?
as integrin t Î ? ? ?
Pi integrin T t ? ? ?
Sdc-2 Î X ? ? ?
KRT8 1 T ? T ?
KRT18 i T ? Î ?
p53 Î t - t Î
t  upregulation, ¿down regulation, - no change, ? not determined
The expression of rho correlated with invasion trends and suggests actin dynamics are 
important in the regulation of invasion alterations induced by 5-FU treatment. Keratin 
8 and 18 regulation and sdc-2 also correlate with invasion and suggest epithelial 
differentiation is important in invasion. Sdc-2 and integrin subunits in lung cancer cell 
lines appear to correlate with invasion and suggest a role in regulation of rho and 
invasion. p53 expression does not correlate with invasion and suggests that its 
regulation is not a determinant in promoting invasion although can indirectly inhibit 
invasion through induction of apoptosis.
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3.1.7 Proteomic analysis of A549 post 5-FU exposure
As already stated, investigation of the proteomic alterations induced by 5-FU 
treatments are poorly described in the literature and no studies have been performed 
on lung cell lines. Investigation of the proteomic alterations induced by 5-FU 
treatment of A549 may indicate pathways and biological processes activated by 5-FU 
that would contribute to the understanding of the anti-metabolites mode of action. 
Furthermore, in conjunction with invasion data presented above an insight into the 
mechanisms that control alteration in invasion would be elucidated. Finally, 
identification of proteins involved in the inhibition of apoptosis would lead to the 
development of drugs that would target such pathways and perhaps lead to enhanced 
future therapies.
To achieve these goals protein analysis was carried out using 2D-DIGE, 
phosphorylated proteins were identified using a phosphospecific fluorescent stain 
called Pro-Q Diamond. Differentially regulated proteins were identified using 
MALDI-ToF MS.
Cell culture of A549 and A549 treated with 5-FU was carried out as described in 
section 2.7.3. Total protein extractions were prepared as described in 2.17. These were 
prepared in biological triplicate. Each biological triplicate was run in technical 
duplicates. Sample labelling with Cy dyes is shown in table 3.1.3. Differentially 
regulated proteins were identified statistically important using the following filters. A 
fold change less than minus 1.2 or greater than plus 1.2 with a t-test score less than 
0.01 was deemed significant or a fold change less than minus 1.5 or greater than plus
1.5 with a t-test less than 0.05 was deemed significant. These filters revealed 186 
proteins differentially regulated between A549 and A549 treated with 5-FU of which 
71 were identified.
Preparative gels for protein identification were prepared as described in sections 2.21- 
25. Differentially regulated proteins were identified using MALDI-ToF MS as 
described in section 2.27. Of the 296 proteins differentially regulated 56 proteins were 
identified. Identified differentially regulated proteins locations are indicated in figure
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3.1.25 and figure 3.1.26 displays the number of differentially regulated proteins 
identified and ontological data on these proteins. The identity of these proteins can be 
seen in table 3.1.4. Proteins identification data from MALDI-ToF MS is included in 
the appendices.
Table 3.1.4: Ettan DIGE experimental design for the analysis of differential protein
expression induced in A549 by exposure to 5-FU for 7 days.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50|ag of protein)
A549, P. 14 
(50|og of protein)
A549, P. 14, 5-FU treated 
(50ng of protein)
2 Pooled internal standard 
(50|j,g of protein)
A549, P. 14 
(50ng of protein)
A549, P. 14, 5-FU treated 
(50ng of protein)
3 Pooled internal standard 
(50|jg of protein)
A549, P. 15 
(50(xg of protein)
A549, P. 15, 5-FU treated 
(50pg of protein)
4 Pooled internal standard 
(50|j,g of protein)
A549, P. 15 
(50|ig of protein)
A549, P. 15, 5-FU treated 
(50|Ag of protein)
5 Pooled internal standard 
(50ng of protein)
A549, P. 16 
(50(j,g of protein)
A549, P. 16, 5-FU treated 
(50|j,g of protein)
6 Pooled internal standard 
(50ng of protein)
A549, P. 16 
(50fxg of protein)
A549, P. 16, 5-FU treated 
(50|xg of protein)
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Figure 3.1.43: 2D-DIGE images of A549 (CY3) and A549 after 7 days treatment with IOjjM 5-FU (CY5). Identified differentially regulated 
protein spots are encircled by blue lines and are given a protein number. Refer to table 3.1.13.1.2 for protein identification.
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Figure 3.1.44: A pie chart demonstrating the number of differentially regulated proteins in each biological process identified in A549 treated 
with 5-FU. Individual proteins in each biological process are included in table 3.1.4. Biological process information obtained from the human 
protein reference database. Some well described proteins are represented in the database as unknown, there actual names are included.
■ Apoptoas
I  Cel gro*thandi or maintenance
■ Metaboisn
■ Protein Met abolis»
■ Régulai ion of nueleobase.ntKleoside,nucleotide ami nucleic acid »et aWis» 
I  Immune Rename
D Signaltransduction.eeirconmninication
■ Transport
■ Unknown
131
Table 3.1.4: List of differentially expressed proteins in A549 treated with 5-FU. Proteins names that are unknown were identified as described in
section 2.16.13.3, names are included.
Protein location
GI accession 
Number Gene symbol Name
Fold
Change T-test Molecular function
Anoptosis
4 gi|30583573l PDCD6EP
programmed cell death 6 interacting protein 
[Homo sapiens] 1.64 1.9x10-5 Unknown
Cell growth and/or maintainance
32 gi|16924319| ACTB
Unknown (protein for IMAGE:3538275) 
[Homo sapiens] P-actin 1.8 5.6 xlO-5 structural molecule activity
46 gi|l 6924319| ACTB
Unknown (protein for IMAGE:3538275) 
[Homo sapiensl P-actin 1.66 3.7x10-4 structural molecule activity
44 gi|62897625| ACTB beta actin variant [Homo sapiens] 1.49 1.3x10-3 structural molecule activity
43 gi|62897671| ACTB beta actin variant [Homo sapiens] 1.5 1.1 xlO-4 structural molecule activity
45 gi|62897671| ACTB beta actin variant [Homo sapiensl 1.34 8.7x10-4 structural molecule activity
38 gi|12653819| KRT18 Keratin 18 [Homo sapiens] -1.51 3.5 xlO-4 structural molecule activity
33 Bi|30311| KRT18 cytokeratin 18 (424 AA) [Homo sapiens] -1.58 1.5 xl0-4 structural molecule activity
39 gi|303111 KRT18 cytokeratin 18 (424 AA) |Homo sapiens] -2.04 4.0 xlO-5 structural molecule activity
37 gi|62897747| KRT18 keratin 18 variant [Homo sapiens] -1.56 1.5 xlO-4 structural molecule activity
41 gi|24234699| KRT19 keratin 19 [Homo sapiens] 3.22 7.2 xlO-6 structural molecule activity
42 gi|24234699l KRT19 keratin 19 [Homo sapiensl 2.55 1.9x10-2 structural molecule activity
26 gi|33875698| KRT8 KRT8 protein [Homo sapiens] -2.16 4.1 xlO-2 structural molecule activity
25 gi|62913980| KRT8 KRT8 protein THomo sapiensl -2.15 3.4 xlO-2 structural molecule activity
8 gi|50318771 LMNB1 lam inBl [Homo sapiens] -1.74 6.6 xl0-3 structural molecule activity
9 gi|50415798| LMNB1 LMNB1 protein [Homo sapiensl -2.17 1.2 xlO-2 structural molecule activity
58 gi|41223219| PCDH11X protocadherin [Homo sapiensl 2.68 3.5 xlO-3 Cell adhesion molecule activity
71 gi|5031851l STMN1 stathmin 1 [Homo sapiens] -5.07 1.5x10-8 cytoskeletal protein binding
60 gi|88928| TPM3 tropomyosin 3, fibroblast - human 2.29 6.6 xl0-3 cytoskeletal protein binding
63 gi!4507651l TPM4 tropomyosin 4 [Homo sapiensl 1.61 2.1 xl0-3 cytoskeletal protein binding
15 gi|14389309| TUBA6 tubulin alpha 6 [Homo sapiens! 1.64 3.2x10-3 structural molecule activity
21 gi|62897639| TUBB3 tubulin, beta, 4 variant [Homo sapiens] 1.51 4.2 xlO-3 structural molecule activity
Metabolism; Energy pathway
50 gi|62738430| AKR1B1 Chain A, Apo R268a Human Aldose 2.38 6.7 xlO-4 Oxidoreductase activity
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Reductase
53 gi|6273 84301 AKR1B1
Chain A, Apo R268a Human Aldose 
Reductase 2.52 4.0 x l0 - l Oxidoreductase activity
24 gi|178400| ALDH1A1 aldehyde dehydrogenase 1 (EC 1.2.1.3) 1.63 7.7 xl0-3 Catalytic activity
20 gi|21832991 ALDH1A1 aldehyde dehydrogenase 1 [Homo sapiens] 1.73 5.0 xlO-2 Catalytic activity
30 gi|283971| ALDH3A1
aldehyde dehydrogenase [NAD(P)] (EC 
1.2.1.5) 3 - human 1.87 1.8 xlO-5 Catalytic activity
22 gi|30583043| ALDH3A1
aldehyde dehydrogenase 3 family, 
memberAl [Homo sapiens] 2.55 1.4x10-3 Catalytic activity
1 gi|219553| CPS1
carbamyl phosphate synthetase I [Homo 
sapiens] -6.38 1.3 xlO-4 Ligase Activity
27 gi|643589| DLST
dihydrolipoamide succinyltransferase [Homo 
sapiens] -1.9 3.4 xlO-2 Acetyltransferase activity
29 gi|30582259| DARS aspartyl-tRNA synthetase [Homo sapiens] 1.48 3.9 xlO-2 ATPase activity
28 gil26224874| G6PD
glucose-6-phosphate dehydrogenase [Homo 
sapiens] 1.47 1.6 xlO-2 Catalytic activity
3 gi|577295| GANAB KIAA0088 [Homo sapiens] 2.14 1.9x10-5 Hydrolase activity
70 gi|29468184| NME1 NM23-H1 [Homo sapiens] 2.14 5.3x10-9 Catalytic activity
18 gi|2245365| PDIA3 ER-60 protein [Homo sapiensl -1.56 4.9 xlO-3 Caiboxyl-lyase activity
31 gi| 17102481 PDIA6
protein disulfide isomerase-related protein 5 
[Homo sapiensl -1.92 1.7 xlO-2 Carboxyl-lyase activity
34 gi| 17102481 PDIA6
protein disulfide isomerase-related protein 5 
[Homo sapiensl 2 2.5x10-2 Carboxyl-lyase activity
19 gi|49168498| TXNRD1 TXNRD1 [Homo sapiensl 1.76 3.4x10-4 Oxidoreductase activity
36 gi|1082896| UOCRB
ubiquinol-cytochrome-c reductase (EC 
1.10.2.2) core protein I - human -1.51 1.4x10-2 Catalytic activity
Protein Metabolism
67 gi!547813551 CAPNS1 calpain, small subunit 1 [Homo sapiens] 2.01 1.7x10-9 Cysteine-type peptidase activity
57 gi|25453472| EEF1BD
eukaryotic translation elongation factor 1 
delta isoform 2 [Homo sapie 1.65 7.1 xlO-4 Translation regulator activity
59 gi|25453472| EEF1BD
eukaryotic translation elongation factor 1 
delta isoform 2 [Homo sapie 2.05 2.5 xlO-2 Translation regulator activity
35 gill5530265l EEF1BG
Eukaryotic translation elongation factor 1 
gamma [Homo sapiens] 2.09 1.5 xlO-6 Translation regulator activity
2 gi|61656607| TRA1 tumor rejection antigen (gp96) 1 [Homo -2.22 9.2 xlO-3 Chaperone activity
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sapiens]
12 gi|21197121 HSPA1A
dnaK-type molecular chaperone HSPA1L - 
human -1.82 5.4 xl0-3 Chaperone activity
11 gi|13676857| HSPA2 heat shock 70kDa protein 2 [Homo sapiensl -2.38 4.7 xlO-4 Chaperone activity
6 gi|16507237| HSPA5 BiP protein [Homo sapiens] -1.61 1.5 xlO-2 Chaperone activity
10 gi|24234688| HSPA9B
heat shock 70kDa protein 9B precursor 
[Homo sapiens] -1.58 2.3 xlO-2 Chaperone activity
64 gi|662841| HSPB1 heat shock protein 27 [Homo sapiensl -1.51 8.8 xlO-4 Chaperone activity
69 gi|662841| HSPB1 heat shock protein 27 [Homo sapiens] 1.7 9.9 xlO-4 Chaperone activity
17 gi|20070125| P4HB
prolyl 4-hydroxylase, beta subunit [Homo 
sapiens] -1.61 3.3 xlO-3 Isomerase activity
52 gi|42490917| PSMD14
26S proteasome-associated padl homolog 
[Homo sapiens] 1.47 3.7 xl0-3 Ubiquitin-specific protease activity
47 gi|47123412| RPLPO RPLPO protein [Homo sapiens] 1.45 2.6 xlO-2 ribosomal subunit
55 gi|62088696| SFRS1 splicing factor, arginine/serine-rich 1 1.59 4.3 xlO-5 RNA binding
13 gi|12653759| CCT1 TCP1 protein [Homo sapiens] 1.46 2.8 xlO-2 Chaperone activity
Regulation o f nucleobase, nucleoside, nucleotide and nucleic acid metabolism
48 gi|7448823| ADK adenosine kinase (EC 2.7.1.20) - human 1.6 6.4 xlO-5 Catalytic activity
23 gi|12655001| HNRPH1 HNRPH1 protein [Homo sapiens] 1.55 8.9 xlO-4 Ribonucleoprotein
16 i|38197650| HNRPK Hnrpk protein [Rattus norvegicus] -1.83 9.1 xlO-5 Ribonucleoprotein
5 gi|510946031 MCM7
MCM7 minichromosome maintenance 
deficient 7 (S. cerevisiae) [Homo sapien -3.52 2.2 xlO-4
Signal transduction and cell communication
54 gi| 14216621 ANXA1
Annexin Family M olid : 1; Molecule: 
Annexin Iii; Chain: Null; Engineered: Yes; 1.66 1.2 xl0-5 Calcium ion binding
14 gi|571139931 GDI1
GDP dissociation inhibitor 1 [Pan 
troglodytes] 2.01 2.9 xlO-3 GTPase activator activity
56 gi|2914387| PCNA Chain E, Human Pena -1.87 2.2 xlO-4 regulation o f cell cycle
49 gil34234| RPSA laminin-binding protein [Homo sapiens] -1.36 6.4 xl0-5 ribosomal subunit
68 gi|213284481 YWHAB
tyrosine 3-monooxygenase/tryptophan 5- 
monooxygenase activation protein 1.38 1.6 xl0-3
Receptor signalling complex scaffold 
activityactivity
65 gi|55930909| YWHAQ
Tyrosine 3/tryptophan 5 -monooxygenase 
activation protein, theta polypep 1.6 2.8 xlO-4
Receptor signalling complex scaffold 
activityactivity
66 gi|491196531 YWHAZ YWHAZ protein [Homo sapiens] 1.45 9.6 xl0-3
Receptor signalling complex scaffold 
activityactivity
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62 gil55961619| CUC1
chloride intracellular channel 1 [Homo 
sapiens] 1.47 3.9 xl0-2
intracellular ligand-gated ion channel 
activity
51 £i!19058741 PDLIM1
carboxyl terminal LIM domain protein 
[Homo sapiens] 1.59 1.6 xl0-3 Unknown
40 gi|12653109| AHSA1
AHA1, activator o f  heat shock 90kDa protein 
ATPase homolog 1 [Homo sapie 1.57 8.0 xl0-6
61 gi|229691|
Chain D, Deoxyribonuclease I Complex 
With Actin 1.48 2.9 xl0-2
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Protein modifications such as protein phosphorylation alter the pi of proteins and thus 
contribute to the various isoforms identified for apparently the same protein. MALDI- 
ToF MS is not capable of distinguishing between such modifications. Pro-Q diamond 
is a fluorescent dye that selectively binds to phosphorylated residues of serine, 
threonine and tyrosine. For analysis of proteins being differentially regulated in this 
experiment a pooled sample of both control and treated was separated by 2D 
electrophoresis and stained and matched to the BVA as described in section 2.25. 
Proteins that were deemed phosphorylated at serine/threonine/thyrosine residues as a 
result of staining with Pro-Q diamond. Locations on 2D gels are indicated in figure 
3.1.27 and are summarised in Table 3.1.4. Modification data is listed in same table 
where available. Gene Symbol conversion and processing where applicable was 
carried as indicated in section 2.28.
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Figure 3.1.45: A pooled protein sample from A549 and A549 5-FU treated separated by 2D electrophoresis and stained with (a) RuPBS to 
visualise total cell lysate proteome and (b) Pro-Q diamond to visualise phosphorylated proteins. Molecular weight ladder run on right side of 
images contains a mixture of 2 phosphorylated and 4 non-phosphorylated proteins.
137
Table 3.1.5 list of proteins differentially expressed proteins from the A549 5-FU treatment DIGE experiment that were found to be
phosphorylated by Pro-Q diamond staining.
Location on 
2D gel
Gene
Symbol GI accession number Protein Name Fold change
Known phospho 
site
Kinases/
phosphorylase
Implication o f  
phosphorylation
14 GDI1 gi|571139931
GDP dissociation inhibitor 1 
[Pan troglodytes] 2.01 ? ? ?
32 ACTB gi|16924319|
Unknown (protein for 
IMAGE:3538275) [Homo 
sapiens] 1.8 ? ? ?
33 KRT18 gi|303111
cytokeratin 18 (424 AA) 
[Homo sapiens] -1.58
521
522 
S24 
S37 
S43 
S74 
S432
MAPK14 
MAPK14 
MAPK14 
ERK2 
P38 kinase
Association o f  14-3-3 
proteins during mitosis
42 KRT19 gi|24234699| keratin 19 [Homo sapiens] 2.55
S10
S35
S46
?
?
?
56 PCNA gi|2914387| Chain E, Human Pena -1.87 ? ? ?
57 EEF1BD gi|25453472|
eukaryotic translation 
elongation factor 1 delta 
isoform 2 [Homo sapie 1.65 S449 CDC2 ?
59 EEF1BD gi|25453472|
eukaryotic translation 
elongation factor 1 delta 
isoform 2 [Homo sapie 2.05 S449 CDC2 ?
61 gi|229691|
Chain D, Deoxyribonuclease I 
Complex With Actin 1.48
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In order to identify the important proteins differentially regulated in A549 by 5-FU 
treatment the gene symbols of these proteins were imported into Pathway Assist 
Software in order to determine the direct interactions between these proteins.
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Figure 3.1.46: Image demonstrating direct 
interactions between differentially expressed 
proteins in the A549 5-FU treatment DIGE 
experiment. Blue nodes indicate a protein is up 
regulated, Red nodes indicate a protein is down 
regulated. A node coloured both red and blue 
indicates two isoforms of that protein have 
been identified were one is up regulated and 
the other is down regulated. Pathway generated 
by Pathway Assist.
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Summary of proteomic alterations induced in A549 by treatment with 5-FU
Figure 3.1.46 was generated by pathway assist and shows the direct interactions 
between differentially regulated protein iso forms listed in figure 3.1.4. In summary, 
direct interactions were identified between 22 of the proteins listed. These proteins 
that are listed are involved in intermediate filament dynamics of Keratin, Lamins, 
Actin and tubulin and include LMNB1, STMN1, ACTB, KRT8, KRT18 and KRT19. 
The HSP70 proteins, HSPA1A and HSPA9B, form complexes with p53 and are 
involved in cytoplasm sequestering and stabalisation of p53, {Selkirk, et al, 1994}. 
The ER proteins TRA1, HSPA5, P4HB which form a multiprotein complex in the ER 
and this complex is important in the folding of secretory proteins (Meunier et al. 
2002). AHSA1 and AKR1B1 play an important role in cell survival {Galvez, et al., 
2003}.
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3.1.8 Proteomic analysis of DLKP post 5-FU exposure
As already stated, investigation of the proteomic alterations induced by 5-FU 
treatment is poorly described in the literature and no studies have been performed on 
lung cell lines. Investigation of the proteomic alterations induced by 5-FU treatment 
of DLKP a NSCLC may indicate pathways and biological processes activated by 5- 
FU that would contribute to the understanding of the anti-metabolites mode of action. 
Furthermore, in conjunction with invasion data presented above an insight into the 
mechanisms that control alterations in invasion would be elucidated. Finally, 
identification of proteins involved in the inhibition of apoptosis would lead to the 
development of drugs that would target such pathways.
Cell culture of DLKP and DLKP treated with 5-FU was carried out as described in 
section 2.7.2. Total protein extractions were prepared as described in 2.17. These were 
prepared in biological triplicate. Each biological triplicate was run in technical 
duplicates. Sample labelling with Cy dyes is shown in table 3.1.6. Protein filters of 
greater than 1.2 or less than -1.2 with a t-test of 0.01 or a fold change of greater than
1.5 or less than -1.5 with a t-test of 0.05 were used to identify differentially regulated 
proteins.These filters identified 373 differentially regulated proteins of which 84 were 
identified.
Differentially regulated proteins were identified as statistically important using the 
following filters. A fold change less than minus 1.2 or greater than plus 1.2 with a t- 
test score less than 0.01 was deemed significant or a fold change less than minus 1.5 
or greater than plus 1.5 with a t-test less than 0.05 was deemed significant. These 
filters revealed 373 proteins differentially regulated between DLKP and DLKP treated 
with 5-FU.
Preparative gels for protein identification were prepared as described in sections 2.21- 
2.25. Differentially regulated proteins were identified using MALDI-ToF MS as 
described in section 2.27. Identified differentially regulated proteins locations are 
indicated in figure 3.1.48 and figure 3.1.49 displays the number of differentially 
regulated proteins identified and ontological data on these proteins. The identity of
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these proteins can be seen in table 3.1.6. Proteins identification data from MALDI-
ToF MS is included in the appendices.
Table 3.1.6: Ettan DIGE experimental design for the analysis of differential protein 
expression induced in DLKP by exposure to 5-FU for 7 days.
Gel
number
CY2 label CY3 label CY5 label
. . 1 t m i l  . . . • • •
1 Pooled internal standard 
(50(j,g of protein)
DLKP, P. 16 
(50(j.g of protein)
DLKP, P. 16, 5-FU treated 
(50|j.g of protein)
2 Pooled internal standard 
(50fxg of protein)
DLKP, P. 16 
(50fj,g of protein)
DLKP, P. 16, 5-FU treated 
(50|j,g of protein)
3 Pooled internal standard 
(50(ig of protein)
DLKP, P. 17 
(50fj,g of protein)
DLKP, P. 17, 5-FU treated 
(50^ig of protein)
4 Pooled internal standard 
(50fj.g of protein)
DLKP, P. 17 
(50|j,g of protein)
DLKP, P. 17, 5-FU treated 
(50jxg of protein)
5 Pooled internal standard 
(50|^g of protein)
DLKP, P. 18 
(50fjg of protein)
DLKP, P. 18, 5-FU treated 
(50fj,g of protein)
6 Pooled internal standard 
(50|xg of protein)
DLKP, P. 18 
(50(J,g of protein)
DLKP, P. 18, 5-FU treated 
(50|xg of protein)
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Figure 3.1.48: 2D-DIGE images of DLKP (CY3) and DLKP after 7 days treatment with 10|J.M 5-FU (CY5). Identified differentially regulated 
protein spots are encircled by blue lines and are given a protein number. Refer to table 3.1.7 for protein identification
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Figure 3.1.49: A pie chart demonstrating the number of proteins in each biological process in DLKP affected by exposure to 5-FU. Individual 
proteins in each biological process are included in table 3.1.7. Biological process information obtained from the human protein reference 
database.
i2  proteins1 protein
7 proteins
2 proteins
9 proteins -
17 proteins
21 proteins26 proteins
■  Apoptosis
■  Cell growth and/or maintenance
■  Metabolism
■  Protein Metabolism
■  Regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolism
■  Immune Response
□  Signal transduction, cell communication
■  Transport
■  Unknown
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Table 3.1.7: Proteins identified from DLKP 5-FU treatment 2D-DIGE experiment. Position number refers to location in figure 3.1.48 for
location on 2D gel. Proteins names that are unknown were identified as described in section 2.16.13.3, names are included.
Protein 
location on 2D 
DIGE eel
GI
accession
Number
Gene
symbol Name
Fold
Change T-test Molecular function
Apoptosis
3 PDCD6IP gi|46249756|
gi|46249756|gb|AAH68454.1 - PDCD6IP 
protein [Homo sapiens] 1.34 0.0091 Unknown
11 PDCD6IP gi|13375569| HP95 [Homo sapiens] 1.69 0.00027 Unknown
Cell growth and/or maintainance
49 ACTB gii 169243191
Unknown (protein for IMAGE:3538275) 
[Homo sapiens] P-actin 1.66 0.00096 structural molecule activity
54 ACTB gi| 169243191
Unknown (protein for IMAGE:3538275) 
[Homo sapiens] P-actin 1.67 0.00031 structural molecule activity
55 ACTB gi|l 52775031 ACTB protein [Homo sapiensl 1.53 0.0019 structural molecule activity
50 ACTB gi|16924319|
Unknown (protein for IMAGE:3538275) 
[Homo sapiens] p-actin 1.73 0.00024 structural molecule activity
48 ARP gi|3819641 actin-related protein 1.28 5.4x10-6 Structural constituent o f  cytoskeleton
65 CAPZA1 gi|12652785| CAPZA1 protein [Homo sapiens] -1.38 0.0092 structural molecule activity
71 CAPZB gi|55665442l
capping protein (actin filament) muscle Z- 
line. beta [Homo sapiens] 1.34 0.0028 cytoskeletal protein binding
81 CFL1 gi|30582531| cofilin 1 (non-muscle) [Homo sapiensl 2.25 0.0002 cytoskeletal protein binding
14 CTTN gi|477079|
mammary tumor/squamous cell carcinoma- 
associated protein EMS1 - human 1.5 0.0024 Cytoskeletal protein binding
15 GSN gi|38044288| gelsolin isoform b [Homo sapiensl 2.07 9.0x10-7 Structural constituent o f  cytoskeleton
57 gCAP39 gi|63252913| gelsolin-like capping protein [Homo sapiens] -1.52 0.0089 Structural constituent o f  cytoskeleton
68 LASPI gi|2135552l Lasp-1 protein - human -1.4 0.00042 cytoskeletal protein binding
23 LMNA gi|57014045|
lamin A/C transcript variant 1 [Homo 
sapiens] 1.3 0.0011 structural molecule activity
20 LMNB1 gi|15126742| Lamin B1 [Homo sapiens] -1.59 5.6x10-5 structural molecule activity
21 PLS3 gi|571624241 plastin 3 (T isoform) [Homo sapiensl 1.73 0.0012 structural molecule activity
82 STMN1 gi|50318511 stathmin 1 [Homo sapiens] -2.1 0.00015 cytoskeletal protein binding
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1 VCL gi|24657579| VCL protein [Homo sapiens] 1.48 0.0068 Cytoskeletal protein binding
Immune Response
84 LG ALS 1 gi145049811
beta-galactosidase binding lectin precursor 
[Homo sapiens] -1.3 0.00032 Receptor Binding
Metabolism; Energy pathway
74 GLOl gi|5729842| glyoxalase I [Homo sapiens] 1.37 3.7x10-5 Gluthathione transferase activity
63 ACAT2 gi|19880019|
acetyl CoA transferase-like protein [Homo 
sapiens] 1.47 0.00062 Acetyl-transferase activity
46 AHCY gi|178277| S-adenosylhomocysteine hydrolase 1.56 2.1x10-5 Hydrolase activity
36 ALDH1A1 gi|21361176|
aldehyde dehydrogenase 1A1 [Homo 
sapiens] 1.86 0.00083 Catalytic activity
17 APEH gi|7144648| Acylpeptide hydrolase 1.6 0.0071 Hydrolase activity
26 ATIC gi|14250818l
5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP cycl 1.4 0.0027 Hydrolase activity
53 CKB gi[l 805701 creatine kinase [Homo sapiens] -1.25 0.00047 Catalytic activity
6 GAN AB gi|577295| KIAA0088 [Homo sapiensl 1.77 4.4x10-6 Hydrolase activity
8 GAN AB gi|577295| KIAA0088 [Homo sapiens] 1.63 0.013 Hydrolase activity
78 GSTA1 gi|348113061
Chain B, A  Folding Mutant O f Human Class 
Pi Glutathione Transferase, Create -1.53 0.0011 Gluthathione transferase activity
75 HPRT1 gi|471152271 HPRT1 [Homo sapiens] 1.53 0.0033 Catalytic activity
45 IDH1 gi|3641398|
NADP-dependent isocitrate dehydrogenase 
[Homo sapiens] 1.8 0.001 Catalytic activity
66 LDHAL6B gi|13786848|
Chain B, Human Heart L-Lactate 
Dehydrogenase H Chain, Ternary Complex 
With -1.3 0.0042 Catalytic activity
69 MDH1 gi|49259212|
Chain D, Human B Lactate Dehydrogenase 
Complexed With Nad+ And 4- Hydroxy-1 1.27 0.004 Catalytic activity
35 PDIA3 gi|2245365| ER-60 protein [Homo sapiens] 1.25 0.0069 Carboxyl-lyase activity
80 PRDX2 gil331884521 peroxiredoxin 2 isoform b [Homo sapiens] -1.4 0.00039 Peroxidase activity
58 SMS gi|791051| spermine synthase [Homo sapiens] 1.51 0.00092 -
59 SMS gi|55716035| Spermine synthase [Homo sapiens] 1.44 0.0027 -
70 SRM gi|56204109| spermidine synthase [Homo sapiens] 1.41 0.0002
64 TXNL1 gi|6840947|
PKCq-interacting protein PICOT [Homo 
sapiens] 1.81 4.4x10-6 Oxidoreductase activity
62 UROD gi|18158958| Uroporphyrinogen Decarboxylase -1.56 0.004 Carboxyl-lyase activity
147
Protein metabolism
28 CCT1 gil 126537591 TCP1 protein [Homo sapiensl 1.77 0.00018 Chaperone activity
37 CCT2 gi|481462591 CCT2 [Homo sapiens] 1.65 2.3x10-6 Chaperone activity
25 CCT3 eil58761484|
chaperonin containing TCP1, subunit 3 
isoform c [Homo sapiensl 1.41 0.0034 Chaperone activity
29 CCT3 gi|315422921
chaperonin containing TCP1, subunit 3 
(gamma) [Homo sapiens] 2.04 5.5x10-5 Chaperone activity
32 CCT5 gi|603955| KIAA0098 protein [Homo sapiens] 1.64 0.00059 Chaperone activity
27 CCT6A gi|62089036|
chaperonin containing TCP1, subunit 6A  
isoform a variant [Homo sapiens! 1.43 0.0021 Chaperone activity
31 CCT6A gi 14517632|
acute morphine dependence related protein 2 
[Homo sapiensl 1.98 0.0023 Chaperone activity
34 CCT8 eil62896539|
chaperonin containing TCP1, subunit 8 
(theta) variant THomo sapiens] 1.64 0.0014 Chaperone activity
43 EEF1BG gil4503481|
eukaryotic translation elongation factor 1 
gamma [Homo sapiens] 1.46 0.00075 Translation regulator activity
12 EEF2 gill9353009|
Similar to Elongation factor 2b [Homo 
sapiens! 1.67 0.0013 Translation regulator activity
13 EEF2 gi|19353009|
Similar to Elongation factor 2b [Homo 
sapiens] 1.32 0.0061 Translation regulator activity
40 EIF3S5 gi|30582627|
eukaryotic translation initiation factor 3, 
subunit 5 epsilon, 47kDa [Ho -1.57 0.00022 Translation regulator activity
73 ERP29 gil5803013|
endoplasmic reticulum protein 29 precursor 
[Homo sapiensl -1.63 8.5x10-7 Chaperone activity
7 HSPA4 gi|62087882|
heat shock 70kDa protein 4 isoform a variant 
[Homo sapiens] 1.54 0.015 Chaperone activity
9 HSPA4 gi|38327039|
heat shock 70kDa protein 4 isoform a [Homo 
sapiens] 1.77 0.003 Chaperone activity
18 HSPA5 gi|6470150| BiP protein [Homo sapiens] -1.42 0.0012 Chaperone activity
19 HSPA5 gi|6470150| BiP protein [Homo sapiens] -1.51 0.0015 Chaperone activity
4 HSPH1 gi|55957725| heat shock 105kDa protein 1 [Homo sapiens] 1.69 0.0002 Heat Shock protein activity
41 PSMC2 gi I41472112| unknown [Homo sapiens] 1.29 0.0037 Ubiquitin-specific protease activity
83
RPS12
gi|51468838|
similar to ribosomal protein S 12 [Homo 
sapiensl -1.36 0.00088 ribosomal subunit
67 SFRS1 gi|62088696| splicing factor, arginine/serine-rich 1 1.24 0.0014 RNA binding
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42 TXNDC5 gii 126547151 TXNDC5 protein [Homo sapiens] -1.38 2.7x10-5 Oxidoreductase activity
22 UBQLN1 gi|55958669| ubiquilin 1 [Homo sapiensl 1.35 0.0072 Ubiquitin-specific protease activity
2 USP5 gi|1585128| isopeptidase T 2.33 9.7x10-5 Ubiquitin-specific protease activity
79 VBP1 gi|54696078|
von Hippel-Lindau binding protein 1 [Homo 
sapiens] -1.61 0.00018 Chaperone activity
regulation o f nucleobase, nucleoside, nucleotide and nuc eic acid metabolism
52 ADK gi|7448823| adenosine kinase (EC 2.7.1.20) - human 1.2 0.0085 Catalytic activity
39 BAT1 gi|55742824] HLA-B associated transcript 1 [Sus scrofa] 1.57 0.00057 RNA binding
5 HDAC1 gi|59016833| hypothetical protein [Homo sapiens] 1.59 0.016 Transcription regulator activity
33 HNRPK gi|59381084|
heterogeneous nuclear ribonucleoprotein K 
transcript variant [Homo sapie -1.45 0.00014 Ribonucleoprotein
16 MCM7 gi|510946031
MCM7 minichromosome maintenance 
deficient 7 (S. cerevisiae) [Homo sapien 1.49 0.007
10 MSH2 gil62898129| mutS homolog 2 variant [Homo sapiens] 1.54 0.019 DNA repair protein
60 OLIG2 gill 1996571
protein kinase C-binding protein RACK17 
[Homo sapiens] 1.75 0.00017 Transcription regulator activity
38 RUVBL1 gi|62896709l
TATA binding protein interacting protein 49 
kDa variant 2.17 2.5x10-5 DNA binding
Signal transduction, cell cummunication
44 ANXA7 gi|62896663|
annexin VII isoform 1 variant [Homo 
sapiens] -1.47 0.0013 Calcium ion binding
76 GRB2 gi|28876l ash protein [Homo sapiens] -1.49 0.0036
Receptor signalling complex scaffold 
activityactivity
24 PPP2R5A gi|4558259|
Chain B, Crystal Structure O f Constant 
Regulatory Domain O f Human Pp2a, Pr65 1.92 0.0019 protein serine/threonine kinase activity
56 RPSA gil34234| laminin-binding protein [Homo sapiens] -2.02 7.3x10-5 ribosomal subunit
30 STIPI gi|54696884|
stress-induced-phosphoprotein 1 
(Hsp70/Hsp90-organizing protein) [Homo s 1.34 6.5x10-5
Receptor signalling complex scaffold 
activityactivity
61 STRAP gi|4519417| WD-40 repeat protein [Homo sapiens] 1.3 0.00042 Regulation o f Cell cycle
72 YWHAZ gi|49119653| YWHAZ protein [Homo sapiens] -1.47 2.6x10-5
Receptor signalling complex scaffold 
activityactivity
Not present in Database
51 C6orf 55 gi|12052892| hypothetical protein [Homo sapiensl 1.29 0.0035
77 DJBP gi|42543006| Chain A, Crystal Structure O f Human Dj-1 1.29 0.00014
47 hfl-B5 gi|62896687| dendritic cell protein variant [Homo sapiens] 1.65 0.00064
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Protein modifications such as protein phosphorylation alter the pi of proteins and thus 
contribute to the various isoforms identified for apparently the same protein. MALDI- 
ToF MS is not capable of distinguishing between such modifications. Pro-Q diamond 
is a fluorescent dye that selectively binds to phosphorylated residues of serine, 
threonine and thyrosine. For analysis of proteins being differentially regulated in this 
experiment a pooled sample of both control and treated was separated by 2D 
electrophoresis and stained and matched to the BVA as described in section 2.25. 
Proteins that were deemed phosphorylated at serine/threonine/thyrosine are indicates 
in figure 3.1.50 and are summarised in Table 3.1.8. Phosphorylation data is listed in 
same table where available.
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Figure 3.1.50: A pooled protein sample from DLKP and DLKP 5-FU treated separated by 2D electrophoresis and stained with (a) RuPBS to 
visualise total cell lysate proteome and (b) Pro-Q diamond to visualise phosphorylated proteins. Molecular weight ladder run on right side of 
images contains a mixture of 2 phosphorylated and 4 non-phosphorylated proteins.
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Table 3.1.8: list of differentially expressed proteins from the DLKP 5-FU treatment DIGE experiment that were found to be phosphorylated by
Pro-Q diamond staining.
Location on 
2D gel
Gene
Symbol GI accession number Protein Name Fold change
Known phospho 
site
Kinases/
phosphorylase
Implication o f  
phosphorylation
24 PPP2R5A PÌI4558259I
Chain B, Crystal Structure Of 
Constant Regulatory Domain 
Of Human Pp2a, Pr65 1.92 S28 Protein Kinase R ER stress
40 EIF3S5 gi|30582627|
eukaryotic translation initiation 
factor 3, subunit 5 epsilon, 
47kDa [Ho -1.57 S46
Cyclin dependent 
kinase 11
Phosphorylation occurs 
during apoptosis
81 CFLN1 QÌI305825311
cofilin 1 (non-muscle) [Homo 
sapiens] 2.25
S3
S3
S3
PAK2
LIMK1/2
TESK1/2 Actin remodelling
63 ACAT2 cji|19880019|
acetyl CoA transferase-like 
protein [Homo sapiens] 1.47 ? ? ?
65 CAPZA1 gi| 126527851
CAPZA1 protein [Homo 
sapiens] -1.38 ? ? ?
In order to determine what biological process was effected by the 5-FU treatment of DLKP the list of differentially regulated protein were 
converted to there gene symbols using the DAVID database conversion tool and imported into Pathway assist to determine direct interactions 
between these proteins and are summarised in figure 3.1.51.
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Figure 3.1.51: Image demonstrating
direct interactions between differentially 
expressed proteins in the DLKP 5-FU 
treatment DIGE experiment. Blue nodes 
indicate a protein is up regulated, Red 
nodes indicate a protein is down 
regulated. A node coloured both red and 
blue indicates two isoforms of that 
protein have been identified were one is 
up regulated and the other is down 
regulated. Pathway generated by Pathway 
Assist.
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;h o a c i
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Proteins found to interact include YWHAZ and cofilin, YWHAZ binds to 
phosphorylated cofilin. Gelsolin, cofilin and actin bind each other and are involved in 
F-actin depolymerisation. Gelsolin caps F-actin and binds to vinculin. The HSP70 
proteins, HSPA1A and HSPA9B, form complexes with p53 and are involved in 
cytoplasm sequestering and stabalisation of p53, {Selkirk, et al., 1994}. EEF2 was 
found to bind p53 in polyribosomes and p53 has been implicated in regulation of its 
own translation rate (Yin et al., 2003). STMN1 has been shown to be directly down 
regulated by the accumulation of p53 and stalls cell cycle progression at G2/M phase 
of the cell cycle (Johnsen et al. 2000).
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3.1.9 Proteomic analysis of NHBE post 5-FU exposure
As stated proteomic alteration induced by 5-FU treatment are poorly described in the 
literature and only two publications have been published to date. Data presented 
above demonstrates how two lung carcinomas respond to 5-FU treatment. Cancer 
contains mutations and as such it response to 5-FU will be properly regulated. To over 
come this treatment of the normal bronchial epithelial cells with 5-FU was carried out 
at two concentration 10 and 30 |^M, equi-molar and equi-toxic concentrations. Thus 
this data should provide an isight into how normal cells respond to 5-FU treatment. 
Further more it should help identify a common response between normal and cancer 
cell line treated with 5-FU.
Cell culture of NHBE and NHBE treated with 5-FU (at 10 and 30fiM) was carried out 
as described in section 2.7.2 and 2.7.3. Total cell lysate protein extractions were 
prepared as described in 2.16.2.1. These were prepared in biological triplicate. Each 
biological triplicate was run in technical duplicates. Sample labelling with Cy dyes is 
shown in table 3.1.9. Protein filters of greater than 1.2 or less than -1.2 with a t-test 
less than 0.01, or a fold change of less than -1.5 or greater than 1.5 with t-test less 
than 0.05 were used to identify differentially regulated proteins. This resulted in the 
identification of 399 differentially regulated proteins of which 60 have been identified 
by MALDI-ToF MS.
Preparative gels for protein identification were prepared as described in sections 
2.16.5-2.16.11. Differentially regulated proteins were identified using MALDI-ToF 
MS as described in section 2.16.12. Identified differentially regulated proteins 
locations are indicated in figure 3.1.53 and figure 3.1.54 displays the number of 
differentially regulated proteins identified and ontological data on these proteins. The 
identity of these proteins can be seen in table 3.1.10. Proteins identification data from 
MALDI-ToF MS is included in the appendices.
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Figure 3.1.56 was generated by pathway assist and shows the direct interactions 
between differentially regulated protein isoforms listed in table 3.1.10 and does not 
distinguish between drug concentration in these images as they are purely for 
visualisation purposes. In summary, direct interactions were identified between 18 of 
the proteins listed. These proteins that are listed are involved in intermediate filament 
dynamics of Keratin, Lamins, Actin and tubulin and include LMNA, STMN1, ACTB, 
YWHAZ, CFLN1, and GSN.
Table 3.1.9: Ettan DIGE experimental design for the analysis of differential protein 
expression induced in NHBE by exposure to 5-FU for 7 days.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50(j,g of protein)
NHBE, 
(50p,g of protein)
NHBE, 10|o.M 5-FU, 
(50|xg of protein)
2 Pooled internal standard 
(50fj.g of protein)
NHBE, 
(50|xg of protein)
NHBE, 30(iM 5-FU, 
(50p,g of protein)
3 Pooled internal standard 
(50|ig of protein)
NHBE, 
(50|xg of protein)
NHBE, 10|4.M 5-FU, 
(50^g of protein)
4 Pooled internal standard 
(50^g of protein)
NHBE, 3O|0,M 5-FU, 
(50|^g of protein)
NHBE, 
(50|xg of protein)
5 Pooled internal standard 
(50|ig of protein)
NHBE, IO^ iM 5-FU, 
(50jj.g of protein)
NHBE, 
(50|ig of protein)
6 Pooled internal standard 
(50|ig of protein)
NHBE, 30|O.M 5-FU, 
(50|xg of protein)
NHBE, 
(50(J,g of protein)
7 Pooled internal standard 
(50|ag of protein)
NHBE, 10(J,M 5-FU, 
(50|j.g of protein)
NHBE, 30|jM  5-FU, 
(50|ag of protein)
8 Pooled internal standard 
(50|xg of protein)
NHBE, 30jaM 5-FU, 
(50|j.g of protein)
NHBE, lOfiM 5-FU, 
(50fj.g of protein)
9 Pooled internal standard 
(50fo,g of protein)
NHBE, 10[jM  5-FU, 
(50|xg of protein)
NHBE, 30|aM 5-FU, 
(50|xg of protein)
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Figure 3.1.53: 2D-DIGE images of (a) NHBE (CY3) and (b) NHBE after 7 days treatment with IOjiM 5-FU (CY5) (c) NHBE after 7 days 
treatment with 30|xM 5-FU (CY-5). Identified differentially regulated protein spots are encircled by blue lines and are given a protein number. 
Refer to table 3.1.10 for protein identification
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Figure 3.1.54: A pie chart demonstrating the number of proteins in each biological process in DLKP affected by exposure to 5-FU. Individual 
proteins in each biological process are included in table 3.1.10 Biological process information obtained from the human protein reference 
database.
■Apoptosis
■  Cell growth and/or maintenance
■  Metabolism
■  Protein Metabolism
■  Regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolism
■  Immune Response
□  Signal transduction, cell communication 
■Transport
■  Unknown
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Table 3.1.10: Proteins identified from NHBE 5-FU treatment 2D-DIGE experiment. Position number refers to location in figure 3.1.53 for 
location on 2D gel. Information of fold changes in both 10|iM and 30^M 5-FU treatments were included. Data from both treatments were 
included even where statistics indicated its expression is not significant in order to demonstrate that the proteins expression is dose dependent (in
significant fold changes are shaded grey).Unknown or unnamed proteins were identified as described in section 2.16.13.3.
Protein 
Location 
on 2D- 
DIGE 
Gels Gene Symbol GI Accession Protein Name
NHBE lOuM 5-FU NHBE 30uM 5-FU
Molecular FunctionFold Change T-test
Fold
Change T-test
Cell growth and/or maintainance
25 ACTB gi|62897625| beta actin variant [Homo sapiens] 1.26 0.0017 1.23 0.0038 structural molecule activity
39 CAPZA1 gi|12652785| CAPZA1 protein [Homo sapiens] -3.53 0.036 -1.94 0.31 structural molecule activity
36 CAPZA2 gi|433308| capping protein alpha [Homo sapiens] -1.09 0.41 1.29 0.0014 structural molecule activity
44 CAPZB gi|55665440|
capping protein (actin filament) muscle 
Z-line, beta [Homo sapiens] 1.3 0.0011 1.23 0.0098 structural molecule activity
58 CFL1 gi|30582531| cofilin 1 (non-muscle) [Homo sapiens] 16.63 1.7x10-8 14.17 1.8x10-8 cytoskeletal protein binding
2 CTTN gi|20357556| cortactin isoform b [Homo sapiens] -1.18 0.3 -1.82 0.0049 Cytoskeletal protein binding
3 GSN gi|38044288| gelsolin isoform b fHomo sapiens] 2.61 0.00053 1.77 0.027
Structural constituent o f  
cytoskeleton
4 GSN gi|38044288| gelsolin isofonn b [Homo sapiens] 2.5 0.0034 1.53 0.099
Structural constituent o f  
cytoskeleton
21 KRT14 gi|27769301| Keratin 14 [Homo sapiens] 4.56 0.00041 3.81 0.0005 structural molecule activity
16 KRT17 gi|21754583|
unnamed protein product [Homo 
sapiens] 5.18 2.9x10-7 3.31 9.6x10-6 structural molecule activity
20 KRT17 gi|21754583|
unnamed protein product [Homo 
sapiens] 2.07 0.0022 1.69 0.034 structural molecule activity
19 KRT18 gi|62897747| keratin 18 variant [Homo sapiens] 2.33 0.00024 2.31 7.8x10-5 structural molecule activity
23 KRT19 gi|34039|
unnamed protein product [Homo 
sapiens] 2.78 0.00019 3.66 0.00021 structural molecule activity
13 KRT5 gi|479406011 Keratin 5 [Homo sapiens] 2.13 0.0038 3 0.00067 structural molecule activity
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15 KRT8 gi|33875698| KRT8 protein rHomo sapiens] -1.47 0.00044 -1.34 0.071 structural molecule activity
5 LMNA gi|57014047|
lamin A/C transcript variant 1 [Homo 
sapiens] 1.92 0.00015 2.05 0.0035 structural molecule activity
10 PLS3 gi|57162424| plastin 3 (T isoform) [Homo sapiens] 2.1 6.2x10-5 2.37 0.00013 structural molecule activity
59 STMN1 gi|5031851| stathmin 1 [Homo sapiens] -2.18 0.0002 -2.78 1.1x10-5 cytoskeletal protein binding
54 TPT1 gi|33285832| TCTP [Homo sapiens] 1.39 0.00049 1.61 4.4x10-5 Calcium ion binding
11 WDR1 gi|62897353|
WD repeat-containing protein 1 isoform 
1 variant [Homo sapiens] 2.29 0.0023 1.99 0.03 cytoskeletal protein binding
Metabolism; Energy pathway
56 GSTA1 gi|23200509|
Chain B, A  Folding Mutant O f Human 
Class Pi Glutathione Transferase, 
Create 1.45 0.00014 1.53 5.0x10-5
Gluthathione transferase 
activity
31 PRPS1 gi|35700|
unnamed protein product [Homo 
sapiens] 1.70 0.019 1.28 0.2 Ligase activity
41 SRM gi|531202| spermidine synthase 1.16 0.46 2.57 0.00028
1 VCP gi|55662798|
valosin-containing protein [Homo 
sapiens] 2.11 0.016 1.48 0.11 ATPase activity
Protein metabolism
51 CAPNS1 gi|40674605| CAPNS1 protein [Homo sapiens] 1.15 0.14 1.56 0.00048
Cysteine-type peptidase 
activity
42 EEF1BD gi|38522|
human elongation factor-1-delta [Homo 
sapiens] 1.08 0.43 1.73 0.015 Translation regulator activity
17 EEF1BG gi|39644794| EEF1BG protein [Homo sapiensl 1.34 0.24 1.9 0.021 Translation regulator activity
32 EIF3S2 gi|56204149|
eukaryotic translation initiation factor 3, 
subunit 2 beta, 36kDa [Homo -3.69 0.013 -1.65 0.36 Translation regulator activity
9 HSPA1B gi|14424588l HSPA1A protein [Homo sapiens] 1.75 0.0045 1.43 0.0077 Chaperone activity
6 HSPA5 gi|6470150| BiP protein [Homo sapiens] 2.82 0.00098 2.42 0.0044 Chaperone activity
7 HSPA8 gi|62896815|
heat shock 70kDa protein 8 isoform 2 
variant [Homo sapiens] 2.00 0.015 1.01 0.12 Chaperone activity
53 HSPB1 gi|15126735|
Heat shock 27kDa protein 1 [Homo 
sapiens] 2.63 6.5x10-6 2.69 3.7x10-6 Chaperone activity
50 HSPB1 gi|15928913|
Unknown (protein for 
IMAGE:3906970) [Homo sapiens] 1.74 6.0x10-5 2.1 2.1x10-5 Chaperone activity
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52 HSPB1 gi|15928913|
Unknown (protein for 
IMAGE:3906970) [Homo sapiens] 2.1 1.0x10-6 2.9 5.0x10-8 Chaperone activity
48 HSPB1 gi|662841| heat shock protein 27 [Homo sapiens] -3.73 0.019 -1.76 0.39 Chaperone activity
14 P4HB gil48735337l
Prolyl 4-hydroxylase, beta subunit 
[Homo sapiens] -1.27 0.019 -1.77 0.0014 Isomerase activity
47 PSMA3 gi|481459831 PSMA3 [Homo sapiens] -1.63 4.1x10-5 -1.24 0.048
Ubiquitin-specific protease 
activity
22 PSMC2 gi141472112| unknown [Homo sapiensl 1.57 0.044 1.58 0.0038
Ubiquitin-specific protease 
activity
35 RPLPO gi|12654583| Ribosomal protein P0 [Homo sapiens] 1.01 0.79 2.06 0.00047 ribosomal subunit
24 SERPINB1 gi|62898301|
serine (or cysteine) proteinase inhibitor, 
clade B (ovalbumin), member 2.53 0.0052 1.89 0.016 Protease inhibitor activity
29 SERPENB5 gi|56554673|
Chain A, 3.10 A  Crystal Structure O f 
Maspin, Space Group 14 2 2 1.78 0.00035 1.58 0.0067 Protease inhibitor activity
30 SERPINB5 gi|56554673|
Chain A, 3.10 A Crystal Structure Of 
Maspin, Space Group 14 2 2 1.22 0.023 1.45 0.00071 Protease inhibitor activity
regulation o f nucleobase, nucleoside, nucleotide and nucleic acid metabolism
12 HNRPK gi|55958547|
heterogeneous nuclear 
ribonucleoprotein K [Homo sapiens] 1.73 0.017 1.4 0.11 Ribonucleoprotein
Sienal transduction, cell cummunication
26 RPSA gi|34234| laminin-binding protein [Homo sapiens] -1.66 0.00012 -1.93 4.8x10-5 ribosomal subunit
60 SI 00 A l l gi|32880167|
SI00 calcium binding protein A l 1 
(calgizzarin) [Homo sapiens] 1.54 2.0x10-5 1.61 2.0x10-6 Calcium ion binding
45 SFN gi|l 63067371 SFN protein [Homo sapiensl 1.65 0.00043 1.97 9.4x10-5
Receptor signalling complex 
scaffold activityactivity
27 STRAP gi|4519417| WD-40 repeat protein [Homo sapiens] -1.38 0.0023 -1.26 0.047 Regulation o f Cell cycle
46 YWHAG gi|82407958|
Chain F, Crystal Structure O f 14-3-3 
Gamma In Complex With A  
Phosphoserine 1.37 0.0019 1.44 0.00056
Receptor signalling complex 
scaffold activityactivity
49 YWHAZ gi|68085578|
Tyrosine 3/tryptophan 5 - 
monooxygenase activation protein, zeta 
polypeptide 1.34 0.0018 1.23 0.012
Receptor signalling complex 
scaffold activityactivity
Not present in database
38 ATP5B gill6741373|
ATP synthase, H+ transporting, 
mitochondrial FI complex -1.53 0.0034 -1.2 0.21
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28 gi|62738526|
Chain B, The 2.8 A  Structure O f A
Tumour Suppressing Serpin 1.82 0.00017 1.38 0.031
8 gii6729803| Heat-Shock 70kd Protein 42kd Atpase 1.17 0.4 2.63 4.8x10-6
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Protein modifications such as protein phosphorylation alter the pi of proteins and thus 
contribute to the various isoforms identified for apparently the same protein. MALDI- 
ToF MS is not capable of distinguishing between such modifications. Pro-Q diamond 
is a fluorescent dye that selectively binds to phosphorylated residues of serine, 
threonine and thyrosine. For analysis of proteins being differentially regulated in this 
experiment a pooled sample of both control and treated was separated by 2D 
electrophoresis and stained and matched to the BVA as described in section 2.25. 
Proteins that were deemed phosphorylated at serine/threonine/thyrosine are indicates 
in figure 3.1.56 and are summarised in Table 3.1.11. Phosphorylation data is listed in 
same table where available.
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Figure 3.1.56: A pooled protein sample from NHBE and NHBE 5-FU treated separated by 2D electrophoresis and stained with (a) RuPBS to 
visualise total cell lysate proteome and (b) Pro-Q diamond to visualise phosphorylated proteins. Molecular weight ladder run on right side of 
images contains a mixture of 2 phosphorylated and 4 non-phosphorylated proteins..
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Table 3.1.11: list of proteins differentially expressed proteins from the NHBE 5-FU treatment DIGE experiment that were found to be
phosphorylated by Pro-Q diamond staining.
Location on 2D gel
Gene
Symbol
GI accession 
rnunber Protein Name Fold change
Known phospho 
site
Kinases/
phosphorylase
Implication of  
phosphorylation
5 LMNA PÌI570140471
lamin A/C transcript 
variant 1 [Homo sapiens] 2.05
S5
T19
S22
T199
S390
S392
S403
S404/S406/S407
T409
T416
S423
T480
S525
PKC 
CDC2 
CDC2 
PKC 
CDC2 
Protein kinase Ca 
Protein kinase Ca 
?/?/?
PKC
?
PKC 
Protein kinase Ca 
? Lamin assembly
20 KRT17 gi|217545831
unnamed protein product 
[Homo sapiens] 1.69 ? ? ?
32 EIF3S2 pi|56204149|
eukaryotic translation 
initiation factor 3, subunit 
2 beta, 36kDa [Homo -1.65 ? TGFBR2 activation
35 RPLPO qi|12654583|
Ribosomal protein P0 
[Homo sapiens] 2.06 ? ? ?
42 EEF1BD PÜ38522I
human elongation factor- 
1-delta [Homo sapiens] 1.73 S449 CDC2 ?
53 HSPB1 gi|151267351
Heat shock 27kDa 
protein 1 [Homo sapiens] 2.69 S15/S78/S82 MAPKAPK2 Cell survival
58 CFLN1 gi|305825311
cofilin 1 (non-muscle) 
[Homo sapiens] 14.17
S3
S3
S3
PAK2
LIMK1/2
TESK1/2 Actin remodelling
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In order to identify biological processes impacted by proteins differentially regulated 
by 5-FU treatment of NHBE protein identifications were converted to gene symbols 
using DAVID database ID conversion tool and imported into Pathway Assist to 
determine direct interactions between these proteins. Figure 3.1.51 was generated by 
Pathway Assist and shows the direct interactions between differentially regulated 
protein isoforms listed in table 3.1.6.
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Figure 3.1.57: Image demonstrating direct interactions between differentially expressed proteins in the NHBE 5-FU treatment DIGE 
experiment. Blue nodes indicate a protein is up regulated, Red nodes indicate a protein is down regulated. A node coloured both red and blue 
indicates two isoforms of that protein have been identified were one is up regulated and the other is down regulated. Pathway generated by 
Pathway Assist.
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In summary, direct interactions were identified between 20 of the proteins listed. 
These proteins that are listed are involved in intermediate filament dynamics of 
Keratin, Lamins, Actin and tubulin and include LMNA, STMN1, ACTB, YWHAZ, 
CFLN1, GSN, KRT 5, 8, 14, 17, and 18. WDR-1 enhances cofilin depolymerisation 
of F-actin (Rodal et al., 1999). YWHAZ binds p-cofilin and prevents its recycling 
during actin depolymerisation (Gohla, et al., 2002; Berkenfeld, et al., 2003). Gelsolin 
and cofilin depolymerise actin as already discussed. HSPA8 associates with the t- 
complex of protein chaperones and actin or tubulin and is responsible for actin or 
tubulin turnover. This complex transports actin in its native form where it ensures its 
correct incorporation into microfilaments (Bourke et al., 2002). Phosphorylated 
Stathmin binds HSP70 and plays a role in regulation of cell growth (Manceau, et al., 
1999).
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3.1.10 Proteomic analysis of MCF-7 post 5-FU exposure
DIGE analysis of protein expression in MCF-7 after 7 days exposure 5-FU at a 
concentration of 10(J.M
To date there have been several DNA microarray experiments performed on the breast 
adenocarcinoma cell line MCF-7 treated with 5-FU. However no proteomic 
experiments have performed on MCF-7 or any other cell line of breast origin. 
Investigation of proteomic alterations will identify differentially regulated proteins 
that contribute to increased invasion induced by 5-FU treatment of MCF-7. 
Furthermore, identified differentially expressed proteins may indicate anti-apoptopic 
mechanisms employed by MCF-7 to survive 5-FU treatment and could contribute to 
the development of drugs that overcome resistance to apoptosis during 5-FU 
treatments. Cell culture of MCF-7 and MCF-7 treated with 5-FU were carried out as 
described in section 2.7.3. Total protein extractions were prepared as described in 
section 2.16.2.1. These were prepared in biological triplicate. Each biological 
triplicate was run in technical duplicates. Sample labelling with Cy dyes is shown in 
table 3.1.12. Protein filters of less than minus 1.2 or grater than plus 1.2 with t-test of 
less than 0.01, and fold change of less than minus 1.5 or greater than plus 1.5 with a t- 
test of 0.05 were used to identify differentially regulated proteins. This resulted in the 
selection of 429 proteins of which 152 have been identified.
Preparative gels for protein identification were prepared as described in sections 2.21- 
2.25. Differentially regulated proteins were identified using MALDI-ToF MS as 
described in section 2.27. Identified differentially regulated proteins locations are 
indicated in figure 3.1.59 and figure 3.1.60 displays the number of differentially 
regulated proteins identified and ontological data on these proteins. The identity of 
these proteins can be seen in table 3.1.13. Proteins identification data from MALDI- 
ToF MS is included in the appendices.
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Table 3.1.12: Ettan DIGE experimental design for the analysis of differential protein 
expression induced in MCF-7 by exposure to 5-FU for 7 days.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50|j,g of protein)
MCF-7, P. 183 
(50|xg of protein)
MCF-7, P. 183, 5-FU 
treated (50^g of protein)
2 Pooled internal standard 
(50|Ag of protein)
MCF-7, P. 183 
(50^g of protein)
MCF-7, P. 183, 5-FU 
treated (50|ag of protein)
3 Pooled internal standard 
(50|xg of protein)
MCF-7, P. 185 
(50|o,g of protein)
MCF-7, P. 185, 5-FU 
treated (50|ig of protein)
4 Pooled internal standard 
(50(j.g of protein)
MCF-7, P. 185 
(50p,g of protein)
MCF-7, P. 185, 5-FU 
treated (50ja,g of protein)
5 Pooled internal standard 
(50ng of protein)
MCF-7, P. 186 
(50(j,g of protein)
MCF-7, P. 186, 5-FU 
treated (50|ig of protein)
6 Pooled internal standard 
(50|j,g of protein)
MCF-7, P. 186 
(50p,g of protein)
MCF-7, P. 186, 5-FU 
treated (50(a.g of protein)
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Figure 3.1.59: Images of representative DIGE gels from (a) MCF-7, (b) MCF-7 after 7 days treatment with 5-FU, (c) close up region 
highlighted in ‘image (a)’ and (d) close up of image highlighted in ‘image (b)\ Identified differentially regulated protein spots are encircled by 
blue lines and are given a protein number. Refer to table 3.1.13 for protein identification.
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Figure 3.1.60: A pie chart demonstrating the number of proteins in each biological process in MCF-7 effected by exposure to 5-FU. Individual 
proteins in each biological process are included in table 3.1.13. Biological process information obtained from the human protein reference 
database.
■  Unknown
■ C e ll growth and/or maintenance
■  Metabolism
■  Protein metabolism
■  regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolism
■  Signal transduction, cell cummunication 
■Transport
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Table 3.1.13: Proteins identified by MALDI-ToF MS that were found to be differentially regulated in MCF-7 cells after 7 days exposure to 5- 
FU. Protein expression data is included in table (fold change and t-test) as well Protein location on 2D gels (see figure 3.1.13.4.1 for locations). 
GI accession number was obtained from MS data and protein name, Gene symbol was found from DAVID database, Human protein reference 
database or swissprot. Molecular and biological functions were obtained from the human protein reference database. Unknown/unnamed
proteins (an artefact of poorly updated databases) names were determined as described in section 2.16.13.3.
Protein
location
GI
accession
Number
Gene
symbol Name T-test
Fold
change Molecular function
Biological Function: Unknown
21 gi 21071030 A1BG alpha lB-glycoprotein [Homo sapiens] 2.4x10"* 1.9
122 gi|20271412| TBC1D16
TBC1 domain family, member 16 
[Homo sapiens] 2.4x10'3 1.79
Biological Function: Cell growth and/or maintenance
144 gi|61679634| TPT1
Chain A, Solution Structure Of Human 
Translationally Controlled Tumor Prote 2.4x10'8 1.91 Calcium ion binding
20 gi 46249758 VIL2 Villin 2 [Homo sapiens] 8.7x10° 3.46 cytoskeletal anchoring activity
23 gi 28436809 RDX Radixin [Homo sapiens] 5.6x10^ 2.27 cytoskeletal protein binding
114 gi 2135552 LASPI Lasp-1 protein - human 1.6x10^ 1.64 cytoskeletal protein binding
148 gi 30582531 CFL1 cofilin 1 (non-muscle) [Homo sapiens] 6.3x10^ 5.08 cytoskeletal protein binding
150 gi 62088144 STMN1 stathmin 1 variant [Homo sapiens] 7.2x10"y -3.43 cytoskeletal protein binding
14 g i8131894 IMMT mitofilin [Homo sapiens] 2.7x10^ 2.79 Motor activity
19 gi|55250201| DYNC1I2
cytoplasmic dynein intermediate chain 
2C [Homo sapiens] 8.4x10'3 1.59 Motor activity
11 g i38044288 GSN gelsolin isoform b [Homo sapiens] 2x10’3 4.03 Structural constituent of cytoskeleton
12 gi 38044288 GSN gelsolin isoform b [Homo sapiens] 1.9x10^ 3.03 Structural constituent of cytoskeleton
13 S138044288 GSN gelsolin isoform b [Homo sapiens] 1.7xl0’6 7.35 Structural constituent of cytoskeleton
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15 gi|38044288| GSN gelsolin isoform b [Homo sapiensl 3.4xl0'b 5.86 Structural constituent of cytoskeleton
28 gi|5031877| LMNB1 lamin B1 [Homo sapiensl 7.7x10'2 -1.24 structural molecule activity
45 gi|27227551| TUBB2A
class II beta tubulin isotype [Homo 
sapiens] 4x10’3 1.49 structural molecule activity
59 gi|39645331 KRT8 KRT8 protein [Homo sapiens] 1.3xl0"3 2.1 structural molecule activity
60 gi|30313| KRT8 cytokeratin 8 (279 AA) [Homo sapiens] 4.6x1 O^ - 2.19 structural molecule activity
62 gill 814001 KRT8 cytokeratin 8 1.8x1 O'3 2.39 structural molecule activity
63 gi 181400 KRT8 cytokeratin 8 3.4x10-' 3.25 structural molecule activity
64 gi 30313 KRT8 cytokeratin 8 (279 AA) [Homo sapiens] 1.8x10'2 2.47 structural molecule activity
67 gi 181400 KRT8 cytokeratin 8 8.2 xlO^ 2.68 structural molecule activity
68 si 39645331 KRT8 KRT8 protein [Homo sapiens] 92 xlO"3 2.02 structural molecule activity
69 gi|39645331| KRT8 KRT8 protein [Homo sapiens] 2 xlO’2 2.87 structural molecule activity
71 gi|39645331| KRT8 KRT8 protein [Homo sapiens] 4.7 xl0‘3 2.37 structural molecule activity
73 gi|30313| KRT8 cytokeratin 8 (279 AA) [Homo sapiens] 5.4x10‘3 1.88 structural molecule activity
75 gi 181400 KRT8 cytokeratin 8 9.8 x l0 '; 2.36 structural molecule activity
76 gi 62897747 KRT18 keratin 18 variant [Homo sapiens] 3.5 xlO 2 1.55 structural molecule activity
81 gi 63309261 KRT18 Keratin 18 [Homo sapiens] 3.1 xlO"1 2.68 structural molecule activity
83 Si 12653819 KRT18 Keratin 18 [Homo sapiens] 3.6 xlO"1 4.01 structural molecule activity
84 gi 62897747 KRT18 keratin 18 variant [Homo sapiens] 1.4xl0"3' 2.27 structural molecule activity
86 gi|12653819| KRT18 Keratin 18 [Homo sapiens] 7.7 xlO’5 1.8 structural molecule activity
87 gi|30311| KRT18
cytokeratin 18 (424 AA) [Homo 
sapiens] 1.9x1 O'2 1.9 structural molecule activity
90 gi|30311| KRT18
cytokeratin 18 (424 AA) [Homo 
sapiens] 3 xlO"3 1.39 structural molecule activity
91 gi|34039| KRT19
unnamed protein product [Homo 
sapiens] keratin 19 4.9 xlO'3 3.79 structural molecule activity
93 gi 453155 KRT9 keratin 9 [Homo sapiens] 2.1 xlO’2 2.71 structural molecule activity
94 gi 14043271 KRT19 Keratin 19 [Homo sapiens] 1.1 xlO'3 2.5 structural molecule activity
95 gi 24234699 KRT19 keratin 19 [Homo sapiens] 6.7 xlO"* 2.33 structural molecule activity
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96 gi|24234699| KRT19 keratin 19 [Homo sapiens] 5 xlO"2 1.82 structural molecule activity
99 gi|34039| KRT19
unnamed protein product [Homo 
sapiens] keratin 19 5.9 xlO'3 1.61 structural molecule activity
100 gi 15277503 ACTB ACTB protein [Homo sapiens] 3.2 xlO'2 1.33 structural molecule activity
101 gi 62897625 ACTB beta actin variant [Homo sapiens] 6.3 xl0‘" 1.64 structural molecule activity
103 gi 15277503 ACTB ACTB protein [Homo sapiens] 1.5 xlO'2 1.53 structural molecule activity
121 gi|30311| KRT18
cytokeratin 18 (424 AA) [Homo 
sapiens] 2x10^ 2.17 structural molecule activity
147 gi|33150590| MTCBP1
submergence induced protein 2 [Homo 
sapiens] 8.1 xlO"1 -1.65
Biological Function: Metabolism; Energy Pathway
58 gi|643589| DLST
dihydrolipoamide succinyltransferase 
[Homo sapiens] 5.8 xlO'3 1.82 Acetyltransferase activity
149 gi|251370| ACPI
acid phosphatase isoenzyme Af [human, 
erythrocytes, Peptide, 157 aa] 3.2 xlO^ 1.55 Acid phosphatase activity
65 gi|62896511| DARS
aspartyl-tRNA synthetase variant 
[Homo sapiens] 4.5 xlO"2 1.62 ATPase activity
105 gi|40889569| hemE
Uroporphyrinogen Decarboxylase 
Single Mutant D86g In Complex With 1.3 xlO'2 2.04 Carboxyl-lyase activity
113 gi|387010| PDHB
pyruvate dehydrogenase El-beta 
subunit precursor 1 xlO"3 1.39 Carboxyl-lyase activity
33 gi 629889421 GPD2 unknown [Homo sapiens] 3.9 xlO 2 1.72 Catalytic activity
55 gi|7546530| G6PD
Chain H, X-Ray Structure Of Human 
Glucose 6-Phosphate Dehydrogenase 3 xlO"3 2.18 Catalytic activity
56 gi|338827| PKM2
cytosolic thyroid hormone-binding 
protein (EC 2.7.1.40) 3.3 xlO'2 2.05 Catalytic activity
85 gi|62896593| ENOl enolase 1 variant [Homo sapiens] 2.1 xlO'2 1.97 Catalytic activity
142 gi 459815 HPRT1 hypoxanthine phosphoribosyltransferase 1.8 xlO3 1.3 Catalytic activity
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146 gi|71773201| APRT
adenine phosphoribosyltransferase 
isoform b [Homo sapiens] 1.6 xlO'5 1.77 Catalytic activity
41 gi|14250818| ATIC
5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP 
cycl 7.8 xlO"3 1.57 Hydrolase activity
92 gi 10241525 AHCY AHCY [Homo sapiens] 5.2 xlO"3 1.8 Hydrolase activity
110 gi|1311149| FBP1
Chain D, Fructose-1,6- 
Bisphosphatase(D-Fructose-1,6- 
Bisphosphate, 1-Phosphoh 1.9x1 O'2 1.53 Hydrolase activity
137 gi 56204402 PRDX6 peroxiredoxin 6 [Homo sapiens] 1.3 xl0"j 2.13 Peroxidase activity
116 gi|47168568| NP
Chain E, Crystal Structure Of Human 
Pnp Complexed With Acyclovir 2.8 xlO^ 2.93 phosphorylase activity
57 gi|321893941 ATP5B
ATP synthase, H+ transporting, 
mitochondrial FI complex, beta subunit 4x10'3 1.67 Transporter activity
72 gi|28940| ATP5B
unnamed protein product [Homo 
sapiens] ATP synthase 4x1 O'2 1.5 Transporter activity
39 gi|23200451| CBS
Chain F, Cystathionine-Beta Synthase: 
Reduced Vicinal Thiols 8.8 xlO'3 2.74
108 gi|8453156| NANS
N-acetylneuraminic acid phosphate 
synthase [Homo sapiens] 1.4 xlO'3 1.65
Biological Function: Protein Metabolism
29 gi|l 0933784 RNPEP aminopeptidase B [Homo sapiens] 2 xlO"3 2.73 Aminopeptidase activity
129 gi 5822091 CTSD Chain H, Cathepsin D At Ph 7.5 1.8 xlO'5 1.62 Aspartic-type signal peptidase activity
130 gi|30582659| CTSD
cathepsin D (lysosomal aspartyl 
protease) [Homo sapiens] 6.5 xlO'7 2.19 Aspartic-type signal peptidase activity
132 gi|30582659| CTSD
cathepsin D (lysosomal aspartyl 
protease) [Homo sapiens] 5 xlO"6 2.62 Aspartic-type signal peptidase activity
1 gi|1794219| HYOU1
150 kDa oxygen-regulated protein 
QRP150 [Homo sapiens] 1.4x10^ 3.49 Chaperone activity
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2 gi|10720185| HYOU1
150 kDa oxygen-regulated protein 
precursor (0rpl50) (Hypoxia up-r 4.6 xlO^ 3.97 Chaperone activity
4 gi|62087882| HSPA4
heat shock 70kDa protein 4 isoform a 
variant [Homo sapiens] 6.5 xlO'3 1.92 Chaperone activity
5 gi|62088648| TRA1
tumor rejection antigen (gp96) 1 variant 
[Homo sapiens] 5x1 O'2 1.81 Chaperone activity
6 gi|62897207| AARS
alanyl-tRNA synthetase variant [Homo 
sapiens] 2 xlO'2 2.31 Chaperone activity
7 gi|57209340| ATG7
ubiquitin-activating enzyme El (A1S9T 
and BN75 temperature sensitivity 9.4x10^ 3.77 Chaperone activity
9 gi|31077164| HSPA4L
Heat shock 70 kDa protein 4L (Osmotic 
stress protein 94) (Heat s 2.7x10'3 2.1 Chaperone activity
22 gi 1143492 HSPA5 BiP [Homo sapiens] 2.5 xlO’2 2.31 Chaperone activity
25 g i1143492 HSPA5 BiP [Homo sapiens] 1.2x10'3 2.46 Chaperone activity
34 gi|51234541 HSPA1B
heat shock 70kDa protein 1A [Homo 
sapiens] 2.3 xlO'2 1.56 Chaperone activity
36 gi|58761484| CCT3
chaperonin containing TCP1, subunit 3 
isoform c [Homo sapiens] 5 xlO'2 1.45 Chaperone activity
38 gi|62089036| CCT6A
chaperonin containing TCP1, subunit 
6A isoform a variant [Homo sapiens] 5.8 xlO'3 1.92 Chaperone activity
40 gi|62087344| CCT3
chaperonin containing TCP1, subunit 3 
(gamma) variant [Homo sapiens] 3.8 xlO’3 1.65 Chaperone activity
42 gi|62089036| CCT6A
chaperonin containing TCP1, subunit 
6A isoform a variant [Homo sapiens] 1.4x1 O’2 1.91 Chaperone activity
134 gi 662841 HSPB1 heat shock protein 27 [Homo sapiens] 4.1 xlO"* 2.39 Chaperone activity
135 gi 662841 HSPB1 heat shock protein 27 [Homo sapiens] 3.4x10^ 2.47 Chaperone activity
43 gi 77702086 HSPD1 heat shock protein 60 [Homo sapiens] 4.2 xlO'2 -1.73 heat shock protein activity
52 gi 6996447 HSPD1 chaperonin 60, Hsp60 [Homo sapiens] 3.2 xlO'2 -1.84 heat shock protein activity
48 gi 1085373 ER-60 protein disulfide-isomerase (EC 5.3.4.1) 5.8 xlO"3 1.43 Isomerase activity
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ER60 precursor - human
49 gi 2245365 ER-60 ER-60 protein [Homo sapiens] 8.2 xlO"J 1.55 Isomerase activity
50 gi|20070125| P4HB
prolyl 4-hydroxylase, beta subunit 
[Homo sapiens] 3.3 xlO'3 1.66 Isomerase activity
104 gi|13489087| SERPINB1
serine (or cysteine) proteinase inhibitor, 
clade B (ovalbumin), member 3.3 xlO'2 1.58 Protease inhibitor activity
118 gi|55646721| SFRS1 splicing factor, arginine/serine-rich 2.7 xlO'3 1.47 RNA binding
89 gi|2136315| TUFM
translation elongation factor EF-Tu 
precursor - human 7.4x10^ 1.83 Translation regulator activity
119 gi|25453474| EEF1BD
eukaryotic translation elongation factor 
1 delta isoform 1 [Homo sapie 3.5 xlO^ 2.18 Translation regulator activity
120 gi|25453472| EEF1BD
eukaryotic translation elongation factor 
1 delta isoform 2 [Homo sapie 3.5 xlO"2 1.58 Translation regulator activity
145 gi|15278174| PSMB3
Proteasome beta 3 subunit [Homo 
sapiens] 3.1 xlO"* 1.43 ubiquitin-specific protease activity
Biological function: Regulation o f nucleobase, nucleoside, nucleotide and nucleic acid metabolism
98 gi|30582415| ADK adenosine kinase [Homo sapiens] 7.6x1 O'3 1.43 Catalytic activity
127 gi|55958718| HMGB1
high-mobility group box 1 [Homo 
sapiens] 2.2 xlO"2 1.54 DNA binding
51 gi|62898690| RAD23B
UV excision repair protein RAD23 
homolog B variant [Homo sapiens] 1.9 xlO'2 1.76 DNA repair protein
136 gi|55650119| LOC456359
PREDICTED: similar to DNA-directed 
RNA polymerase I I23 kDa polypeptid 1.5 xlO'5 2.28 DNA-directed RNA polymerase
82 gi 40788956 DDX48 KIAA0111 [Homo sapiens] eIF4AIII 1.1 xlO"3 1.73 NMD ofmRNA
35 gi|62896771| G3BP
Ras-GTPase-activating protein SH3- 
domain-binding protein variant [Homo 3.7x1 O'2 2.27 Ribonuclease activity
47 £ 55958547 HNRPK heterogeneous nuclear 2.4x1 O'2 1.68 Ribonucleoprotein
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ribonucleoprotein K [Homo sapiens]
61 gi 12655001 HNRPH1 HNRPH1 protein [Homo sapiens] 4.3 xlO'3 1.36 Ribonucleoprotein
79 gi 15990432 HNRPF HNRPF protein [Homo sapiens] 1.7 xlO"3 2.34 Ribonucleoprotein
54 gi|46370086| TCF12
transcription factor 12 isoform c [Homo 
sapiens] 2.9 xlO'3 2.55 Transcription factor activity
109 gi|2564242| NFYC
CCAAT transcription binding factor, 
gamma subunit [Homo sapiens] 1.5 xlO'3 1.93 Transcription factor activity
74 gi|4506439| RBBP7
retinoblastoma binding protein 7 [Homo 
sapiens] 5.8 xlO"3 -1.62 Transcription regulator activity
151 gi|3318698| Crabp2
Chain B, Apo-Cellular Retinoic Acid 
Binding Protein Ii 6.6 xlO"6 2.12 Transcription regulator activity
152 gi|33186981 Crabp2
Chain B, Apo-Cellular Retinoic Acid 
Binding Protein Ii 1.2 xlO'8 2.48 Transcription regulator activity
18 gi|510946031 MCM7 MCM7 3.7 xlO 2 -1.97
Biological Function: Signal transduction, cell communication
31 gi|71773415| ANXA6 annexin VI isoform 2 [Homo sapiens] 1.9x10 2 2.1 Calcium ion binding
111 gi|56967119| ANXA2
Chain B, Structure Of Human Annexin 
A2 In The Presence Of Calcium Ions 1.4 xlO'5 1.68 Calcium ion binding
115 gi|56967119| ANXA2
Chain B, Structure Of Human Annexin 
A2 In The Presence Of Calcium Ions 3.3 xlO'2 1.29 Calcium ion binding
117 gi|1421662| ANXA3
Annexin Family M olid: 1 ; Molecule: 
Annexin Iii; Chain: Null; Engineered: 
Yes; 1.3 xlO"5 2.17 Calcium ion binding
123 gi|1703319| ANXA4
Annexin A4 (Annexin IV) (Lipocortin 
IV) (Endonexin I) (Chromobind 2.2 xlO"2 1.52 Calcium ion binding
124 gi|1421662| ANXA3
Annexin Family Mol id: 1; Molecule: 
Annexin Iii; Chain: Null; Engineered: 
Yes; 5 xlO'2 1.43 Calcium ion binding
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37 gi|32483399| PAK2 p21-activated kinase 2 [Homo sapiens! 5.8x10^ 2.58
protein serine/threonine kinase 
activity
112 gi|6537210| PPP6C
serine/threonine protein phosphatase 
catalytic subunit [Homo sapiens] 2.3 xlO'3 1.56
protein serine/threonine phophatase 
activity
44 gi|54696884| STIPI
stress-induced-phosphoprotein 1 
(Hsp70/Hsp90-organizing protein) 
[Homo s 1 xlO"2 1.76
Receptor signalling complex scaffold 
activityactivity
46 gi|54696884| STIPI
stress-induced-phosphoprotein 1 
(Hsp70/Hsp90-organizing protein) 
[Homo s 3.4 xlO’3 1.55
Receptor signalling complex scaffold 
activityactivity
131 gi|460153741 ARHGDIB
Chain D, Crystal Structure Of Rhogdi 
K(199,200)r Double Mutant 2.5 xlO’5 1.74
Receptor signalling complex scaffold 
activityactivity
132 gi182407958] YWHAG
Chain F, Crystal Structure Of 14-3-3 
Gamma 3.3 xlO'2 1.53
Receptor signalling complex scaffold 
activityactivity
139 gi|68085578| YWHAZ
Tyrosine 3/tryptophan 5 - 
monooxygenase activation protein, zeta 1.4x10'3 1.66
Receptor signalling complex scaffold 
activityactivity
107 gi|34234| RPSA
laminin-binding protein [Homo 
sapiens] lx l O'2 -1.33 ribosomal subunit
97 gil 169043741 RISI
Ras-induced senescence 1 [Homo 
sapiens] 1.8x1 O'2 1.86 Unknown
Biological Function: Transport
128 gi|4588526| CLIC1 nuclear chloride channel [H. sapiens] 3.5x10"* 1.86 intracellular ligand-gated ion channel
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Protein modifications such as protein phosphorylation alter the pi of proteins and thus 
contribute to the various isoforms identified for apparently the same protein. MALDI- 
ToF MS is not capable of distinguishing between such modifications. Pro-Q diamond 
is a fluorescent dye that selectively binds to phosphorylated residues of serine, 
threonine and tyrosine. For analysis of proteins being differentially regulated in this 
experiment a pooled sample of both control and treated was separated by 2D 
electrophoresis and stained and matched to the BVA as described in section 2.16.10. 
Proteins that were deemed phosphorylated at serine/threonine/thyrosine are indicates 
in figure 3.1.61 and are summarised in Table 3.1.14. Phosphorylation data is listed in 
same table where available.
181
Figure 3.1.61: 2D-Gel images of (a) RuPBS stained and (b) Pro-Q diamond stained protein sample pool of MCF-7 and MCF-7 treated with 5- 
FU (c) close up view of region in red box in “image (a)”, and (d) close up view of region in red box in “image (a)”. Phosphorylated proteins are 
stained with Pro-Q diamond stain while all proteins are stained with RuPBS.
# .GS k PH
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Table 3.1.14: list of proteins differentially expressed proteins from the MCF-7 5-FU treatment DIGE experiment that were found to be
phosphorylated by Pro-Q diamond staining. Known phosphorylation sites are listed and protein kinases and phosphorylases.
Location on 2D gel
Gene
Symbol
GI accession 
number Protein Name Fold change
Known phospho 
site
Kinases/
phosphorylase
Implication o f  
phosphorylation
19 gi|55250201|
cytoplasmic dynein 
intermediate chain 2C 
[Homo sapiens] 1.59 ? ? ?
35 G3BP gi|62896771|
Ras-GTPase-activating 
protein SH3-domain- 
binding protein variant 
[Homo 2.27
S149
S231
5231
5232
?
?
?
?
Nuclear localisation
?
?
?
37 PAK2 gi|32483399|
p21-activated kinase 2 
[Homo sapiens] 2.58
519
520 
S55
Y130
S141
S192
S197
T403
PAK2
PAK2
PAK2
Src
PAK2
PAK2
PAK2
PAK2
67 KRT8 gi|181400| cytokeratin 8 2.68
521
522 
S24 
S3 7 
S43 
S74 
S432
MAPK14 
MAPK14 
MAPK14 
ERK2 
P38 kinase
69 KRT8 gi|39645331|
KRT8 protein [Homo 
sapiens] 2.87
S23
S74
S432
MAPK14 
ERK2 
P38 kinase
75 KRT8 gi|181400| cytokeratin 8 2.36
S23
S74
S432
MAPK14 
ERK2 
P38 kinase
76 KRT18 gi|62897747|
keratin 18 variant [Homo 
sapiens] 1.55
S34
S53
CDC2
CAMK2A
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S53
S53
S53
RPS6KA3
PRKCE
PRKCA
79 HNRPF gi|15990432| HNRPF protein 2.34 S310
86 KRT18 gi|12653819|
Keratin 18 [Homo 
sapiens] 1.8
S34
S53
S53
S53
S53
CDC2
CAMK2A
RPS6KA3
PRKCE
PRKCA
95 KRT19 gil24234699l
keratin 19 [Homo 
sapiensl 2.33
S10
535
536
?
?
?
?
?
?
109 NFYC gi|2564242|
CCAAT transcription 
binding factor, gamma 
subunit [Homo sapiens] 1.91 ? ? ?
119 EEF1BD gi|25453474|
eukaryotic translation 
elongation factor 1 delta 
isoform 1 [Homo sapie 2.18 S449 CDC2 ?
120 EEF1BD gi|25453474|
eukaryotic translation 
elongation factor 1 delta 
isoform 2 [Homo sapie 1.58 S449 CDC2 ?
135 HSPB1 gi|662841|
heat shock protein 27 
[Homo sapiens] 2.47
S15
S78
S82
MAPKAPK2
MAPKAPK2
MAPKAPK2
Clell survival (actin 
stability)
141 PSMA6 gi|8394076|
proteasome (prosome, 
macropain) subunit, 
alpha type 6 [Rattus 
norvegicu 1.68 ? ? ?
148 CFLN1 gi|30582531]
cofilin 1 (non-muscle) 
[Homo sapiens] 5.08
S3
S3
S3
PAK2
LIMK1/2
TESK1/2 Actin remodelling
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Figure 3.1.62: Figure shows direct 
interactions known between 
proteins found to be differentially 
regulated in the MCF-7 5-FU 
exposure 2D-DIGE experiment, the 
protein p53 was included in protein 
list as it was found to be up 
regulated by western blot. Proteins 
in blue are up regulated and those in 
red are down regulated. Blue arrows 
indicate positive regulation. Purple 
lines indicate binding partners, 
green arrows indicate protein 
modifies another protein and green 
arrows with green boxes indicate 
proteins localise a protein. Direct 
interaction pathway was generated 
using Pathway assist software.
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Figure 3.1.62 was generated by pathway assist and shows the direct interactions 
between differentially regulated protein isoforms listed in table 3.1. In summary, 
direct interactions were identified between 42 of the proteins listed. These proteins 
that are listed are involved in intermediate filament dynamics of Keratin, Lamins, 
Actin and tubulin and include LMNA, STMN1, ACTB, YWHAZ, CFLN1, and GSN. 
The HSP protein, HSPA1A, HSPA8, STIP1 and HSPA4 are direct interactors with 
p53 and stabilise it in the cytoplasm {Manceau, et al., 1999; Fourie, et al.,1997; 
Scheufler, et al., 2000; Wang, et al., 2003; Péng, ét al., 20Û1; Wadhwa, et al., 2002; 
Liao, et al., 1995; Selkirk, et al., 1994). HSPB1 promotes cell survival through 
several mechanisms and is regulated by various stresses {Parcellier, et al., 2006}. 
TRA1 associates with HSPA5, P4HB and HSP A4 and is important in the folding of 
secretory proteins {Meunier, et al., 2002} PAK2 when activated by phosphorylation 
directly phosphorylates cofilin {Misra, et al., 2005}. Figure 3.1.48 shows both cofilin 
and PAK2 proteins are phosphorylated. p53 bound to DNA is stabilised by binding of 
HMGB1 and HNRPK and participate in transcription together . All proteins are up 
regulated and suggest there cooperation in transcription
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3.1.11 Proteomic analysis of HMEC exposed to 5-FU for 7 days
As already stated, proteomic analysis of breast cell lines treated with 5-FU is not 
described in the literature and thus investigation of the proteomic alterations induced 
by 5-FU would substantially contribute to the understanding in the field. 
Characterisation of proteomic alterations induced in normal breast cells treated with 
5-FU would expand the understanding of how normal breast cells respond to 5-FU 
exposure. In addition, data obtained from this experiment would contribute greatly to 
the understanding of how normal cells respond to 5-FU treatment and how generally 
cells respond to 5-FU treatment in conjunction with other experiments.
In order to compare the alterations induced in the proteome of HMEC after 7 days 
treatment with 5-FU protein samples were prepared from HMEC and HMEC after 7 
days treatment with 5-FU at the concentrations of 10(j,M and 30foM(see materials and 
methods for conditions). These were prepared in biological triplicate. Each biological 
triplicate was run in technical duplicates. Sample labelling with Cy dyes is shown in
table 3.1.15.
Table 3.1.15: Ettan DIGE experimental design for the analysis of differential protein 
expression induced in A549 by exposure to 5-FU for 7 days.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50jj.g of protein)
HMEC 
(50[ig of protein)
HMEC 5-FU lOfxM 
(50|j.g of protein)
2 Pooled internal standard 
(50|j,g of protein)
HMEC 
(50|ag of protein)
HMEC 5-FU 30(xM 
(50|ag of protein)
3 Pooled internal standard 
(50|ag of protein)
HMEC 
(50|j.g of protein)
HMEC 5-FU 10|oM 
(50|j,g of protein)
4 Pooled internal standard 
(50^g of protein)
HMEC 5-FU 10|uM 
(50p,g of protein)
HMEC 
(50^g of protein)
5 Pooled internal standard 
(50jj,g of protein)
HMEC 5-FU 10|xM 
(50|xg of protein)
HMEC 5-FU 30nM 
(50p,g of protein)
6 Pooled internal standard 
(50p.g of protein)
HMEC 5-FU 10|jM 
(50fxg of protein)
HMEC 5-FU 30fxM 
(50fig of protein)
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7 Pooled internal standard 
(50|xg of protein)
HMEC 5-FU 30|jM  
(50^g of protein)
HMEC 5-FU 10(J.M 
(50(j.g of protein)
8 Pooled internal standard 
(50|xg of protein)
HMEC 5-FU 30jj.M 
(50|j.g of protein)
HMEC 
(50fo,g of protein)
9 Pooled internal standard 
(50|j,g of protein)
HMEC 5-FU 30^M 
(50|J,g of protein)
HMEC 
(50fo,g of protein)
Images were scanned using the typhoon scanner and were processed and imported 
into Decyder (see materials and methods). Protein spots in gels were semi- 
automatically matched (i.e. matched automatically by the software and reviewed 
individually by user to ensure matching was correct, spots that were not matched 
properly were corrected) using Biological Variation Analysis (BVA), a software 
component of the Decyder software. Proteins with a fold change of greater than 1.2 
and less than -1.2 with a t-test less than 0.01 were deemed significant. Proteins with a 
fold chane gretar than 1.5 and less than -1.5 with a t-test less than 0.05 were deemed 
significant. A total of 361 protein spots were found to have statistically significant 
fold changes were marked as “pick” and this list of proteins is referred to as “the pick 
list”. Preparative gels were prepared as described in materials and methods and the 
pick list in the BVA was manually matched to each preparative gel. Identified 
proteins were imputed back into the BVA. A total of 29 proteins were identified by 
MALDI-ToF MS. Locations of Identified proteins from the pick list in this 
experiment can be seen in figure 3.1.64 and the identity of these proteins can be seen 
in table 3.1.16. Proteins were identified using MALDI-ToF MS and this data is 
included in the appendices.
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Figure 3.1.64: Images of representative DIGE gels from (a) HMEC, (b) HMEC after 7 days treatment with lOpM 5-FU, and (c) HMEC after 7 
days treatment with 30fxM 5-FU. Identified differentially regulated protein spots are encircled by blue lines and are given a protein number. 
Refer to table 3.1.14 for protein identification.
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Figure 3.1.65: A pie-chart demonstrating the number of proteins in each biological process in HMEC affected by exposure to 5-FU. Individual 
proteins in each biological process are included in table 3.1.15. Biological process information obtained from the human protein reference 
database.
13 proteins
6 proteins
■Apoptosis
■Cell growth and/or maintenance
■Metabolism
■Protein Metabolism
■Regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolism
■ Immune Response
□Signal transduction, cell communication
■Transport
■Unknown
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Table 3.1.16: Proteins identified by MALDI-ToF MS that were found to be differentially regulated in HMEC cells after 7 days exposure to 5- 
FU. Protein expression data is included in table (fold change and t-test) as well Protein location on 2D gels (see figure 3.1.13.4.1 for locations). 
GI accession number was obtained from MS data and protein name, Gene symbol was found from DAVID database, Human protein reference
database or swissprot. Molecular and biological functions were obtained from the human protein reference database.
Location 
on 2D 
Gels Gene Symbol
GI
Accession Protein Name
HMEC 10uM 5-FU HMEC 30 uM 5-FU
Molecular
Function
Fold
Change T-test
Fold
Change T-test
Cell growt i and/or maintainance
27 TPT1 gi|33285832|
Translation controlled tumour protein TCTP 
[Homo sapiens] 2.14 2.1xl0'7 2.26 2.5 xlO"8
Calcium ion 
binding
28 CFL1 gi|30582531| cofilin 1 (non-muscle) [Homo sapiens] 10.71 5.7x1 O'11 7.85 4.1 xlO'8
cytoskeletal 
protein binding
29 STMN1 gi|50318511 stathmin 1 [Homo sapiens] -3.18 l.lx lO '8 -3.19 1.1 xlO"9
cytoskeletal 
protein binding
9 TUBB gi|338695| beta-tubulin -2.34 7.9X10-6 -2.36 2.9 xlO'5
cytoskeletal 
protein binding
6 WDR1 gi|3420181| WDR1 protein [Homo sapiens] 2.47 3.2x1 O'5 3.47 2.1 xlO'7
cytoskeletal 
protein binding
10 KRT6A gii 155595841 Keratin 6A [Homo sapiens] 2.01 2.2x10"* 2.07 3x10"
structural 
molecule activity
12 KRT14 gi|30583211|
keratin 14 (epidermolysis bullosa simplex, 
Dowling-Meara, Koebner) [Homo sapiens] 1.39 3.7x1 O'2 1.56 9.8 xlO-4
structural 
molecule activity
13 KRT17 gi|21754583[ unnamed protein product [Homo sapiens] 2.04 4.3x1 O'2 1.94 1.9 xlO'2
structural 
molecule activity
Metabolism; Energy pathway
8 ALDH1A3 gi1466216701 Aldehyde dehydrogenase 1A3 [Homo sapiensl 2.47 5.9xl0'5 2.7 3.3 xlO Catalytic activity
24 CAPNS1 gi| 183144961 Calpain, small subunit 1 [Homo sapiens] 1.62 7.0x10‘5 1.75 6.0 xl0"s Catalytic activity
17 SMS gi|7910511 spermine synthase [Homo sapiensl -1.22 2.4xlO~J -1.33 3.3 xlO"
11 DARS gi|78394948| DARS protein [Homo sapiens] 1.71 1.4xl0'3 2.14 1.8 xlO" ATPase activity
5 GPD2 gi|62988942| unknown [Homo sapiensl 1.68 l.óxlO'5 1.59 2.9 xlO'3 Catalytic activity
26 HPRT1 gi|459815| hypoxanthine phosphoribosyltransferase 1.3 9.6xl0"3 1.47 9.7 xlO'3 Catalytic activity
Protein metabolism
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21 CTSD gi|30582659|
cathepsin D (lysosomal aspartyl protease) [Homo 
sapiensl 2.42 5.3xl0'8 2.47 2.9 xlO"8
Aspartic-type 
signal peptidase 
activity
22 CTSD gi|30582659|
cathepsin D (lysosomal aspartyl protease) [Homo 
sapiens] 1.92 5.8X10-6 1.9 3.0 xlO'7
Aspartic-type 
signal peptidase 
activity
2 HSPA5 gi|6470150| BiP protein [Homo sapiens] -1.45 3.5xl0"7 -1.46 2.3 xlO-6
Chaperone
activity
3 HSPA5 gi|6470150| BiP protein [Homo sapiens] -1.52 6.7xl0'7 -1.46 6.6 xlO“6
Chaperone
activity
1 HYOU1 gi1479389131 HYOU1 protein [Homo sapiens] -1.82 1.3xl0"6 -2.12 1.4 xlO'7
Chaperone
activity
23 HSPB1 gi|15928913|
Unknown (protein for IMAGE:3906970) [Homo 
sapiens] 1.52 3.5xl0'6 1.69 3.3 xlO-6
Chaperone
activity
25 HSPB1 gi|15928913|
Unknown (protein for IMAGE:3906970) [Homo 
sapiens] 2.08 3.3X10"4 2.75 8.7 xlO"5
Chaperone
activity
4 HSPA5 gi|6470150| BiP protein [Homo sapiens] -1.45 2.4xl0'3 -1.51 4x10"
Chaperone
activity
7 P4HB gi|48735337|
Prolyl 4-hydroxylase, beta subunit [Homo 
sapiens] -1.47 1.2xl0'5 1.55 2.4x1 O'6
Isomerase
activity
18 SFRS1 gil55646721|
PREDICTED: similar to splicing factor, 
arginine/serine-rich 1 (ASF/SF2) 1.77 l.OxlO'2 2 2 xlO'3 RNA binding
15 EEF1BG gi|15530265|
Eukaryotic translation elongation factor 1 gamma 
[Homo sapiens] 2.46 3.7X10-6 2.49 9.9 xlO-6
Translation 
regulator activity
19 EEF1BD gi|25453472|
eukaryotic translation elongation factor 1 delta 
isoform 2 [Homo sapiens] 2.25 4.8x10‘5 2.74 4.6 xlO'8
Translation 
regulator activity
20 TPM1 gi|825723| tropomyosin (227 AA) [Homo sapiens] 3.26 5.4xl0's 2.96 6.1 xlO'5
Translation 
regulator activity
regulation o f nucleobase, nucleoside, nucleotide and nucleic acid metabolism
14 DDX48 gi|60655857| DEAD-box polypeptide 48 [synthetic construct] 2.07 2.1xl0"3 2.64 1.4 xlO" NMD ofm RNA
Signal transduction, cell communication
16 RPSA gi|34234| laminin-binding protein [Homo sapiens] -1.46 l.OxlO'3 -1.56 2.3 xlO-6
ribosomal
subunit
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Proteins listed in table 3.1.15 were converted to their gene symbols using the DAVID 
database conversion tool and were imported into Pathway Assist. The gene list was 
processed to determine direct interactions between proteins. A summary image can be 
seen in figure 3.1.66.
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Figure 3.1.66: Figure shows direct interactions known between proteins found to be 
differentially regulated in the HMEC 5-FU exposure 2D-DIGE experiment, the 
protein p53 was included in protein list as it was found to be up regulated by western 
blot.
In summary 5-FU induces genotoxic stress which leads to DNA lesions and the 
generation of reactive oxygen species. This triggers Cathepsin D to induce 
cytochrome C release from the mitochondria. HSPB1 is upregulated and inhibits 
apoptosis at this point by sequestering cytochrome c, further more HSPB1 induces the 
upregulation of Glucose 6 phosphate dehydrogenase which generates NADPH and 
reduces the extent of ROS damage. Increased expression of the epithelial markers are 
observed, KRT 14 and 17, which promote cell survival.
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3.1.12 Validation of proteomics data by western blot
In order to validate expression observed by 2D-DIGE and identifications by MALDI- 
ToF several western blots were carried out on protein lysates separated by SDS PAGE 
aswell as on 2DE-separated samples, respectively.
The expression BiP/HSPA5 and GSN were investigated to confirm expression trends.
Figure 3.1.67: Increased expression of BiP/HSPA5 in A549 and A549 after 7 days 
exposure to 5-FU (lO^ig of protein per lane) -  confirmation of result
Figure 3.1.68: Decreased expression of BiP/HSPA5 in DLKP and DLKP after 7 days 
exposure to 5-FU (lOjig of protein per lane) -  confirmation of result
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Figure 3.1.69: Increases expression of BiP/HSPA5 in NHBE and NHBE after 7 days
exposure to 5-FU (lOjxg of protein per lane) -  confirmation of result
w
Figure 3.1.70: Increase expression of BiP/HSPA5 in MCF-7 and MCF-7 after 7 days 
exposure to 5-FU (10|xg of protein per lane) -  confirmation of result
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Figure 3.1.71: Decreased expression of BiP/HSPA5 in HMEC and HMEC after 7 
days exposure to 5-FU (10|ig of protein per lane) -  confirmation of result
Summary of HSPA5 expression in all cell lines treated with 5-FU 
The expression trend of HSPA5 follows that of the 2D-DIGE experiments. In 
summary HSPA5 is upregulate in NHBE and MCF-7 treated with 5-FU. This data in 
dicates a possible induction of ER stress in MCF-7 and NHBE.
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Gelsolin expression confirmed by western blot in DLKP, MCF-7 and NHBE
Gelsolin is an important protein in invasion and stress. Thus confirmation of its 
expression will validate the fold changes observed in the 2D-DIGE experiment.
Figure 3.1.72: Increased expression of GSN in DLKP and DLKP after 7 days 
exposure to 5-FU (10(ig of protein per lane) -  confirmation of result
Figure 3.1.73: Increased expression of GSN in NHBE and NHBE after 7 days 
exposure to 5-FU (lOpM) (10(ig of protein per lane) -  confirmation of result
Figure 3.1.74: Increased Expression of GSN in MCF-7 and MCF-7 after 7 days 
exposure to 5-FU (10|ig of protein per lane) -  confirmation of result
Summary of GSN expression in DLKP, MCF-7 and NHBE 
Data reveals the accumulation of GSN in DLKP, MCF-7 and NHBE. All three cell 
lines showed increased invasion post 5-FU treatment and suggest a link with invasion. 
GSN is involved in F-actin dynamics a process important in regulating invasion.
3.1.13 Summary analysis of 5-FU’s treatments on the lung and breast cancer 
and normal cells
As stated in sections 3.1.5-9 there remains a large proportion of the differentially 
regulated proteins that remain unidentified. However, sufficient numbers of proteins 
have been identified across experiments to identify common and different responses. 
Common and different responses between DLKP and A549 are listed in table 3.1.17, 
this would show how lung carcinomas respond to 5-FU. Common and different 
responses between A549 and NHBE are listed in table 3.1.18, this would show how a 
lung adenocarcinoma would respond differently to normal cells when exposed to 5- 
FU. Common and different responses between DLKP and NHBE are listed in table 
3.1.19, this would show how DLKP, a NSCLC, would respond differently to normal 
lung cells in response to 5-FU. Common and different responses between A549, 
DLKP and NHBE are listed in table 3.1.20, this would show how lung cells regardless 
of disease state respond to 5-FU. Common and different responses between MCF-7 
and HMEC are listed in table 3.1.21, this would show how a breast adenocarcinoma 
cell line, MCF-7, and normal breast cell line would respond to 5-FU exposure and 
how normal cells respond differently to cancer cells in response to 5-FU exposure. 
Common and different responses between HMEC and NHBE are listed in table 
3.1.22, this would show how normal cells respond to 5-FU and how organ origin can 
alter the response to 5-FU. Common and different responses between HMEC and 
A549 are listed in table 3.1.23, this would show how cells that appear to become less 
invasive due to exposure to 5-FU respond at a protein level. Common and different 
responses between DLKP, MCF-7 and NHBE are listed in table 3.1.24, this would 
show how cells that appear to become more invasive in response to 5-FU exposure do 
so at a protein level. Common and different responses between MCF-7 and NHBE are 
listed in table 3.1.25, this would identify potential proteins involved in the progression
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from non-invasive to invasive in response to 5-FU. Common response in all cell lines 
to 5-FU exposure is shown in table 3.1.26. A summary of protein identification 
success rate in the various cell lines is listed in table 3.1.28 and demonstrate that 
protein identification
199
Table 3.1.17: Common and different responses between DLKP and A549 in response
to 5-FU exposure
Gene Symbol A549 DLKP
Common trend
ACTB 1.8 1.66
ADK 1.6 1.2
ALDH1A1 1.63 1.86
CCT1 1.46 1.77
EEF1BG 2.09 1.46
GANAB 2.14 1.77
HNRPK -1.83 -1.45
HSPA5 -1.61 -1.42
HSPA5 -1.47 -1.51
LMNB1 -1.74 -1.59
PDCD6IP 1.64 1.34
RPSA -1.36 -2.02
SFRS1 1.59 1.24
STMN1 -5.07 -2.1
Different trend
YWHAZ 1.45 -1.47
MCM7 -3.52 1.49
PDIA3 -1.56 1.25
Table 3.1.18: Common and different responses between A549 and NHBE in response
to 5-FU exposure. *Dose dependent similarities
Gene Symbol A549 NHBE 10uM NHBE 30nM
Common trend
ACTB 1.8 1.26 1.23
CAPNS1 2.01 1.15 1.56
EEF1BD 1.65 1.08 1.73
EEF1BG 2.09 1.34 1.9
HSPB1 1.7 1.74 2.1
KRT19 3.22 2.78 3.66
KRT8 -2.16 -1.47 -1.34
P4HB -1.61 -1.27 -1.77
RPLP0* 1.45 1.01 2.06
RPSA -1.36 -1.66 -1.93
STMN1 -5.07 -2.18 -2.78
YWHAZ 1.45 1.34 1.23
Different Trend
HNRPK -1.83 1.73 1.4
HSPA5 -1.61 2.82 2.42
HSPB1 -1.51 2.63 2.69
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Table 3.1.19 Common and different responses between DLKP and NHBE in response
to 5-FU exposure
Gene Symbol DLKP NHBE 10uM NHBE 30uM
Common trend
ACTB 1.66 1.26 1.23
CAPZA1 -1.38 -3.53 -1.94
CAPZB 1.34 1.3 1.23
CFL1 2.25 16.63 14.17
EEF1BG 1.46 1.34 1.9
GSN 2.07 2.61 1.77
LMNA 1.3 1.92 2.05
PLS3 1.73 2.1 2.37
PSMC2 1.29 1.57 1.58
RPSA -2.02 -1.66 -1.93
SRM 1.41 1.16 2.57
STMN1 -2.1 -2.18 -2.78
Different trend
GSTA1 -1.53 1.45 1.53
HNRPK -1.45 1.73 1.4
HSPA5 -1.42 2.82 2.42
STRAP 1.3 -1.38 -1.26
YWHAZ -1.47 1.34 1.23
Table 3.1.20 Common and different responses between A549, DLKP and NHBE in
response to 5-FU exposure
Gene Symbol DLKP A549 NHBE lOuM NHBE 30nM
Common Trend
ACTB 1.66 1.8 1.26 1.23
EEF1BG 1.46 2.09 1.34 1.9
RPSA -2.02 -1.36 -1.66 -1.93
STMN1 -2.1 -5.07 -2.18 -2.78
NHBE different trend
HNRPK -1.45 -1.83 1.73 1.4
HSPA5 -1.42 -1.61 2.82 2.42
DLKP different trend
YWHAZ -1.47 1.45 1.34 1.23
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Table 3.1.21: Common and different responses between MCF-7 and HMEC in
response to 5-FU exposure.
Gene Symbol MCF-7 HMEC 10nM HMEC30nM
Common trend
CFL1 5.08 10.71 7.85
CTSD 2.19 2.42 2.47
DARS 1.62 1.71 2.14
DDX48 1.73 2.07 2.64
EEF1BD 2.18 2.25 2.74
GPD2 1.72 1.68 1.59
HPRT1 1.3 1.3 1.47
HSPB1 2.39 1.52 1.69
RPSA -1.33 -1.46 -1.56
SFRS1 1.47 1.77 2
STMN1 -3.43 -3.18 -3.19
TPT1 1.91 2.14 2.26
Different trend
HSPA5 2.31 -1.45 -1.46
HYOU1 3.49 -1.82 -2.12
P4HB 1.66 -1.47 1.55
Table 3.1.22: Common and different responses between HMEC and NHBE in
response to 5-FU exposure. * Dose dependent expression
Gene Symbol NHBE lOuM NHBE 30nM HMEC 10pM HMEC30nM
Common trend
CAPNS1 1.15 1.56 1.62 1.75
CFL1 16.63 14.17 10.71 7.85
EEF1BD* 1.08 1.73 2.25 2.74
EEF1BG* 1.34 1.9 2.46 2.49
HSPB1 2.63 1.53 1.52 1.69
HSPB1 1.74 1.53 2.08 2.75
KRT14 4.56 2.42 1.39 1.56
KRT17 2.07 2.69 2.04 1.94
P4HB -1.27 -1.77 -1.47 1.55
RPSA -1.66 -1.93 -1.46 -1.56
STMN1 -2.18 -2.58 -3.18 -3.19
TPT1 1.39 1.58 2.14 2.26
Different trend
HSPA5 2.82 2.42 -1.45 -1.51
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Table 3.1.23: Common and different responses between HMEC and A549 in
response to 5-FU exposure
Gene Symbol A549 HMEC 10uM HMEC30nM
Common trend
CAPNS1 2.01 1.62 1.75
DARS 1.48 1.71 2.14
EEF1BD 2.05 2.25 2.74
EEF1BG 2.09 2.46 2.49
HSPA5 -1.61 -1.45 -1.46
HSPA5 -1.47 -1.52 -1.46
HSPB1 -1.51 1.52 1.69
HSPB1 1.7 2.08 2.75
P4HB -1.61 -1.47 1.55
RPSA -1.36 -1.46 -1.56
SFRS1 1.59 1.77 2
Table 3.1.24: Common and different responses between DLKP, MCF-7 and NHBE in
response to 5-FU exposure
Gene Symbol MCF-7 DLKP NHBE 10uM NHBE 30nM
Common trend
ACTB 1.64 1.66 1.26 1.23
p-CFLl 5.08 2.25 16.63 14.17
GSN 7.35 2.07 2.61 1.77
RPSA -1.33 -2.02 -1.66 -1.93
STMN1 -3.43 -2.1 -2.18 -2.78
Different trend
HNRPK 1.68 -1.45 1.73 1.4
HSPA5 2.31 -1.42 2.82 2.42
YWHAZ 1.66 -1.47 1.34 1.23
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Table 3.1.25: Common and different responses between MCF-7 and NHBE in
response to exposure to 5-FU. * Dose dependent
Gene Symbol NHBE 10uM NHBE 30nM MCF-7
Common trend
ACTB 1.26 1.23 1.64
CFL1 16.63 14.17 5.08
EEF1BD* 1.08 1.73 2.18
GSN 2.61 1.77 7.35
GSN 2.5 1.53 5.86
HNRPK 1.73 1.4 1.68
HSPA1B 1.75 1.43 1.56
HSPA5 2.82 2.42 2.31
HSPB1 2.63 2.69 2.39
HSPB1 1.74 2.1 2.47
KRT18 2.33 2.31 4.01
KRT19 2.78 3.66 3.79
RPSA -1.66 -1.93 -1.33
SERPINB1 2.53 1.89 1.58
STMN1 -2.18 -2.78 -3.43
TPT1 1.39 1.61 1.91
YWHAG 1.37 1.44 1.53
YWHAZ 1.34 1.23 1.66
Different trend
ATP5B -1.53 -1.2 1.5
KRT8 -1.47 -1.34 2.1
P4HB -1.27 -1.77 1.66
Table 3.1.26: Common response to 5-FU exposure in all cell lines.
Gene
symbol
A549
10uM
DLKP
10uM
NHBE
10nM
NHBE
30uM
MCF-7
10uM
HMEC
10uM
HMEC
30jiM
RPSA -1.36 -2.02 -1.66 -1.93 -1.33 -1.46 -1.56
STMN1 -5.07 -2.1 -2.18 -2.78 -3.43 -3.18 -3.19
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3.1.14 Summary of differentially regulated protein identification success rates 
using MALDI-ToF MS.
As stated a large portion of proteins remain unidentified in the previously described 
experiments and are summarised in table 3.1.27. Assuming all preparative gels are 
equal, then factors that would influence the success rate of identification include 
protein abundance, protein purity (i.e. is spot a mixture of two or more proteins), 
protein modifications, ability to locate protein on preparative gel, the abundance of 
trypsin sites per protein, and ease of peptide ionisation during MALDI-ToF MS. 
Table 3.1.27: Summary of differentially regulated proteins in all cell lines treated
with 5-FU.
Cell line Total regulated 
in experiment
Fold change Phosphorylated
+/-1 .2 + /-1 .5 Total regulated Up regulated
A549 187 124 179 20 18
DLKP 373 317 248 4 2
NHBE (10uM) 290 164 202 8 6
NHBE (30uM) 290 173 243 8 6
MCF-7 376 160 237 18 17
HMEC (lOuM) 361 309 223 not available not available
HMEC (30nM) 361 321 264 not available not available
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3.2 Analysis o f the fluoropyrimidine treatments o f DLKP
As stated in the introduction section 1.0, 5-FU is progressively being replaced in the 
clinic with third generation drugs such as capcitabine. Capcitabine is converted to 
55FdU in the liver and at the site of the tumour 55FdU is converted into 5-FU. Thus 
to simulate capcitabine treatments in vitro cells should be treated with 55FdU. By 
comparing 5-FU to 55FdU treated DLKP the degree of over lap between the two 
experiments should indicate how the knowledge base of 5-FU treatments is 
transferable to the knowledge base on 55FdU treatments. Further more 
characterisation of 55FdU treatments may indicate how cells respond to treatment 
with the drug and how the capcitabine derivative 55FdU induces inhibition of cell 
growth.
Previous work performed in the laboratory found that 52FdU induced expression of 
KRT8 and 18 in the cell line DLKP - similar to 5-FU (McMorrow, Ph. D. thesis 
2004). To characterise its differentiation effect treatments were carried out on DLKP 
and compared to 5-FU to determine if cell lines respond in a significantly dififent 
manner to 52FdU than 5-FU. Furthermore identification of differences between the 
drugs responces may indicate situation were treatment with 52fdU is preferable over 
treatment with 5-FU.
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3.2.1 Determination of ICso drug concentration for each fluoropyrimidine in 
the cell line DLKP
Determination of the drug concentration that would inhibit the growth of DLKP after 
7 days culture in media supplemented with 52FdU and 55FdU was carried out as 
described in section 2.7.2. This was done in order to compare ICgo drug effects of the 
fluoropyrimidines and to determine unique differences between the drugs.
Figure: 3.2.1 Growth inhibition after 7days exposure to by 52FdU compared to 5-FU 
at concentration ranging from 0 to 10|J,M in the cell line DLKP.
5-fU drug concentration
Figure: 3.2.2 Growth inhibition after 7days exposure to by 52FdU compared to 5-FU 
at concentration ranging from 0 to 10|iM in the cell line DLKP.
M U *a in i— nlnBwi
A similar ICgo growth inhibition of 10|iM was found for all fluoropyrimidines 
however comparison between ICso’s show 52FdU is more toxic.
3.2.2 Proteomic analysis of 5-fluoro-2’-deoxyuridine’s treatment of DLKP
Cell culture of DLKP and DLKP treated with 5-FU were carried out as described in 
section 2.7.3. Total protein extractions were prepared as described in 2.16.2.1. These 
were prepared in biological triplicate. Each biological triplicate was run in technical 
duplicates. Sample labelling with Cy dyes is shown in table 3.2.1. Protein filters of 
greater than plus 1.2 or less than minus 1.2 fold with t-test of less than 0.01, and fold 
change of greater than plus 1.5 or less than minus 1.5 with t-test of 0.05 were used to 
identify differentially regulated proteins.
Table 3.2.1: Ettan DIGE experimental design for the analysis of differential protein 
expression induced in DLKP by exposure to 5-FU for 7 days.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50fj,g of protein)
DLKP, P.16 
(50|j.g of protein)
DLKP, P. 16, 52FdU 
treated (50|ag of protein)
2 Pooled internal standard 
(50|ig of protein)
DLKP, P.16 
(50|o.g of protein)
DLKP, P. 16, 52FdU 
treated (50|ag of protein)
3 Pooled internal standard 
(50fJ.g of protein)
DLKP, P. 17 
(50|ig of protein)
DLKP, P. 17, 52FdU 
treated (50|ig of protein)
4 Pooled internal standard 
(50j^g of protein)
DLKP, P. 17 
(50fj.g of protein)
DLKP, P. 17, 52FdU 
treated (50jag of protein)
5 Pooled internal standard 
(50jLtg of protein)
DLKP, P. 18 
(50|o.g of protein)
DLKP, P. 18, 52FdU 
treated (50|ag of protein)
6 Pooled internal standard 
(50fig of protein)
DLKP, P. 18 
(50fxg of protein)
DLKP, P. 18, 52FdU 
treated (50^g of protein)
Preparative gels for protein identification were prepared as described in sections 2.21- 
25. Differentially regulated proteins were identified using MALDI-ToF MS as 
described in section 2.27. Identified differentially regulated proteins locations are 
indicated in figure 3.2.3. The identity of these proteins can be seen in table 3.2.2. 
Proteins identification data from MALDI-ToF MS is included in the appendices.
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Figure 3.2.3: Images of representative DIGE gels from (a) DLKP, (b) DLKP after 7 days treatment with IO^ iM 55FdU. Identified differentially 
regulated protein spots are encircled by blue lines and are given a protein number. Refer to table 3.2.2 for protein identification.
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Table 3.2.2: Proteins differentially regulated in DLKP treated with 52FdU that overlap with differentially regulated protein in DLKP treated
with 5-FU.
Protein
location on 2D- 
DIGE gel
GI
accession
Number
Gene
symbol Name T-test
Fold
change Molecular function
Similar expression trend
1 gi|491196531 YWHAZ YWHAZ protein [Homo sapiens] -1.68 0.0027
2 gi|54696078| VBP1
von Hippel-Lindau binding protein 1 
[Homo sapiens] -1.41 0.0041
3 gi|5031851| STMN1 stathmin 1 [Homo sapiens] -1.53 0.003
6 qi|471152271 HPRT1 HPRT1 [Homo sapiens] 1.35 0.0018
7 gi|5729842| GLOl glyoxaiase I [Homo sapiens] 1.29 0.00027
8 gi|38044288| GSN gelsolin isoform b [Homo sapiens] 1.32 0.0001
9 gi145034811 EEF1BG
eukaryotic translation elongation factor 1 
gamma [Homo sapiens] 1.27 0.00018
10 gi|30582531| CFLN1 cofilin 1 (non-muscle) [Homo sapiens] 1.64 0.023
11 qi|31542292I CCT1
chaperonin containing TCP1, subunit 3 
(gamma) [Homo sapiens] 1.23
1.8x10-
5
12 gi|62896663| ANXA7
annexin VII isoform 1 variant [Homo 
sapiens] -1.58 0.0036
Opposite expression trend to 5-FU treatment
4 gi1193530091 EEF2
Similar to Elongation factor 2b [Homo 
sapiensl -1.98 0.02
5 gi|2135552| LASPI Lasp-1 protein - human 1.19 0.0037
2 1 0
3.2.3 Proteomic analysis of 5-fluoro-5’-deoxyuridine’s treatment of DLKP
Cell culture of DLKP and DLKP treated with 5-FU were carried out as described in 
section 2.7.3. Total protein extractions were prepared as described in 2.17. These were 
prepared in biological triplicate. Each biological triplicate was run in technical 
duplicates. Sample labelling with Cy dyes is shown in table 3.2.3. Protein filters of 
>+■/<-1.2 fold with t-test of 0.01, and fold change of >+/<-1.5 with t-test of 0.01 were 
used to identify differentially regulated proteins.
Table 3.2.3: Ettan DIGE experimental design for the analysis of differential protein 
expression induced in DLKP by exposure to 5-FU for 7 days.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50fxg of protein)
DLKP, P. 16 
(50(j,g of protein)
DLKP, P. 16, 55FdU 
treated (50^g of protein)
2 Pooled internal standard 
(50f^g of protein)
DLKP, P.16 
(50|xg of protein)
DLKP, P. 16, 55FdU 
treated (50fag of protein)
3 Pooled internal standard 
(50|j,g of protein)
DLKP, P. 17 
(50|xg of protein)
DLKP, P. 17, 55FdU 
treated (50|ig of protein)
4 Pooled internal standard 
(50|ag of protein)
DLKP, P. 17 
(50fxg of protein)
DLKP, P. 17, 55FdU 
treated (50fig of protein)
5 Pooled internal standard 
(50^g of protein)
DLKP, P. 18 
(50(j,g of protein)
DLKP, P. 18, 55FdU 
treated (50^g of protein)
6 Pooled internal standard 
(50|ag of protein)
DLKP, P. 18 
(50(j,g of protein)
DLKP, P. 18, 55FdU 
treated (50(j,g of protein)
Preparative gels for protein identification were prepared as described in sections 2.21- 
25. Differentially regulated proteins were identified using MALDI-ToF MS as 
described in section 2.27. Identified differentially regulated proteins locations are 
indicated in figure 3.2.4. The identity of these proteins can be seen in table 3.2.4. 
Proteins identification data from MALDI-ToF MS is included in the appendices.
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Figure 3.2.4: Images of representative 2D-DIGE gels from (a) DLKP, (b) DLKP after 7 days treatment with lO^M 55FdU. Identified 
differentially regulated protein spots are encircled by blue lines and are given a protein number. Refer to table 3.4.2.2 for protein identification.
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Table 3.2.4: Proteins differentially regulated in DLKP treated with 55FdU that
overlap with differentially regulated protein in DLKP treated with 5-FU..
Protein
location
GI
accession
Number
Gene
symbol Name
Fold
change T-Test
Molecular
function
1 gi|15277503| ACTB
ACTB protein
[Homo
sapiens] 1.27 0.0015
2 gi|15277503| ACTB
ACTB protein
[Homo
sapiens] 1.34 0.00038
3 gi|5729842| GLOl
glyoxalase I
[Homo
sapiens] 1.38
3.9x10-
5
4 gi|5031851| STMN1
stathmin 1
[Homo
sapiens] -1.23 0.0095
3.2.4 Summary
Fluoropyrimidine exposure of DLKP causes similar inhibition of cell growth at 
10|jM. However, examination of the proliferation curve shows that 52FdU is far more 
toxic than 5-FU. Proteomic analysis of DLKP treated with 52FdU showed more in 
common with 5-FU than 55FdU. None of the heat shock proteins that were 
differentially regulated in the 5-FU DIGE experiment showed differential expression 
in the other fluoropyrimidine treatment DIGE experiments. A total of 12 proteins 
showed overlap between DLKP 5-FU treatment and DLKP 52FdU treatment, 4 
proteins showed over lap between DLKP 5-FU treatment and DLKP 55FdU 
treatment. STMN1 and GLOl are the only proteins that appear to be differentially 
expressed in all 3 fluoropyrimidine experiments.
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3.3 Analysis of DLKP-55, a 5-FU resistant cell line
Resistance to 5-FU is a major obstacle in the treatment of cancer. 5-FU resistance is 
mediated by over expression of a combination of or individual over expression of TS 
TP or DHPD. Development of 5-FU resistant are described in this section and the 
identification of a stable resistant variant of DLKP, DLKP-55, is described. Few 
proteomic based investigation of 5-FU resistance have been published in the 
literature. Thus to address this and discover potential new mechanisms of 5-FU 
resistance and alternative drug targets during therapy of 5-FU resistant cell lines 
protein preps from DLKP and DLKP-55 were prepared and analysed.
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3.3.1 Pulse selection process
The cell lines DLKP and A549 were pulse selected for 10 4-hour pulses with three 
fluoropyrimidine anti-metabolite drugs. These drugs were 5-Fluorouracil (5-FU), 5- 
Fluoro-2-deoxyuridine (52FdU), a metabolic derivative of 5-FU, and 5-fluoro-5- 
deoxyuridine (55FdU), a 5-FU prodrug. The interval between pulsing ranged from 1 
week to 8 weeks and timing of subsequent pulses was determined by two factors. 
These factors are (a) cells appear to be proliferating and (b) cells are at a confluency 
of between 50-80%. See figure 3.2.1 drug concentrations at each pulse, see section 
2.10 for further details on pulse selection methodology.
100
Figure 3.3.1: The concentration of 55FdU for each pulse used in the generation of the 
5-FU resistant cell line DLKP-55
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3.3.2 Fluoropyrimidine drug resistance model, DLKP versus DLKP-55
Drug resistance generated in pulse selection with the fluoropyrimidines on the cell 
lines DLKP and A549. A549 displayed no stable resistance to any drug, DLKP 
selected with 52FdU did not survive 10 pulses and DLKP selected with 5-FU failed to 
show stable resistance. Only DLKP selected with 55FdU showed a stable resistance to 
any of the fluoropyrimidines and was given the: name DLKP-55.
Toxicity assays performed on DLKP-55 compared to DLKP (Passage 18-25) showed 
that DLKP-55 showed resistance to 5-FU and 55FdU, and showed cross-resistance to 
Adriamycin (Adr), see figures 3.3.1, 3.3.2 and 3.3.3. Resistance was assessed to 
Bromodeoxyuridine (BrdU) and taxol (Txl) as it was hoped that resistance would not 
be shown to one of these drugs and thus would act as a control for the toxicity assay. 
The bromopyrimidine, BrdU, was selected as 5-FU resistance has been linked to 
Thymidylate Synthetase (TS) over expression. The bromo- metabolic derivatives of 
BrdU are not processed in the same manner as fluoro- derivatives. Specifically the 
literature shows that bromouracil can not irreversibly bind to TS and thus can not 
cause inhibition of its activity. Thus 5-FU resistance mediated by TS over expression 
would not cause BrdU resistance. Taxol was also used as a control as its mechanism 
of action inhibits microtubule polymerisation thus inducing apoptosis, while 5-FU’s 
anti-proliferative effect induces apoptosis by incorporation into RNA and DNA 
inducing apoptosis through the genotoxic response. Thus resistance to Txl would be 
unexpected. Toxicity assays showed no resistance to these drugs, see figures 3.3.4 and 
3.3.5. Summary of resistance can be seen in figure 3.3.6.
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Figure 3.3.1: Toxicity assays of DLKP and DLKP-55 to adriamycin demonstrating 
DLKP-55 is approximately 2 fold more resistant to DLKP (n=3).
S- FU cmmmMMm  ml era«
Figure 3.3.2: Toxicity assays of DLKP and DLKP-55 to 5-FU demonstrating DLKP- 
55 is approximately 4 fold more resistant to DLKP (n=3).
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Figure 3.3.3: Toxicity assays of DLKP and DLKP-55 to 55-FdU demonstrating 
DLKP-55 is approximately 4 fold more resistant to DLKP (n=3).
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Figure 3.3.4: Toxicity assays of DLKP and DLKP-55 to BrdU demonstrating DLKP- 
55 and DLKP share equal resistance to BrdU (n=3).
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Figure 3.3.5: Toxicity assays of DLKP and DLKP-55 to Taxol demonstrating DLKP- 
55 and DLKP share equal resistance to taxol (n=3).
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Figure 3.3.6: Summary of fold change resistance between DLKP-55 and DLKP 
between the chemotherapeutic and anti-metabolite drugs in figures 3.3.1 to 3.3.5.
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3.3.3 Western blots on protein extracts from DLKP versus DLKP-55
Western blots were performed on DLKP versus DLKP-55 to investigate proteins 
found regulated as a result of 5-FU treatment of DLKP. This includes the 
investigation of integrin subunit Pi, BiP, Gelsolin, and Rho. Thymidylate synthetase 
(TS) was investigated as it is reported to correlate with 5-FU resistance. TS is only 
protein that showed up regulation by western blot.
»/->I
Figure 3.3.7: Western blot for the integrin subunit Pi on protein extracts from DLKP 
and DLKP-55 (10|j.g of protein per lane).
The integrin subunit pi doespnot show a difference in expression between DLKP and 
DLKP-55. ^ h i  s may rule cgt signal transduction from the Pi integrin protein been 
involved in 5-FU resistance (see figure 3.3.7).
Figure 3.3.8: Western blot for HSPA5 on protein extracts from DLKP and DLKP-55 
(1 O^ ig of protein per lane).
Western blot revealed no expression difference between DLKP and DLKP-55 for the 
ER protein -  HSPA5. Data confirms 2D-DIGE data (see figure 3.3.8).
220
Figure 3.3.9: Western blot for Gelsolin on protein extracts from DLKP and DLKP-55 
(10(ag of protein per lane).
Western blot revealed no expression difference between DLKP and DLKP-55 for the 
actin binding protein gelsolin. Data confirms 2D-DIGE data (see figure 3.3.9).
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Figure 3.3.10: Western blot for Rho on protein extracts from DLKP and DLKP-55 
(1 Ofag of protein per lane).
Indicates a decreased expression of Rho and suggested decreased invasion rates in 
DLKP-55 (see figure 3.3.10).
V)*/“)i
Figure 3.3.11: Western blot for TS on protein extracts from DLKP and DLKP-55 
(10|xg of protein per lane).
DLKP-55 shows over expression of TS a protein shown to be the major cause of 5- 
FU resistance (see figure 3.3.11)
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3.3.4 Proteomic analysis of DLKP versus DLKP-55
In order to compare the proteomes of DLKP and DLKP-55 -  the 5-FU/55FdU 
resistant variant of DLKP - protein samples were prepared for 2D-DIGE as described 
in section 2.16.2.1. These samples were prepared in biological triplicate. Each 
biological triplicate was run in technical duplicates. Proteomic samples were prepared 
from cells used to set up toxicity assays in section 3.2.2. Sample labelling with Cy 
dyes is shown in table 3.3.1. Protein filters of greater than 1.2 or less than -1.2 fold 
with t-test of less than 0.01, or a fold change of greater than 1.5 or less than -1.5 fold 
with t-test of less than 0.05 were used to identify differentially regulated proteins.
Table 3.3.1: Ettan DIGE experimental design for the analysis of differential protein 
differential expression between DLKP and DLKP-55.
Gel number CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50(j,g of protein)
DLKP, P.20 
(50fj.g of protein)
DLKP-55, P.53 
(50|J,g of protein)
2 Pooled internal standard 
(50|^g of protein)
DLKP-55, P.53 
(50fig of protein)
DLKP, P.20 
(50(j,g of protein)
3 Pooled internal standard 
(50|xg of protein)
DLKP, P.21 
(50|j.g of protein)
DLKP-55, P.54 
(50|j,g of protein)
4 Pooled internal standard 
(50[j.g of protein)
DLKP-55, P.54 
(50|j,g of protein)
DLKP, P.21 
(50p,g of protein)
5 Pooled internal standard 
(50jj.g of protein)
DLKP, P.22 
(50jag of protein)
DLKP-55, P.55 
(50|J,g of protein)
6 Pooled internal standard 
(50|j,g of protein)
DLKP-55, P.55 
(50|j.g of protein)
DLKP, P.22 
(50fJ,g of protein)
Representative DIGE images of Cy labelled protein lysates separated by 2DE can be 
seen in figure 3.3.7. Differentaillay regulated proteins were identified by MALDI-ToF 
MS as described in section 2.27. Locations of identified proteins from the pick list in 
this experiment can be seen in figure 3.3.7 and the identity of these proteins can be 
seen in table 3.3.2. The distribution of differentially regulated proteins amongst 
ontologies can be seen figure 3.3.8.
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Metabolism is an important aspect of 5-FU resistance. The locations of upregulated 
enzymes in each respective pathway can be seen in figures 3.3.9 to 3.3.12.
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Figure 3.3.7: Images of representative DIGE gels from (a) DLKP, (b) DLKP-55. Differentially regulated proteins that have been identified are 
encircled by a blue line and are marked by number. The number refers to the protein identity, and the identity, statistical data and molecular and 
biological functions of the protein can be found in table 3.3.2. Red box indicates the predicted region in which TS occurs on 2D-gels.
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Figure 3.3.8: Pie chart demonstrating the number of proteins in each biological process differentially expressed between DLKP and DLKP-55. 
Identity of proteins can be found in table 3.3.2.
Table 3.3.2: Proteins identified by MALDI-ToF MS that were found to be differentially regulated between DLKP and DLKP-55 cells. Protein 
expression data is included in table (fold change and t-test) as well Protein location on 2D gels (see fig. 3.3.7 for locations). Stathmin included as 
its expression is shown to correlate with resistance to Taxol and indicates that there is no difference in resistance to taxol as data toxicity assays
suggest (see fig. 3.3.5).Three unidentified upregulated protein are shown in table and there location falls in the predicted locations of TS.
Protein
location
GI accession 
Number Gene symbol Name T-test
Fold
change Molecular function Enzyme Code
Cell growth and/or maintenance
16 STMN1 1 gi|50318511 stathmin 1 [Homo sapiens] 0.58 -1.05 - -
Metabolism; Energy pathway
4 G6PD gi|7546530|
gi|7546530|pdb|lQKI|H - Chain H, X-Ray 
Structure O f Human Glucose 6-Phosphate 
Dehydrogenase (Variant 9.6X10-4 1.34 Catalytic activity EC:1.1.1.49
5 PKLR fii|338827|
cytosolic thyroid hormone-binding protein (EC 
2.7.1.40) (Pyruvate Kinase) 2.2 xlO"6 2.01 Catalytic activity EC 2.7.1.40
6 ALDH1A1 gi|21361176| aldehyde dehydrogenase 1A1 [Homo sapiens] 3.3 xlO* 2.43 Catalytic activity EC:1.2.1.36
8 SMS gi|7910511 spermine synthase [Homo sapiens] 9.9 xlO"4 -2.02 - EC:2.5.1.16
13 GLOl gi|5729842| glyoxalase I [Homo sapiens] 3.4 xlO'5 -1.59
Gluthathione 
transferase activity EC:4.4.1.5
14 PRDX2 gi|331884521 peroxiredoxin 2 isoform b [Homo sapiens] 5.2 xlO“1 -1.35 Peroxidase activity EC : 1.11.1.15
15 NME1 gi|29468184| NM23-H1 [Homo sapiens] 1.4 xlO’4 1.76 Catalytic activity EC:2.7.4.6
Protein Metabolism
1 EEF2 gi|19353009| Similar to Elongation factor 2b [Homo sapiens] l.lx lO '3 1.49
Translation regulatory 
activity .
3 CCT3 (îi|587614841
chaperonin containing TCP1, subunit 3 isoform c 
[Homo sapiens] 3.8 xlO'3 1.41 Chaperone activity
12 ERP29 gi|5803013|
endoplasmic reticulum protein 29 precursor 
[Homo sapiens] 4.1 xlO'3 1.25 Chaperone activity
2 PPP2CB gi|4558259|
Chain B, Crystal Structure O f Constant Regulatory 
Domain Of Human Pp2a, Pr65 5.9 xlO'3 -1.56
Protein
serine/threonine 
phosphatase activity
Signal transduction
7 - gi|62896687| dendritic cell protein variant [Homo sapiens] 2 x l0 'J -1.35 -
Unidentified
9 - - Possibly TS 8.3 x l0 ‘J 2.00 - -
10 - - Possibly TS 1.30x10" 3.51 - -
11 - - Possibly TS 1.6 xlO'4 2.39 - *
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Analysis of Proteomic implication in metabolism
5-FU is an anti-metabolite as stated earlier and thus metabolism is important in 5-FU 
resistance. Seven proteins listed in table 3.3.2 are involved in metabolism four of which 
are up regulated. These four proteins location in various metabolic pathways are shown 
in figures 3.3.9-12 and there location in
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Figure 3.2.9: Figure displaying 
the pyrimidine metabolism 
pathway. Location of NME1 in 
the pyrimidine metabolism 
pathway is shown. It is 
responsible for the reversible 
conversion of dUTP to dUDP. 
Image downloaded from the 
KEGG web site.
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Figure 3.2.10 Figure 
displaying the pentose 
phosphate metabolism 
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shown. It is a rate 
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Figure 3.2.11: Figure displaying 
the Retinol metabolism pathway. 
Location of ALDH1A1 in the Retinol 
metabolism pathway is shown. It is 
responsible for the conversion of 
all-trans-Retinal to all-trans- 
Retinoate. Image downloaded from 
the KEGG web site.
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Figure 3.2.12: Figure displaying the Glycolysis pathway. Location of PKLR in this 
pathway is shown. PKLR is responsible for the conversion of phosphoenolpyruvate to 
pyruvate. Image downloaded from the KEGG web site.
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3.3.5 Summary of analysis of DLKP-55 versus DLKP
The 5-FU/55FdU resistant variant of DLKP was generated by selection with the 5-FU 
prodrug 55FdU. It displayed an approximate 4-fold resistance to 5-FU and an 
approximate 2-fold resistance to 55FdU and Adr. No resistance to BrdU or taxol was 
observed.
Proteomic analysis of DLKP-55 versus DLKP resulted in the successful identification 
of 11 proteins differentially expressed between the groups -  7 of which were 
enzymes. Those proteins upregulated includes G6PD, PKLR, ALDH1A1 and NME1 
and are involved in the Pentose Phosphate Pathway, Gluconeogenesis, Retinol 
Metabolism and Pyrimidine Metabolism, respectively.
Comparison to 5-FU treatments
Comparison between 5-FU treatment and 5-FU resistant variant may indicate a 
mechanism responsible for 5-FU resistance induced by 5-FU treatment. The data 
identified 7 proteins differentially regulated in both experiments 3 of which showed 
the same expression trend. These are PRDX2, EEF2, and CCT3. This may implicate 
EEF2 expression as a factor in 5-FU resistance.
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3.4 Analysis o f DLKP and its subpopulations; DLKP-SQ, DLKP-I and DLKP-
M.
As stated NSCLC are often heterogeneous in nature and characterisation of these 
subpopulations is important in determining the nature of cancer biology. DLKP is 
described as being composed of at least 3 distinct subpopulation; DLKP-SQ, DLKP-I 
and DLKP-M and named based on morphological differences. Previous 
characterisations of these cell lines observed that DLKP-M displayed decreased 
growth rates compared to other populations and increased adherence rate to 
fibronectin. No differences were observed in drug resistance (McBride S., Ph. D. 
thesis, 1996). Characterisation of invasion and motility rates has not been described in 
these populations and here data is presented on invasion and motility differences 
between the clones and parent. Proteomic analysis was undertaken to investigate 
mechanisms controlling the differentiation processes governing the interconversion 
process in DLKP and to add to knowledge base of motility and invasion in NSCLC. 
Proteomic investigation was targeted at the total protein and the hydrophobic and 
hydrophobic associated protein complexes. Motility and invasion require cytoskeletal 
to membrane connection, thus analysis of this fraction between the clones will 
indicate what proteins are important in regulating motility/invasion in the DLKP 
clonal subpopulations.
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3.4.1 Analysis of motility and invasion in DLKP and its subpopulations
Analysis of motility and invasion rates in DLKP and its subpopulations; DLKP-SQ, 
DLKP-I and DLKP-M was performed by Helena Joyce. Invasion rates are a result of  
two factors, motility and the ability to degrade ECM. Thus for thorough analysis o f  
invasion both motility and invasion rates need to be determined.
Data revealed that DLKP-I and DLKP-M display apparent higher invasion rates than 
DLKP and DLKP-SQ (see figure 3.4.1). However analysis o f motility showed that 
this trend was the same in the subpopulations (see figure 3.4.2). Motility assays 
presented here are saturated for DLKP-M and DLKP-I and are only included to 
demonstrate that the trend observed in invasion assays is present in motility assays.
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Figure 3.4.1: Analysis of invasion rates in DLKP and it sub populations, (a) DLKP 
48 hour invasion assay, (b) DLKP-SQ 48 hour invasion assay, (c) DLKP-I 48 hour 
invasion assay, and (d) DLKP-M 48 hour invasion assay (e) summary of statistics and 
fold changes between populations. Data indicates that DLKP-I and DLKP-M are more 
invasion then DLKP or DLKP-SQ or the other populations.
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Figure 3.4.2: Analysis of motility rates in DLKP and it sub populations, (a) DLKP 48 
hour Motility assay, (b) DLKP-SQ 48 hour Motility assay, (c) DLKP-I 48 hour 
Motility assay, (d) DLKP-M 48 hour motility assay. Data indicates that DLKP-I and 
DLKP-M are apparently more motile than DLKP and DLKP-SQ and (e) Bar chart 
summarising of motility and fold changes.
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3.4.2 Total proteomic analysis in DLKP and its subpopulations
In order to compare the alterations induced in the proteome of DLKP and its 
subpopulations, and for determination of the underlying mechanism that governs the 
interconversion between DLKP-SQ, DLKP-I and DLKP-M protein samples were 
prepared from each population. Total protein extracts were prepared as described in 
section 2.17. These were prepared in biological triplicate. Each biological triplicate 
was run in technical duplicates. Sample labelling with Cy dyes is shown in table 3.4.1. 
Differentially regulated proteins were based on a fold change of greater than 3 or less 
than -3 fold change between two of the populations and a t-test less than 0.01. A 
summary of protein trends is highlighted in table 3.4.2.
Table 3.4.1: Ettan DIGE experimental design for the analysis of differential protein
expression induced in MCF-7 by exposure to 5-FU for 7 cays.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(50ng of protein)
DLKP, P.30, 
(50|j,g of protein)
DLKP-M, P.30, 
(50|ig of protein)
2 Pooled internal standard 
(50|og of protein)
DLKP, P.30, 
(50pig of protein)
DLKP-M, P.30, 
(50|j.g of protein)
3 Pooled internal standard 
(50ng of protein)
DLKP, P.32, 
(50pig of protein)
DLKP-M, P.32, 
(50|ig of protein)
4 Pooled internal standard 
(50p.g of protein)
DLKP, P.32, 
(50ug of protein)
DLKP-M, P.32, 
(50|o,g of protein)
5 Pooled internal standard 
(50|j,g of protein)
DLKP, P.34, 
(50p.g of protein)
DLKP-M, P.34, 
(50|j,g of protein)
6 Pooled internal standard 
(50|jg of protein)
DLKP, P.34, 
(50(ig of protein)
DLKP, P.34, 
(50|ig of protein)
7 Pooled internal standard 
(50ng of protein)
DLKP-SQ, P.30, 
(50|ig of protein)
DLKP-I, P.30, 
(50(j,g of protein)
8 Pooled internal standard 
(50jig of protein)
DLKP-SQ, P.30, 
(50(j.g of protein)
DLKP-I, P.30, 
(50|a,g of protein)
9 Pooled internal standard 
i50|ig of protein)
DLKP-SQ, P.32, 
(50fjg of protein)
DLKP-I, P.32, 
(50|j,g of protein)
10 Pooled internal standard 
(50 jig of protein)
DLKP-SQ, P.32, 
(50jj.g of protein)
DLKP-I, P.32, 
(50|ag of protein)
11 Pooled internal standard 
(50|ig of protein)
DLKP-SQ, P.34, 
(50|j,g of protein)
DLKP-I, P.34, 
(50p.g of protein)
12 Pooled internal standard 
(50|ig of protein)
DLKP-SQ, P.34, 
(50p.g of protein)
DLKP-I, P.34, 
(50|ig of protein)
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Table 3.4.2: Summary table of protein fold changes between each population. Only 15 
of the proteins regulated between the sub populations have been identified and are 
summarised in table 3.4.3
Statistical Alters Population comparison
Fold
change
filter
Fold
change
t-test
DLKP/
DLKP-SQ
DLKP/
DLKP-I
DLKP/
DLKP-M
DLKP-SQ 
/ DLKP-M
DLKP-I / 
DLKP-M
DLKP-SQ 
/ DLKP-I
+/-1.2 <0.01 880 891 847 639 492 628
+/-1.5 <0.01 726 256 448 484 330 487
+/-3 <0.01 120 27 51 63 38 67
DLKP-I shows the least differences between the subpopulations and the parental 
population appears to be the most similar however DLKP-I and DLKP-M appear to 
more similar than DLKP-I and DLKP-SQ.
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Figure 3.4.3: Images protein extracts labelled with CY dyes and separated by 2D-electrophoresis over a pH gradient of 4-7 from (a) DLKP, (b) 
DLKP-SQ, (c) DLKP-I, and (d) DLKP-M.
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Table 3.4.2: Proteins identified by MALDI-ToF MS that were differentially regulated between DLKP and its subpopulation in the total 
proteomes. Protein expression data is included in table (fold change and t-test) as well Protein location on 2D gels (see figure 3.1.10.4.1 for 
locations).Proteins that correlate with invasion are highlighted in yellow and those abundant in DLKP are highlighted in blue. Proteins 
expression data was included between all clones to show that expression of protein between some of the population is not significant and
Location 
on 2D
Gel Protein Name
Accession
Number
Gene
Name
Molecular
Function
Proteins negative in all three fields indicate 
the protein has a higher expression in DLKP 
than the clonal subpopulations
Protein with fold positive fold changes in all 
three fields become enriched from DLKP-SQ- 
>DLKP-I->->DLKP-M
DLKP-M / 
DLKP DLKP-I / DLKP
DLKP-SQ / 
DLKP
DLKP-I / DLKP- 
SO
DLKP-M / 
DLKP-SO
DLKP-M / 
DLKP-I
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Biological Function: Cell growth and/or maintenance
1
type III preprocollagen alpha 
1 chain [Homo sapiens]
gi|16197601|
COL3A1
ECM
protein 23.35
3.9
xlO'12 2.65 0.22 -2.08
3.3
xlO'3 5.52 0.059 48.65
1.4
xlO-8 8.82
3.7
x l0 J
2
type III preprocollagen alpha 
1 chain fHomo sapiens]
gj| 161976011
COL3A1
ECM
protein 3.63
6.4x10
-5 2.28 0.051 1.11 0.94 2.06 0.09 3.28
6.9
xlO"1 1.59
6.3
xlO'2
3*
type III preprocollagen alpha 
1 chain [Homo sapiens]
gi|16197601|
COL3A1
ECM
protein 39.36
8.9
xlO'8 3.97 0.3 1.25 0.05 3.17 0.45 31.43
7.2
xlO'9 9.92 0.0062
4
type III preprocollagen alpha 
1 chain [Homo sapiens]
gi|16197601|
COL3A1
ECM
protein 22.27
3.20E-
11 2.98
3.4x10-
1 1.1
5.1x1
0-1 2.72 0.42 20.27
3.1
x l0 ‘u 7.47
1.3
xlO'3
6* VCL protein fHomo sapiens|
gi 246575791
VCL
Cytoskeletal
protein
binding -1.41
1.6
xlO'6 -1.58 0.11 -5.21
6.9
xlO"1 3.29 0.31 3.7 0.0025 1.13 0.25
13*
Tubulin, beta polypeptide 
[Homo sapiens]
gi| 180887191
TUBB2A
Structural
molecule
avtivitv 7.48
1.5
xlO'8 2.72
2.8
xlO'5 6.64
2.8
XlO'8 -2.44
2.8
xlO'7 1.13 0.0067 2.75
8.0
xlO-8
Biological Function: histone deacetvlation
7*
hypothetical protein [Homo 
sapiens]
gi|59016833
HDAC1
histone
deacetylase
activity -1.38
3.5
xlO'7 -1.83 0.0072 -3.06
8.6
xlO"6 1.67 0.09 2.22 0.00013 1.33 0.098
Biological Process: Protein metabolism
8*
GANAB protein [Homo 
sapiens]
gi|40807091|
GANAB
Hydrolase
activity -1.39
6.3
xlO-6 -1.92 0.0038 -3.84
1.0
xlO'7 2
1.6
xlO'2 2.77
1.8
xlO'6 1.39 0.066
5*
HYOU1 protein [Homo 
sapiens]
gi|479389I3|
HYOU1
Chaperone
activity -2.76
1.6
x lO 10 -2.29 0.0033 -4.83
1.3
x l0 ‘5 2.1 0.052 1.75
1.0
xlO'2 -1.2 0.83
9
Tumour rejection antigen 
(gp96) 1 [Homo sapiens]
gi|616566071
TRAI
Heat Shock
protein
activity -1.27
3.2
xlO'* -1.66 0.014 -3.26
1.2
x l0 ‘! 1.97
2.9
xlO'2 2.57
8.5
xlO’5 1.3 0.11
10* Similar to Elongation factor gi 193530091 EEF2 translation 5.55 1.3 5.25 0.00022 1.17 0.26 4.5 0.00066 4.76 5.9 1.06 0.48
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2b [Homo sapiens] regulator
activity
x l0 'lu xlO-8
11*
HSPA1A protein [Homo 
sapiens]
gi|14424588]
HSPA1A
Chaperone
activity -3.65
2
xlO'10 -1.5 0.064 -1.98
7.6
xlO"3 1.33 0.48 -1.84
7.5
xlO'2 -2.44 0.017
12
Chain A, The Crystal 
Structure O f The Human 
Hsp70 Atpase Domain
gi [425436981
HSPA1A
Chaperone
activity 7.43
5.0
xlO'6 2.6 0.0059 19.41
3.7
xlO'7 -7.46
4.2
xlO-6 -2.61
2.4
xlO" 2.86 0.00028
Biological Process: Signal transduction ; Cell communication
14
regulator o f G protein 
signaling 6 beta [Homo 
sapiens]
gi|19908833|
RGS6
GTPa.se
activator
activity 5.38
2.0
xlO'6 1.95 0.0026 4.1
1.0
x l0 ‘5 -2.1
1.6
xlO-6 1.31 0.0017 2.76
4.3
xlO-8
15* AnnexinI
gi|442631|
ANXA1
Calcium ion 
binding 2.08 0.0007 4.83
1.5
xlO’3 1.6 0.027 3.01 0.00051 1.3 0.14 -2.32 0.0021
In summary comparison between the subpopulations shows the accumulation of extracellular matrix protein type III preprocollagen alpha 1 
chain in DLKP-M. An accumulation of ER proteins is also seem in DLKP-M and include GANAB (responsible for processing secreted and 
membrane proteins), VCL (responsible for connecting F-actin to the cell membrane), HYOU1 (involved in hypoxic response and tissue repair), 
HSPA1A, EEF2 (translation elongation factor), and HDAC1 (responsible for altering chromatin structure and regulating transcription) and the 
role of these proteins are discussed in section 4.4.1.
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Figure 3.4.4: Standardised log abundance for each of the protein spots (a) CoBAl, (b) TUBB2A, (c) HDAC1, (d) GANAB, (e) HYOU1, (f)
In summary the data shows an increased accumulation of Col3al suggesting DLKP-M produces extracellular matrix. Col3al, and EEF2 
correlate with invasion. Amongst the clonal populations HDAC1, GANAB and TUBB2A correlate with invasion.
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3.4.3 Membrane and membrane associated proteomic analysis in DLKP and its 
subpopulations
In order to compare the alterations induced in the proteome of DLKP and its 
subpopulations, and for determination of the underlying mechanism that governs the 
interconversion and altered motility rates between DLKP-SQ, DLKP-I and DLKP-M, 
protein samples were prepared from each population using a fractionation process that 
selectively isolates proteins of the membrane and proteins associated to the membrane 
These hydrophobic protein and protein complexes were prepared as described in 
section 2.17. These were prepared in biological triplicate. Each biological triplicate 
was run in technical duplicates. Sample labelling with Cy dyes is shown in table 3.4.4. 
Fractionation process resulted in a low recovery of protein and this is due to the nature 
of the fractionation process. Previous 2D-DIGE experiments required 50|ig of protein 
from each sample however due to the low level of protein recovery 25 (jg of protein 
was used for each sample in the DIGE experiment. This did not present a problem as 
fractionated samples contain fewer protein species and thus there individual 
abundance are enriched.
Differentially regulated proteins were selected based on a fold change of >+/<-3 fold 
change between two populations.
Representative DIGE images of Cy labelled protein lysates separated by 2DE can be 
seen in figure 3.4.5. Differentially regulated proteins were identified by MALDI-ToF 
MS as described in section 2.27. Locations of identified proteins from the pick list in 
this experiment can be seen in figure 3.4.4 and the identity o f these proteins can be 
seen in table 3.4.4. The distribution of differentially regulated proteins amongst 
biological processes can be seen in figure 3.4.5.
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Table 3.4.4: Ettan DIGE experimental design for the analysis of differential protein
expression induced in MCF-7 by exposure to 5-FU for 7 cays.
Gel
number
CY2 label CY3 label CY5 label
1 Pooled internal standard 
(25jig of protein)
DLKP, P.30, 
(25jig of protein)
DLKP-M, P.30, 
(25|ig of protein)
2 Pooled internal standard 
(25jig o f protein)
DLKP, P.30, 
(25|a.g of protein)
DLKP-M, P.30, 
(25|ag of protein)
3 Pooled internal standard 
(25jig of protein)
DLKP, P.32, 
(25 jig of protein)
DLKP-M, P.32, 
(25 ng of protein)
4 Pooled internal standard 
(25|j,g of protein)
DLKP, P.32, 
(25jig of protein)
DLKP-M, P.32, 
(25 jig of protein)
5 Pooled internal standard 
(25jig of protein)
DLKP, P.34, 
(25jig of protein)
DLKP-M, P.34, 
(25 jig of protein)
6 Pooled internal standard 
(25jig of protein)
DLKP-SQ, P.34, 
(25|ig of protein)
DLKP-I, P.34, 
(25 jig o f protein)
7 Pooled internal standard 
(25jig of protein)
DLKP-SQ, P.30, 
(25jig of protein)
DLKP-I, P.30, 
(25 jig of protein)
8 Pooled internal standard 
(25 |jg of protein)
DLKP-SQ, P.30, 
(25|ig of protein)
DLKP-I, P.30, 
(25|ig of protein)
9 Pooled internal standard 
(25jig of protein)
DLKP-SQ, P.32, 
(25jig of protein)
DLKP-I, P.32, 
(25|ig of protein)
10 Pooled internal standard 
(25 jig of protein)
DLKP-SQ, P.32, 
(25|jg of protein)
DLKP-I, P.32,
(25 jig of protein)
11 Pooled internal standard 
(2 5 j^ g of protein)
DLKP-SQ, P.34, 
(25 jig of protein)
DLKP-I, P.34, 
(25 jig of protein)
12 Pooled internal standard 
(25 ng of protein)
DLKP-SQ, P.34, 
(25 jig of protein)
DLKP-I, P.34, 
(2 5 jig of protein)
Table 3.4.5: Summary of nuubers of differentially regulated proteins between each of
the sub populations
Statistical filters Population comparison
Fold
change
filter
Fold
change
t-test
DLKP/
DLKP-SQ
DLKP/
DLKP-I
DLKP/
DLKP-M
DLKP-SQ 
/ DLKP-M
DLKP-I / 
DLKP-M
DLKP-SQ 
/ DLKP-I
+/-1.2 <0.01 43 506 545 554 93 524
+/-1.5 <0.01 43 505 541 553 87 522
+/-3 <0.01 8 304 346 367 24 318
Analysis of the hydrophobic proteome and associated complexes reveal a remarkable
similarity between lowly invasive populations (DLKP and DLKP-SQ, 8 proteins 
differentially regulated above 3 fold). The highly invasive population also show a 
remarkable similarity to each other (DLKP-I and DLKP-M only 24 protein 
differentially regulated between each clone). At least 300 proteins show regulation 
between each other comparison and each of these comparisons contains a highly and a
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lowly invasive population. Thus this data contains an enormous amount of proteins 
that are potentially highly important in motility and invasion.
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Figure 3.4.5: Images of hydrophobic proteins and associated protein extracts labelled with CY dyes and separated by 2D-electrophoresis over a 
pH gradient of 4-7 from (a) DLKP, (b) DLKP-SQ, (c) DLKP-I, and (d) DLKP-M.
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Table 3.4.6: Proteins identified by MALDI-ToF MS that were differentially regulated between DLKP and its subpopulation in the hydrophobic 
proteomes. Protein expression data is included in table (fold change and t-test) as well Protein location on 2D gels (see figure 3.1.10.4.1 for 
locations). GI accession number was obtained from MS data. Protein name, Gene symbol were found from DAVID database, Human protein 
reference database or swissprot. Molecular and biological functions were obtained from the human protein reference database. Proteins that 
correlate with invasion are highlighted in Yellow those that are enriched in DLKP are highlighted in Blue. Proteins expression data was included
Positio
n Protein Name
Accession
Number Gene Symbol
Molecular
Function
DLKP-M / 
DLKP DLKP-I / DLKP
DLKP-SQ / 
DLKP
DLKP-I /DLKP 
-SQ
DLKP-M / 
DLKP-SQ
DLKP-M / 
DLKP-I
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Av.
Ratio T-test
Biological Function: Cell growth and/or maintenance
5
alpha-tubulin [Homo 
sapiens]
gi 37492|
TUB A3
Structural 
constituent of 
cvtoskeleton 111.13
6.0x10'
6 69.15
7.7x10
-7 -2.39
1.8x10'
l 9.24
2.2x10'
6 -1.91
8.2x10'
4 -1.01
8.0x10'
i
6
alpha-tubulin [Homo 
sapiens]
gi|37492|
TUB A3
Structural 
constituent of 
cvtoskeleton 26.40
5.3x10'
5 13.85
1.9x10'
4 -1.03
9.6x10'
t 3.07
1.0x10'
3 -1.61
2.0x10'
1 -1.24
5.5x10'
i
7
Tubulin, beta polypeptide 
[Homo sapiens]
gi|18088719|
TUBB2A
Structural 
constituent of 
cvtoskeleton 24.67
7.3x10'
7 51.36
2.3x10'
7 2.27
8.6x10'
t 19.52
2.4x10'
5 -1.54
5' 1? 10
-1.19
5.0x10'
i
g
Tubulin, beta polypeptide 
[Homo sapiens]
gi|18088719|
TUBB2A
Structural 
constituent of 
cytoskeleton 93.38
2.8x10'
4 16.05
3.8x10'
7 1.06
9.6x10'
i 2.57
1.3x10'
3 -1.82
6.2x10'
I -1.47
7.3x10'
i
12
beta actin variant [Homo 
sapiens]
gi 62897625
ACTB
Structural 
constituent of 
cytoskeleton 45.25
1.4x10'
6 43.88
4.8x10'
7 -1.15
3.0x10'
i -5.13
4.7x10'
4 -1.03
9.7x10'
t -1.08
9.8x10'
i
13 Beta Actin
AAH17450.
1 ACTB
Structural 
constituent of 
cytoskeleton 33.39
3.7x10'6 28.17
4.9x10'
6 1.44
9.8x10'
i 22.60
1.1x10'
4 -1.19
5.0x10'
i -1.82
6.2x10'
i
14
ACTB protein [Homo 
sapiens]
gi|15277503
ACTB
Structural 
constituent of 
cytoskeleton 28.15
5.2x10'
7 34.37
3.5x10'
7 -1.43
1.5x10'
i 5.87
7.7x1 O' 
5 1.22
3.1x10'
i 1.17
3.5x10'
I
15
ACTB protein [Homo 
sapiens]
gi 15277503
ACTB
Structural 
constituent of 
cytoskeleton 80.71
9.9x10'
« 50.01
3.3x10'
7 -1.93
1.5x10'2 1.97
3.4x10'2 -1.61
9.7x10'
3 -1.51
5.1x10'2
21 gamma-actin
gi[178045|
ACTG1
Structural 
constituent of 
cytoskeleton -2.75
1.4x10'2 1.87
3.9x10'
-1.14
5.7x10'
i -2.86
5.0x10'2 5.14
5.2x10'
4 -1.21
8.0x10'
i
9
ATP synthase, H+ 
transporting,
gi|16741373]
ATP5B
Transporter
activity 3.40
8.4x10'2 2.31
2.6x10'2 -1.11
8.4x10'
i 15.13
3.1x10'
7 -1.47
7.3x10'
i -1.54
5.1x10'
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mitochondrial FI 
complex, beta 
polypeptide [Homo 
sapiens]
10
ATP synthase, H+ 
transporting, 
mitochondrial FI 
complex, beta 
polypeptide [Homo 
sapiens]
gi|16741373|
ATP5B
Transporter
activity -5.69
3.2x10'
3 -10.15
3.9x10'
3 1.07
8.6x10'
I 2.13
9.1x10'
i 2.20
3.6x10'
l 5.14
5.2x10‘
4
11
ATP synthase beta 
subunit
gi|179279|gb|
ATP5B
Transporter
activity -8.37
6.8x10'
3 -2.59
4.1x10'2 1.10
8.8x10'
l -3.49
4.6x10'
3 -1.21
8.0x10'
l 1.80
2.4x10'
l
1
heat shock 70kDa protein 
8 isoform 2 variant 
[Homo sapiens]
gi|62896815| HSPA8
ATP binding 3.52
1.9x10'2 3.49
3.4x10'
3 1.20
4.9x10'
l 33.15
1.9x10'
9 -1.01
8.6x10'
l -1.91
8.2x10'
4
2
heat shock 70kDa protein 
8 isofonn 2 variant 
[Homo sapiens]
gi|62896815| HSPA8
ATP binding 12.89
1.2x10'
4 12.71
1.8x10'
< 1.37
3.3x10'
l 71.11
3.6x1 O'
9 -1.01
8.0x10'
t -1.61
2.0x10'
l
3
Ubiquilin 1, isoform 1 
[Homo sapiensl
gi|24659706|
UBQLN1
Ubiquitin-
specific
protease
activity 8.07
2.0x10'
4 5.35
6.6x10'
4 2.71
1.0x10'
l 57.72
3.4x10'
6 -1.51
5.1x10'2 -1.03
9.7x10'
l
4 MTHSP75
gi|292059|
HSPA9B
Chaperone
activity -4.92
1.5x10'2 -5.32
3.6x10'
3 -1.04
9.3x10'
l 84.90
5.7x10'
10 -1.08
9.8x10'
l -1.61
9.7x10'
3
20 elongation factor 2
gi|181969|
EEF2
Translation
regulator
activity -11.50
1.1x10'
3 -6.39
8.7x10'
3 -1.83
2.9x10'
l -10.81
5.7x10'
4 1.80
2.4x10'
i 2.20
3.6x10'
l
17 Annexin I
gi|442631|
ANXA1
Calcium ion 
binding 1.44
4.2x10'
l 3.78
1.0x10'
3 1.22
3.9x10'
l 1.80
2.7x10'
3 2.30
2.4x10'2 -1.40
1.3x10'2
18
annexin A1 [Homo 
sapiens]
gi|55959292|
ANXA1
Calcium ion 
binding 1.64
2.2x10'
l 3.50
7.4x10'
4 1.40
2.2x10'
l 2.92
2.1x10'
3 2.43
1.5x10'2 -1.01
8.6x10'
l
19
guanine nucleotide 
binding protein (G 
protein), beta polypeptide 
1 [Homo sapiens]
gi|30583449|
GNB1
Heterotrimeric
G-protein
GTPase
activitv 4.43
2.8x10'
4 3.16
1.1x10’
3 1.76
3.8x10'2 3.10
7.9x10'
4 -1.40
1.3x10'2 2.43
1.5x10'2
16
HSPC108 [Homo 
sapiens]
gi|6841440|
STOML2
Auxiliary
transport
protein
activitv 12.89
1.2x10'
4 12.71
1.8x10'
< 1.37
3.3x10'
l 71.11
3.6x10'
9 -1.01
8.0x10'
l -1.61
2.0x10'
l
22
Chain A, X-Ray 
Structure O f The Small G 
Protein Rabl la  In 
Complex With Gdp
gi|60593433| R ab lla Signal
transduction
4.90
1.7x10'
3 5.73
5.4x10'
4 -1.02
9.8x10'
l 49.30
1.4x10'6 1.17
3.5x10'
l 1.22
3.1x10'
l
248
Association of f-actin and microtubules to cell membrane are required for movement of cell by causing membrane ruffles. The upregulation of 
proteins in the hydrophobic and hydrophobic associated caomplexes indicates an increased association of these proteins with the membrane and 
suggests a functional link with motility. Annexin A1 is involved in regulation attachment of F-actin to membrane although little is understood 
about its role. G proteins associate with activated integrins and their increase association to the hydrophobic fraction would suggest integrin 
activation and signal transduction. EEF2 associates with F-actin, the isoform identified is a low molecular weight complex comparison of this 
protein with the total protein for expression of EEF2 shows an inverse relation ship between the two isoforms and is highly suggestive that EEF2 
regulation is important in the regulation of invasion and motility The implication of the regulation of these proteins is discussed in section 4.4.2.
Interesting proteins indicated by * in table 3.4.6 are represented in figure 3.4.6. This figure shows plots of proteins relative standard log 
abundance for each protein in comparison to each of the populations of DLKP.
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Figure 3.4.6: Standardised log abundance for each of the protein spots (a) TUB A3, (b) TUB2A, (c) ACTB (d) ATP5B(e) EEF2, (f) ANXA1, (g) 
GNB1, (h) STOML2 and (h) Rabl la.
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3.4.4 Unidentifed protein enriched in DLKP
The detection of proteins present in the parental population of DLKP that are much lower in the mixed population
Locations of three unidentified 
protein that are enriched in the 
mixed population of DLKP and 
may indicate cell-cell
communication or the presence of 
an additional subpopulation
Unidentified Protein 1
DLKP DLKP-SQ DLKP-I DLKP-M
Unidentified Protein 2 Unidentified Protein 13
lUnjdarlified 3 1
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3.4.5 Summary analysis of DLKP and its clonal subpopulations
Invasion and motility assays reveal that DLKP and its subpopulations display altered 
invasion and motility rates. DLKP-I and DLKP-M were found to have high motility 
and invasion rates while DLKP-SQ and DLKP were found to have low motility and 
invasion rates.
Analysis of proteomic data in both total cell lysate proteome and hydrophobic 
proteome revealed a selection of proteins that correlate with the motility and invasion 
trends and are highlighted in table 3.4.2 and table 3.4.6 and are plotted in figures 3.4.4 
and 3.4.6. Analysis of the hydrophobic proteome suggests increased association of 
actin filaments and tubulin filaments to the membrane and as stated previously 
microfilament connection to the membrane are important in the formation of 
membrane ruffles required for motility/invasion.
A potential marker protein was identified for the DLKP-M/DLKP-I population and 
this is Col3Al.
Finally, a selection of proteins highlighted in blue in tables 3.4.2 and 3.4.4 are more 
highly abundant in DLKP and figure 3.4.7 shows the location of 3 unidentified 
proteins that are more highly expressed in DLKP than any of the clonal 
subpopulations. This may be a result of cell-cell interactions or evidence of additional 
unidentified subpopulations and is discussed in section 4.4.3.
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4.0 Discussion
Overview
Treatment of normal and cancer cells of the lung and breast with the anti-metabolite 
5-FU at an IC80 concentration resulted in altered invasion status (see section 3.1.4), 
alteration in adherence profiles (see section 3.1.2), and a temporary inhibition of 
growth (see section 3.1.1) were cells appear to be halted in S-phase of the cell cycle as 
indicated by accumulation of p53 a marker of stalled DNA replication (see section 
3.1.6) and alter keratin 8 and 18 expression in the cell lines A549, DLKP, and MCF-7 
(see section 3.1.6) and the normal cell lines NHBE and HMEC (keratin expression not 
assessed in normal cell lines by western although in NHBE were found upregulated 
by 2D-DIGE). Proteomic analysis o f 5-FU treated cells was undertaken (see sections 
3.1.9, 10, 11, 12, and 13) and this data is discussed in section 4.1.
In order to investigate differences in the proteomic alterations induced by the 
fluoropyrimidines, 52FdU and 55FdU, DLKP was treated with both anti-metabolites 
under similar IC80 conditions (see section 3.2.1). Proteomic alterations induced by 
the treatment with these fluoropyrimidines that overlapped with DLKP treated with 5- 
FU are presented in section 3.2.2 and 3.2.3 and are discussed in section 4.2.
A 5-FU resistant (~4 fold) variant of DLKP was developed by pulse selection with the 
fluoropyrimidine 55FdU (see section 3.3.1) and resistance was characterised (see 
section 3.3.2). A proteomic comparison between DLKP and the resistant variant 
DLKP-55 was performed (see section 3.3.3) and potential mechanisms of resistance 
to 5-FU are discussed in section 4.3.
DLKP is a poorly differentiated NSCLC cell line consisting of at least 3 
subpopulations that are shown to interconvert with each other. Invasion and motility
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were investigated in DLKP and its subpopulations (see section 3.4.1) and analysis of 
its proteome (total cell extract see section 3.4.2) and hydrophobic proteome (see 
section 3.4.3) revealed a large selection of proteins that showed similar expression 
trends to motility/invasion phenotypes of these populations. These data are discussed 
in section 4.4.
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Clinically 5-FU is used in the treatment of Breast and Lung carcinomas amongst 
others. In order to investigate the effect 5-FU would have on the proteome an in vitro 
approach was taken to investigate the effect of 5-FU treatment on the lung carcinoma 
cell lines DLKP (NSCLC) and A549 (adenocarcinoma) and the breast cell line MCF- 
7 (adenocarcinoma). In addition to this normal cells o f epithelial origin of the lung 
and breast were treated with 5-FU to determine how normal cells respond to 5-FU 
treatment and if normal cell proteomic response is distinct or similar to cancer cell 
response.
All cell lines were treated at concentration of 5-FU that induced an approximate IC80 
to IC90 inhibition of cell growth and was found to be 10(iM, analysis of normal cell 
line inhibition of growth revealed a a equal or higher tolerance to 5-FU than cancer 
cell lines of similar tissue origin. An additional concentration of 30(j.M inhibition of 
cell growth was included in the analysis of the normal cell lines for this reason and as 
the literature was would suggest that normal cells would have lower incorporation 
frequencies of 5-FU into DNA and RNA (although incorporation rates were not 
investigated in our experiments) {Rutman, et a l, 1954}. A common response to 5-FU 
treatment was observed including the down regulation of non-phosphorylated 
Stathmin and the Ribosomal protein SA (RPSA). Non-phosphorylated Stathmin 
depolymerises tubulin and the implications of its regulation are discussed in terms of 
microtubule polymerisation and the chemotherapeutic drugs the taxanes in section
4.1.1,
4.1 Overview of 5-FU treatments of normal and cancer cells
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Down regulation of RPSA is also a common response to 5-FU. Its role in ribosome 
dynamics, translation elongation and the role of other proteins involved in translation 
regulation are discussed in section 4.1.2,
Previous work in the laboratory showed that the fluoropyrimidines, in common with 
the halogenated pyrimidines, induced the accumulation of the simple epithelial 
markers keratin 8 and 18 (O ’ Sullivan, Ph.D. thesis 1999; McMorrow, Ph.D. thesis 
2004; McBride etal. 2000; Walsh etal., 2002). Keratin 8/18 transfection into keratin 
8/18 null cells has been shown to induce invasion 2-3 fold and induced focal 
adherence formation, and the upregulation of Pi integrin. However keratin 8/18’s 
precise role in the regulation of invasion is not known (Chu et al., 1996; and Izawa et 
al., 2006). Work performed here in this thesis sought to investigate if 5-FU could alter 
invasion status and adherence profiles of the cell lines DLKP, A549 and MCF-7 and 
the normal epithelial cell lines HMEC and NHBE (cultured without retinoic acid - 
retinoic acid induces epithelial differentiation in NHBE and would be expected to 
promote migration/invasion). The data shows that 5-FU treatment promoted invasion 
in low level invasive cell lines (DLKP, MCF-7 and NHBE) and induction of the 
epithelial markers, Keratin 8/18, was observed (see section 3.1.4 figures 3.1.12-16). 
This suggests that 5-FU treatment has the capacity to promote invasion through 
promotion of simple epithelial differentiation. In contrast A549 was shown to reduce 
expression of keratin8/18 protein (not determined in HMEC) and invasion of A549 
was reduced following 5-FU treatment. Investigation of proteomic alterations was 
investigated and regulation of actin dynamics is discussed in section 4.1.3,
A model for Keratin dynamics in the regulation of actin dynamics is discussed and 
presented in section 4.1.4,
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Growth rates post-treatment were assessed in A549, DLKP, and MCF-7 (see figures 
3.1.6-9), but not in the normal cell lines due to a limited supply of cells and unstable 
phenotype associated with high cellular doublings, which can lead to cell death and or 
immortalisation with altered phenotype (>15 doublings (supplier guide lines see 
website www.cambrex.com)). The data indicates that the majority of cells survived 
the 5-FU treatment and a mechanism by which apoptosis may be inhibited in these 
cell lines is proposed and a possible link with the regulation of invasion and 
adherence (section 3.1.3-4) is discussed in section 4.1.5,
Several transcription factors and mRNA processing proteins were found to be 
regulated in the proteomics data presented in tables 3.1.4, 7, 10, 13 and 16 and their 
involvement with proposed 5-FU related transcription models are discussed in section 
4.1.6.
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4.1.1 Stathmin and microtubule filament stability -  implications in taxol/vinca 
aIkaloid/5-FU combinations
In all cell lines investigated stathmin (STMN1) was down regulated by 5-FU 
treatment (A549, DLKP, NHBE, MCF-7 and HMEC at all 5-FU concentrations). 
Stathmin is reported to be down regulated directly by p53 accumulation in cells 
{Johnsen, et al. 2000}. 5-FU is well known to induce p53 accumulation (Gilkes, et 
al., 2006), however p53 did not accumulate in NHBE cells as a result of 5-FU 
exposure (data only on 10 and not 30|iM 5-FU treatment see section 3.1.4). This 
suggests that Stathmin down-regulation may be regulated by an additional mechanism 
or possibly the down-regulation is a result of isoform conversion - depleting one 
isoform and enriching another. Stathmin is an important protein in tubulin dynamics 
and 12 isoforms of this protein are known to exist. All stathmin isoforms 
phosphorylated at either Serl6 or Ser63 displayed a significantly reduced tubulin- 
binding affinity {Steinmetz, 2006}. Down-regulation of Stathmin by siRNA causes 
accumulation of cells in the G2/M phase of the cell cycle and the formation of 
atypical microtubules (Rubin et al., 2004). The stathmin isoform observed to be 
down-regulated is non-phosphorylated (although the phosphorylation status in HMEC 
has not been determined by comparison to other cell lines 2D images it is likely to be 
non-phophorylated due to its location). This may indicate that 5-FU prevents cells 
from progressing past G2/M phase of the cell cycle and p53 accumulation would 
indicate that cells are in S phase (p53 accumulates in response to DNA damage, 5-FU 
causes DNA damage only during S-phase -  DNA synthesis stage of the cell cycle). 
The down regulation of non-phosphorylated stathmin may suggest phosphorylation of 
stathmin and would promote mitotic spindle formation at the G2/M phase of the cell 
and the formation of mitotic spindles required for mitosis (reviewed by Rubin and 
Atweh, 2004). The mechanism of tubulin depolymerisation and the role of stathmin 
are outlined in figure 4.1.
The Vinca alkoloids such as vincristine inhibits tubulin polymerisation and taxanes 
such as taxol stabilises microtubule filaments (Mollinedo et al., 2004). Deactivation of 
stathmin by phosphorylation or decreased expression of non-phosphorylated stathmin 
is required for the formation of mitotic spindles (Rubin and Atweh 2004). As stated
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non-phosphorylated stathmin is down regulated and this may suggest that cells are 
producing or are about to produce mitotic spindles. Thus application of taxol or the 
vinca alkoloids may reveal that one of these drugs may interfere with mitotic spindle 
formation or function. Based on 5-FU down-regulation of non-phosphorylated 
stathmin this may indicate that mitotic spindles are being polymerised or are 
polymerised and are playing an active role in the cellular functions. Thus if tubulin is 
being polymerised into mitotic spindles treatment with vinca alkaloids would inhibit 
their formation and lead to cell death. Alternatively taxane treatment may lead to the 
stabilisation of taxanes and may prevent the separation of chromosomes by mitotic 
spindles at this stage of the cell cycle. However as 5-FU inhibits DNA synthesis it is 
likely that the nucleus is intact and that microtubulae are being polymerised. Thus it is 
more likely that vinca alkoliods would have a more effective role in combination with 
5-FU treatments. Thus, this may indicate a potential synergistic mode of activity 
between 5-FU and microtubule interfering drugs in producing apoptosis. Further more 
experimental data here suggests that if taxol is used in combination with 5-FU it 
should be applied immediately post 5-FU treatment. As application with 5-FU would 
inhibit cell cycle progression past S-phase. However application of 5-FU with the 
vinca alkaloids may allow cell cycle at S/Gl phase of the cell cycle and may produce 
a synergistic activation of apoptosis.
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Figure 4.1: (a) Current model for the role o f stathmin in the regulation of microtubule 
dynamics. Microtubule (MT) filaments continuously switch between phases of 
polymerization and depolymerization. Stathmin sequesters unpolymerized tubulin by 
binding two a/p-tubulin heterodimers (represented by light and dark shaded circles), 
thus reducing the pool of tubulin heterodimers available for polymerization. Stathmin 
can also bind to the end of polymerized microtubules and increase the rate of 
catastrophe (process leading to tubulin depolymerisation) by inducing a 
conformational change that promotes microtubule depolymerization, (b) Current 
model for the role of stathmin in the mitotic phase of the cell cycle. Chromosomes 
(represented in grey) condense and segregate during the mitosis (4 phases - prophase, 
metaphase, anaphase, and telophase) while cytoplasmic division occurs by 
cytokinesis. At the onset of mitosis, interphase microtubules (mt) depolymerize 
(illustrated by the interrupted lines) then repolymerize to assemble the mitotic spindle. 
The inactivation of stathmin by phosphorylation allows mitotic spindle assembly and 
entry into mitosis. Stathmins reactivation by dephosphorylation promotes mitotic 
spindle disassembly and exit from mitosis (Rubin and Atweh 2004).
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4.1.2 Regulation of translation elongation in 5-FU treatments
Several ribosomal proteins and proteins involved in translation initiation and 
elongation were found regulated in the 5-FU treatments and are summarised in table
4.1. Their role in translation and their relationship to the cell cycle are discussed in the 
following subsections.
Table 4.1: Summary of translation elongation related proteins in All cell lines treated
with 5-FU
Cell line EEF1BG p-EEFlBD RPSA RPLPO TCTP DARS
A549 •- Î 1 Î ? Î
DLKP t ? 4 ? ? ?
NHBE -j'* 4 Î* ? ?
MCF-7 ? t 1 ? Î Î
HMEC Î Î 4 ? Î t
*In a dose dependent manner (only at 30|iM); |  increased accumulation; j  decreased expression; ? 
unknown.
4.1.2.1 Ribosomal protein SA (RPSA) and 5-FU treatments
The laminin binding protein Laminin receptor 1 binds to the extracellular matrix 
protein Laminin a  2. However the ribosomal protein SA (RPSA) is a product of the 
processing of this laminin receptor and generates the 40KDa protein observed 
regulated in these experiments and thus its regulation is to do with ribosome 
regulation and not adherence regulation (Sato et al., 1999). RPSA was observed to 
associate polyribosomes to the cytoskeleton (polyribosome - mRNA with numerous 
ribosomes attached indicating mRNA with high translation efficiency) (Auth D., 
1992). Thus its down regulation would suggest a loss of cytoskeletal localisation of 
polyribosomes. Very little is known about the implication of RPSA expression, 
however RPSA may play a role in translation control and regulate association of 
polyribosomes to the cytoskeleton during 5-FU treatments.
4.1.2.2 The elongation factor 1 complex and 5-FU treatments
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The translation elongation factor EEF1 is composed of two subunits, EEF1A and 
EEF1B. EEF1A (eukaryotic elongation factor 1 alpha) complex binds aminoacyl- 
tRNA to the ribosome with the hydrolysis of GTP. The EEF1B complex is composed 
of three subunits in mammals and these are EEF1B Beta, EEF1B Gamma and EEF1B 
Delta. The beta-gamma-delta complex facilitates the exchange of GDP for GTP in 
order to initiate another round of peptide elongation during translation (Sheu, et al., 
1999). Phosphorylation of the Gamma and Delta subunits of EEF1BD was found to 
promote association of Valine tRNA synthetase and promote translation of Valine 
rich proteins. The EEF1B complex plays an important role in progression from the S- 
phase to G2/M-phase of the cell cycle and it relocalises from the endoplasmic 
reticulum to the nucleus prior to nuclear membrane breakdown where EEF1B 
complexes form a ring around the nucleus where it specifically facilitates the 
formation of mitotic spindles (Boulben et al. 2003). The subunits of EEF1B, EEF1B- 
gamma and EEFlB-delta, were found to be generally up-regulated in response to 5- 
FU exposure. Specifically, EEF1B gamma was found upregulated in A549, DLKP, 
NHBE and HMEC in response to 5-FU treatment. Phosphorylated-EEFIB delta was 
found up-regulated in A549, MCF-7, NHBE and HMEC in response to 5-FU 
treatment. In NHBE cells the response was dose dependent (accumulated at 30 (iM 
and not 10(iM 5-FU) and suggests a link with toxicity and not cell cycle progression 
and as Stathmin was downregulated at both concentrations it would suggest that its 
accumulation cannot be attributed to cell cycle stalling alone.
The expression of EEF1B delta was found to be enhanced by ionising radiation that 
caused oxidation and double strand breaks of DNA (Jung et al., 1994). This suggests 
a role for translation elongation in the genotoxic response. Taking this data with the 
data presented above it would support a stronger role for the elongation factors in a 
general DNA damage response.
The translationally controlled tumour protein, TPT1, has been shown to inhibit GDP- 
GTP exchange function of EEFIB-Beta, but not the gamma or delta subunits -  and 
additionally stabilises the EEF1BG-EEF1BD translation elongation complex {Cans, 
C. et al. 2003). This data would further support a role for the translation elongation 
factor IB complex in the genotoxic response and may rule out the requirement for the 
EEFlB-beta subunit. This data would suggest an important role for the elongation
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factors in both cell cycle and genotoxic response and is a novel finding in regards to 
5-FU treatment.
The combination of stathmin downregulation, EEF1 subunit regulation may indicate 
that mitotic spindles are been formed and adds weight to the argument in section
4.1.1.1. The downregulation of RPSA may be important in the cell cycle. As stated in 
section 4.1.2.1 RPSA associates polyribosomes to the cytoskeleton and its common 
downregulation may facilitate the relocalisation of ribosomes to the nucleus and may 
facilitate the translation of proteins involved in the formation of mitotic spindles.
4.1.2.3 5-FU may induce selective translation by incorporation of amino acids 
during translation
Aminoacyl-tRNA synthetases ligate amino acids to their cognate tRNAs (Sang Lee, 
et al., 2002). The increased association of valine tRNA synthetase to EEF1B 
promoted increased expression of mRNA whose protein products contained high 
levels of valine (Le Sourde et al., 2006). The asparatate tRNA lygase - DARS - is 
responsible for the efficient channelling of aspartyl residues to the ribosome and 
binds to the EEF1 complex through EEF1BG (Sang Lee, et al., 2002). DARS shows 
a common up regulation between A549, MCF-7 and HMEC treated with 5-FU. Its 
expression together with data presented above may suggest a role in genotoxicity 
response or cell cycle. This may indicate that 5-FU treatment promotes increased 
expression of proteins that contain high levels of aspartyl residues.
Furthermore EEF1BD contains a phosphorylation site at serine 133 and is a substrate 
of CDC2 and controls translation efficiencies {Kawaguchi, Y. et al. 2003}. 
Phosphorylation of EEF1BD was found to increase selective incorporation rates of 
amino acid residues into synthesised proteins and caused the selective accumulation 
of protein enriched with Valine {Monnier, A. et al. 2001}. The EEF1BD isoform up- 
regulated by 5-FU treatment in all cell lines bar DLKP was found to be 
phosphorylated. This suggests a selective preference for amino acid incorporation 
during translation. Thus this data further supports the idea that 5-FU may alter 
translation efficiencies through regulation of EEF1 activity and translation elongation
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efficiency. This data may indicate that phosphorylation of EEF1BD is important in 
production of proteins enriched in aspartyl residues and is important during 5-FU 
treatments,
The ribosomal phosphoprotein PO (RPLPO) forms a complex with ribosomal 
phosphoprotein 1/2 (RPLP1/2) and plays a role in selection of the translation 
elongation factors EEF1A and EEF2 during translation elongation (Uchiumi, et al.
2002). RPLPO showed accumulation in A549 treated with 5-FU and in NHBE treated 
with 30fiM 5-FU but not 10^M 5-FU. Its expression trend was similar to that of 
translation elongation factor EEF1BD. These data indicates a role for RPLPO in the 
5-FU genotoxic response and its increased expression is not just a product of cell 
cycle stalling.
4.1.2.4 eIF3 subunits may regulate translation during 5-FU treatments
The translation initiation factor eIF3S5 is down regulated in over 30% of NSCLC and 
breast cancers. It plays an important role in cap-dependent translation initiation and its 
down-regulation was found to promote cap independent translation through IRES 
mediated translation (LeFebvre et al., 2006). The translation initiation factor eIF3S5 
was found down-regulated in DLKP cells treated with 5-FU, suggesting that 5-FU 
promotes a decrease in cap dependent translation initiation.
The identification of eIF3S5 protein in other cell lines investigated in this thesis by 
2D-DIGE is highly challenging as is occurs in a region where keratin spots focus by 
2D electrophoresis and thus keratin proteins will mask eIF3S5. DLKP is a keratin- 
negative cell line and as such allows for the identification of eIF3S5.
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eIF3S2 is an important protein in the eIF3 complex and is involved in the recruitment 
of the translation canonical factors eIF2 (complexed in the translation pre-initiation 
complex), eIF5 during cap dependent translation initiation (Valasek et a t, 2002). 
eIF3S2 was downregulated in NHBE treated with lOfiM 5-FU. Down regulation of 
eIF3S2 would suggest that 5-FU promotes a reduction in cap dependent translation in 
NHBE. However its expression recovered at the higher 5-FU treatment in NHBE and 
suggests that its expression is important in the translation events regulated by the 
EEF1 protein as discussed above and may implicate it in translation regulation during 
genotoxicity.
eIF3S3 was reported down-regulated in Hela cells treated with 5-FU (Yim et at, 
2006). Thus this combined with data presented above may indicate that 5-FU 
generally causes a down regulation of eIF3 activity and may promote selective 
translation or global repression of translation through down regulation of the eIF3 
subunits.
A possible inhibition of cap dependent translation initiation is apparent but not 
conclusive by the common down regulation of eIF3 subunits. Cap-independent 
translation initiation of viruses requires the recruitment EEF1A and EEF2 (Pestova et 
al., 2003). Internal ribosome entry site-mediated translation or IRES-mediated 
translation is an important mechanism during cellular stresses, and its exact 
mechanism of translation is poorly described. Viral models are often used as a basis 
for the understanding of cellular driven IRES (Jackson, 2005). Thus the accumulation 
of the EEF1 proteins generally seen in all cell lines treated with 5-FU and 
accumulation of EEF2 in DLKP treated with 5-FU, may indicate that 5-FU promotes 
cap independent translation through regulation of the eIF3 subunits and upregulation 
of the elongation factors. Furthermore the selectivity of translation may be enhanced 
by the up regulation of DARS and may indicate selective translation of aspartyl rich 
proteins in an IRES driven translation regulated system.
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4.1.3 Actin dynamics during 5-FU treatment and its potential role in regulation 
invasion in 5-FU treatments
Proteomic analysis of normal and cancer cell lines of the lung and breast identified a 
list of proteins involved in actin architecture and actin regulation to be differentially 
expressed as a result of 5-FU treatment (see tables 3.1.4, 7, 10, 13 and 16). Invasion 
status was found altered in all cell lines as a result of 5-FU treatment and adherence 
was found to be altered in A549 but not DLKP and MCF-7 (not investigated in 
normal cell lines due to limited number of cells), see sections 3.1.3, and 3.1.4. This 
data is briefly summarised in table 4.2 but refer to specific sections for more detailed 
data.
Table 4.2: A summary of invasion trends in cell lines post 5-FU treatment and the 
regulation of actin binding and regulating proteins identified by proteomic analysis.
Phenotype 
change or 
protein trend
A549 treated 
with 5-FU
DLKP treated 
with 5-FU
NHBE treated 
with 5-FU
MCF-7 treated 
with 5-FU
HMEC treated 
with 5-FU
Invasion trend 1 t t T I
Adherence to 
fibronectin 
and collagen
t
Actin T t t t -
ARP t
CAPZA1 4
CAPZB t t
p-CFLl t t t t
GSN t t t
PLS3 t t
LASP-1 i t
g-CAP39 i
CTTN T t
VCL t
WDR-1 r t
PPP2CB T
TPM1 t
TPM3 t
TPM4 t
NME1 t
CAPNS1 T t
VTL2 t
RDX t
YWHAZ t 1 t t t
YWHAG r t t t
KRT8 i T t t
KRT18 i t t t
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4.1.3.1 Actin accumulation and potential regulators of actin dynamics
The protein P-actin (ACTB) showed accumulation in all cell lines bar HMEC treated 
with 5-FU. Four isoforms in both DLKP and A549 cell lines showed accumulation. 
Matching of proteins between A549 and DLKP show that protein positions 46, 44, 43 
and 45 on the A549 2DE DIGE images (figure 3.1.43) correspond with 55, 54, 50 
and 49 on the DLKP 2D DIGE images (figure 3.1.48), respectively. DLKP shows 
about 1.5-1.7 fold change in all ACTB isoforms with position 50 (1.73 fold) showing 
the greatest accumulation. DLKP position 50 corresponds with the actin up-regulated 
in the NHBE experiment. A549 shows the greatest accumulation at position 46 (1.66) 
and least at position 45 (1.34). This may indicate that ACTB dynamics are altered by 
treatment with 5-FU. The alteration in ACTB dynamics that result in the 
accumulation of the ACTB most highly abundant in DLKP and NHBE may be 
important in the promotion of invasion while the alteration that promote the 
formation of ACTB isoform preferentially enriched in A549 result in decreased 
invasion. As ACTB is an important component of the actin threadmilling process (see 
section 1.4.8) in cellular motility and may explain in part why A549 shows decreased 
invasion post 5-FU exposure. In MCF-7 cells treated with 5-FU ACTB was found to 
be upregulated. A total of 3 isoforms were upregulated and isoform at position 101 
corresponds with the most highly upregulated actin isoform in NHBE and DLKP 
treated with 5-FU (see figure 3.1.53 and 3.1.58). No actin isoforms showed 
upregulation in HMEC treated with 5-FU.
The cytoskeletal protein ACTB can be modified by various post transcriptional 
modifications and these include acétylation, metylation and ADP-ribosylation at D2, 
Y53 and V96, H73, and R177, respectively (Gavaert, et al., 2002; Schuler et al., 
2000; and Nyman el al., 2002). ADP-Ribosylation of ACTB prevents ADP ATP 
exchange and prevent actin recycling (Schuler et al, 2000). These modifications 
could contribute to the various isoforms identified on the 2D gels. Further 
identification of the modifications present in the differentially regulated isoforms of 
ACTB may indicate a tentative role for these post translational modifications in the 
processes of motility and invasion.
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This data suggests preferential accumulation of ACTB isoforms are associated with 
increased invasion. This data suggests that 5-FU treatments may promote and 
decrease invasion through altered actin dynamics.
As described in section 1.4.6-1.4.12, actin architecture is highly regulated and actin 
threadmilling is an essential component of migration and invasion (dos Remedios, et 
al. 2003). As can be seen from table 4.2 a selection of proteins are regulated by 5-FU 
treatment that influence actin architecture and are discussed in the following sections.
4.1.3.2 Regulation of actin dynamics by 5-FU treatment
No actin binding proteins were commonly regulated between NHBE, DLKP and 
A549 or DLKP and A549. However, between DLKP and NHBE five actin binding 
proteins were commonly regulated. These include CAPZA1, CAPZB, CFL1, GSN 
and PLS3. Table 3.1.7 subsection cell growth and/or maintenance lists 11 actin 
binding proteins regulated in DLKP treated with 5-FU. Those found upregulated 
include CAPZB, phosphorylated CFL1, CTTN, GSN, PLS3 and VCL and those down 
regulated include CAPZA1, LASPI and gCAP 39. The actin binding proteins 
CAPZB, CFL1, PLS3 and GSN play important roles in actin dynamics and are thus 
important in motility and invasion (dos Remedios, C.G. et al. 2003).
CAPZB and CAPZA1 are up and down regulated, respectively. CAPZ proteins play 
an important role in nucleation of actin assembly, capture of pre-existing actin 
filaments, regulation of actin assembly at the barbed ends of filaments and elimination 
of annealing at the barbed ends of filaments (Sept D, et al 1999). CAPZB, CAPZAl 
and CAPZA2 form a complex at the barbed end of actin filaments and prevent 
severing of actin, while CAPZB binds monomeric actin and stimulates its elongation 
(Cassella et al., 1986; and Sept, et al., 1999). The regulation of this CAPZ proteins in 
DLKP and NHBE treated with 5-FU may indicate increased actin nucleation and 
severing of F-actin.
Cofilin can nucleate actin in the presence of CAPZ and plays an important role in 
motility. Cofilin is diffusely distributed in the cytoplasm of quiescent cells. However,
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in active cells, it translocates to cortical regions where the actin cytoskeleton is highly 
dynamic and drives the ruffling of membranes of motile cells. Cofilin depolymerises 
actin filaments. It removes actin-ADP from the pointed end of F-actin in the form of 
an actin-ADP-Cofilin complex which exists freely in the cytosol. Phosphorylation of 
cofilin releases actin and ADP from cofilin (dos Remedios, et al. 2003). Thus the 
observed increase in phosphorylated cofilin would increase the free actin monomers 
in solution available for F-actin elongation. Non-phophorylated cofilin was not 
detected on the 2D gels and it is not expected to as the pi of cofilin is greater than pH 
7. Thus it is difficult to determine from this data if 5-FU induces accumulation of just 
phosphorylated cofilin or promotes the upregulation of both isoforms suggesting 
cofilin recycling and increased expression of cofilin. Clearly 5-FU treatment caused 
phosphorylation of cofilin which overall would contribute to increased levels of 
monomeric actin available for F-actin nucleation and elongation. Thus 5-FU promotes 
increased accumulation of phosphorylated cofilin. Taking into account the functions 
of cofilin and the high degree of cofilin accumulation in 5-FU treatment experiments 
it would suggest that its expression is highly important in promoting invasion in 
response to 5-FU treatment.
Cortactin (CTTN) is a c-src substrate associated with sites of dynamic actin assembly 
at the leading edge of migrating cells. CTTN binds to Arp2/3 complex, the essential 
molecular machine for nucleating actin filament assembly. CTTN potently inhibits the 
debranching of the filament networks. CTTN is necessary for direct activation of the 
Arp2/3 complex and stabilization of newly generated actin filament branch points. 
Thus, CTTN may promote the formation and stabilization of the actin network that 
drives protrusion at the leading edge of migrating cells (Weave, et al., 2001). CTTN 
was found to accumulate in DLKP and NHBE treated with 5-FU and would suggest a 
role in promoting F-actin elongation.
Gelsolin (GSN) is an actin binding protein and binding of gelsolin initiates the F-actin 
severing from the pointed end, but while binding to filaments is rapid, its severing 
action is slow (dos Remedios, et al. 2003). GSN acts more as a Ca2+-regulated 
capping protein. Depolymerization is mainly caused by dissociation of actin subunits 
from the pointed ends of actin filaments and that inhibition of polymerization was 
achieved by gelsolin binding at the barbed ends. The rate of capping at the barbed end
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was directly proportional to the free Ca2+ concentration and high calcium levels 
activate gelsolins F-actin severing functions (Gremm D and Wegner A, 2000). 
Gelsolin forms a complex with talin -  the integrin binding protein -has been shown to 
attach of F-actin to the cell membrane via integrin intercellular domain and F-actin 
membrane connections are important in cell migration (Fischer et al., 1998; Chen H. 
et al. 2006). The mRNA expression of Gelsolin was reported to be up-regulatid by 5- 
FU treatment in MCF-7, however this altered expression could not be confirmed by 
Northern blotting (Maxwell et al., 2003). The increased expression of gelsolin in 
DLKP, NHBE and MCF-7 by 5-FU treatment is shown here and the combination of 
its expression in these cell lines and the data presented above on its activity would 
suggest a highly important role for Gelsolin in promoting invasion during treatment 
with 5-FU.
Thus increased expression of Gelsolin shown here in MCF-7 seems important in 
promoting invasion in these systems. Furthermore this data also implicates a degree of 
similarity between the MCF-7 5-FU microarray experiments published by Maxwell et 
al., 2003 and the MCF-7 5-FU treatment data presented here. Maxwell et al., (2003) 
found that Gelsolin mRNA was up-regulated 7.3 in their DNA microarray 
experiments although northern blots failed to validate this result. The fold change for 
gelsolin in these 5-FU treated MCF-7 proteomic experiment found four Gelsolin 
isoforms were upregulated by 4-7.35 fold. (Additional data showing overlaps; 
Annexin II, and Annexin IV expression; on DNA microarray were 12.3, and 9.3, 
(Maxwell et al., 2003) and proteomic data 1.7, and 1.6, respectively) Down loading of 
this microarray data and analysis of both data sets (proteomic and DNA-microarray) 
may reveal further insights into the regulation of invasion and 5-FU treatment 
response in MCF-7 by 5-FU treatment and identify possible targets that are 
translationally regulated in 5-FU treatments.
The gelsolin like capping protein gCAP39 was down-regulated by 5-FU treatment of 
DLKP. It plays a role in invasion and caps F-actin however unlike gelsolin it does not 
have severing activity (Yu et al. 1991) Taken together with CAPZ protein expression 
and GSN expression it would suggest alteration in F-actin capping proteins and a 
preference for gelsolin capping of F-actin during 5-FU treatments in cell lines that 
become more invasive post 5-FU treatment.
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Plastins are actin binding proteins which form parallel actin filaments known as actin 
bundles. At least in vitro, actin bundling through plastin-3 is inhibited if the 
concentration of calcium is increased and allows severing of F-actin filaments. 
Calcium gradients are important during migration and thus as an actin filament enters 
regions of high calcium plastin-3 would dissociate and in theory allow Gelsolin and 
cofilin to depolymerise F-actin filaments (Pacaud et al., 1983). Plastin-3, or T-Plastin, 
(PLS3) was found to inhibit depolymerisation of actin by cofilin, and is expressed 
predominantly in mesenchymal and epithelial cells. L-plastin disassociates from F- 
actin in high calcium gradients which are formed in F-actin depolymerising regions 
during migration and thus L-plastin would contribute to organised actin 
polymerisation and depolymerisation. Like L-plastin, T-plastin contains a calcium 
binding domain and calcium binding to L-Plastin induces disassociation from F-actin 
and T-plastin is probably similarly regulated (Arpin, et a l, 1994). Plastin-3 also 
promotes branching through association of the ARP2/3 complex and thus is vital 
during migration (Giganti, et al., 2005). Plastin-3 accumulates in both DLKP and 
NHBE in response to 5-FU treatment and this would suggest formation of actin 
bundles important in migration.
Vinculin (VCL) as stated above plays an important role in connecting gelsolin capped 
F-actin to the membrane and plays and important role in the formation of focal 
contacts (Fischer et al,, 1998; Chen H. et al. 2006). VCL expression is increased in 
DLKP treated with 5-FU.
WDR-1 (AIP1 -  actin interacting protein 1) cooperates with ADP/cofilin in its 
severing activity of F-actin (Ono S. et al., 2004). WDR-1 accumulated in both HMEC 
and NHBE treated with 5-FU. Its increased expression in NHBE and HMEC would 
promote actin depolymerisation.
PPP2CB phosphorylates and activates calpains responsible for breaking of actin-focal 
adherence contacts and is reported to promote invasion. Breaking of the talin contacts 
is important in the disassociation of integrins from ECM contacts {Xu, L. et al. 2006}. 
Increased expression of PPP2CB is observed in DLKP treated with 5-FU and suggests 
increased calpain activity.
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Villin 2 (VTL2) also known as ezrin, anchors the F- actin to radixin and FAK and 
activates autophosphorylation of FAK (Shuster et al. 1995) and Radixin (RDX) binds 
ezrin (Bharthur et a l, 1998). Both Vil2 and RDX are ERM proteins and require 
binding to moesin to regulate the activity of G-proteins. Protein kinase C activates 
ERM proteins by phosphorylation of Villin 2 and this forms a link between the 
membrane and F-actin (.Larsson C., 2006) and activation is important in wound 
healing and invasion (Jensen et al., 2004). The ERM proteins were also found to bind 
syndecan-2 (Granes et a l, 2004) and this would be consistent with a role in wound 
healing as syndecan-2 is required for ECM assembly. The accumulation of non- 
phosphorylated ezrin and radixin may suggest deactivation of the ERM proteins as 
suggested by the accumulation of non- phosphorylated isoforms. Villin is also a 
calcium dependent actin bundling and actin depolymerising protein. At high calcium 
levels it depolymerises and at low calcium levels it forms actin bundles (Molitoris et 
al., 1997). RDX and Vil2 were not found to be phosphorylated but were upregulated 
which suggests accumulation of the inactivated form of the ERM proteins (Larsson 
2006). Further investigation is required to determine if phosphorylated forms are 
regulated on 2D gels. However this data would indicate a decreased association of  
ERM proteins to integrins and in combination with gelsolin expression may indicate 
an alteration in proteins present in the focal contacts. This may further indicate a 
transformation from a fibroblast like behaviour to epithelial like behaviour. Syndecan- 
2 is highly expressed in fibroblast and is important in the assembly of ECM proteins 
and promotes increased adherence to ECM proteins and decreased invasion (Villena 
et al., 2003). Although expression of syndecan-2 was not assessed in MCF-7 the data 
presented above may indicate a role for Syndecan-2 in invasion in MCF-7 5-FU 
treatments. Further more Syndecan-2 expression was found to accumulate in A549 
and decrease in DLKP (see table 3.1.3) further suggesting a role for syndecan-2 
expression in regulation of invasion during 5-FU treatment.
These proteins work synergistically together and it would be expected that small 
changes in these proteins expression would have large changes in phenotypic 
behaviour. Taking these data in context of NHBE MCF-7 and DLKP it would suggest 
that invasion is promoted by altered actin dynamics in regards to actin nucleation and
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elongation, F-actin depolymerisation, F-actin bundling and F-actin attachment to 
membrane all processes important in migration.
In contrast A549 treated with 5-FU increased expression of the actin binding proteins 
tropomyosin-3 (TPM-3) and TPM4 in response to 5-FU exposure. In HMEC increase 
d expression of TPM 1 was observed. TPM proteins stabilise actin filament. TPM3 
has been shown to inhibit the branching activity of ARP2/3 and ARP2/3 is an 
important protein in promoting motility (Blanchoin et a.l 2001). TPM-1 mRNA 
expression has been shown to correlate with decreased motility in a DNA microarray 
experiment (Okubo et al., 2002). Thus tropomyosin family member expression 
appears to inhibit invasion by possible inhibition of actin branching and stabilisation 
if actin filaments.
NME1 expression has also been shown to inversely correlate with invasion and its up 
regulation is suggested to interfere with PKC signalling pathway (Nie Q. et al., 2006). 
NME1 is upregulated in A549 treated with 5-FU and indicates a possible role in the 
inhibition PKC signalling.
Calpain 1 (CAPNS1) is a protease whose substrates include phosphorylated CTTN, 
GSN, talin, Plastin-3 and VCL. These proteins are important in maintaining cell 
cytoskeletal contacts with focal contacts. Calpains have been implicated in migration 
and have been shown to be important in breaking actin-focal contacts complexes 
through proteolytic cleavage of talin {Lebart, M.C. 2006}. Increased phosphorylation 
of CAPNS1 is linked with increased invasion and phosphorylation is enhanced by 
MEK, ERK1/2 and PKC signalling pathways. Dephosphorylation of CAPNS1 is 
associated with decreased cell migration and metastasis in the lung {Xu, L. et al. 
2006}. There is an accumulation of non-phosphorylated CAPNS1 in A549 and 
accumulation of non-phosphorylated CAPNS1 may indicate decreased 
phosphorylation rates. Furthermore in NHBE a statistically significant increase in 
non-phosphorylated CAPNS1 was observed at the higher 30|jM concentration of 5- 
FU and may indicate that high toxic doses of 5-FU pushes cells into a non-invasive 
state through down regulation PKC signalling pathway.
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Tropomyosin 1 and HSPB1 were observed up regulated in HMEC and they contribute 
to actin stabilisation and decreased motility rates (Gunning et al., 1997; Concannon,
2003). This may explain how invasion is inhibited in HMEC. Less than 10% of 
proteins regulated in HMEC have been identified and further work needs to be done 
to explain the inhibition of invasion observed.
Cofilin and its regulation
The up-regulated Cofilin isoform is phosphorylated in MCF-7, DLKP and NHBE 
(indicated by pro-diamond staining) and probably in HMEC (as shares same location 
as phosphorylated cofilin in all other cell lines) and only one phosphorylation site is 
known to exist oncofilin. Cofilin is a substrate of phosphorylated LIMK which is 
phosphorylated by PAK2. Phosphorylated PAK2 accumulated in MCF-7 treated with 
5-FU. The p-21 activated kinase PAK2 is activated by G-proteins such as CDC42, 
Rac or p21 and PAK2 activity was shown to be essential for the activation of 
metastasis by increased secretion of proteases and increased migration in 
macrophages (Misra et al. 2005). Transcription of p21 is well known to be activated 
by p53 accumulation and this indicates that 5-FU genotoxic stress leads to p53 
accumulation, leading to transcriptional up-regulation of p21 (Schumm et a l 2006) 
leading to PAK2 activation and phosphorylation of LIMK which subsequently 
phosphorylates cofilin and promotes of invasion (Misra et a l 2005). PAK2 increased 
expression and activation are worth investigation in all other cell lines treated with 5- 
FU. PAK2 activation is an important observation in MCF-7 5-FU treatments and 
provides a functional link between 5-FU aenotoxicitv and migration in the carcinoma 
cell line MCF-7.
Activated PAK2 phosphorylates eIF4G and inhibits its role in cap dependent 
translation (Ling et al., 2005). This data further supports the possibility that 5-FU 
treatments cause an inhibition of translation.
4.1.4 The role of Keratin intermediate filaments and 14-3-3 protein in 
regulation of actin dynamics during 5-FU treatment
The 14-3-3 proteins YWHAZ and YWHAG binds to keratin 18 phosphorylated at 
serine 33 and is important in regulating keratin dynamics (Ku et a l 1998; Ku et al, 
2002). The 14-3-3 proteins bind to phosphorylated cofilin, and to slingshot a protein
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responsible for dephosphorylating cofilin and allowing it to continue depolymerising 
F-actin (Pan S. et al, 2006; Soosairajah J. et al. 2004/ Competition between 
phosphorylated keratin 18, p-cofilin and slingshot can be predicted from these 
regulations.
2D-DIGE data presented in tables 3.1.4, 7, 10, 13 and 16 shows that several 14-3-3 
proteins accumulate in A549, NHBE, MCF-7 and HMEC. Members of the 14-3-3 
protein family were observed up regulated; in A549 5-FU treatments include
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Figure 4.2: Potential role of phosphorylated keratin 18 and 14-3-3 proteins in the 
regulation of actin dynamics
YWHAZ, YWHAB and YWHAQ; in NHBE 5-FU treatments SFN and YWHAG; in 
MCF-7 5-FU treatments YWHAZ and YWHAG; in HMEC 5-FU treatments non 
were observed regulated; in DLKP YWHAZ was down regulated. Expression of 
keratin 18 was observed upregulated in DLKP, MCF-7 and NHBE while decreased 
expression of phosphorylated keratin 18 was observed in A549 and no alterations 
were observed in HMEC. Based on this expression data and known competition 
between 14-3-3 proteins and phosphorylated Keratin 18, phosphorylated cofilin and 
slingshot it is likely in DLKP, NHBE and MCF-7 14-3-3 proteins would accumulate 
in keratin filaments preventing sequestering of cofilin and promoting invasion by 
allowing cofilin recycling. In A549 the downregulation of p-keratin 18 would free 14- 
3-3 proteins into the cytoplasm and allow it to sequester p-cofilin and slingshot 
inhibiting invasion. In HMEC no regulation was observed however this may be a 
result of limited data from this experiment.
Thus a proposed model of regulation of cofilin recycling bv 5-FU treatment is as 
follows. 14-3-3 protein are sequestered in the cvtokeratin filaments thus promoting 
cofilin recycling bv (O releasing increased levels of slingshot proteins to regenerate 
cofilin (2) prevent the formation of 14-3-3 protein complex with phosphorylated 
cofilin.
BrdU treatments were found to upregulate keratin 18 expression in A549 (McBride et 
al., 1999). This data would suggest that 5-FU acts on A549 in a uniquely different 
manner than BrdU. However, retinoic acid treatment of A549 cells was shown to 
down-regulate keratin 18 expression in A549 and inhibit invasion -  very similar to 5- 
FU data presented here- and cause an upregulation of the cellular retinoic acid binding 
protein Crabp (Fazely et al., 1990). Also, 5-FU was found to induce an upregulation 
of the epithelial markers keratin 18, 14 and 17 amongst others in NHBE and Crabp2 
was found upregulated in NHBE. This data may indicate that 5-FU functions in a 
similar manner to all-trans retinoic acid in inducing differentiation.
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The heat shock protein 27, HSPB1, has been shown to play an important role in cell 
survival as indicated by section 1.1.9. Over expression ofHSPBl increases resistance 
to various forms of apoptotic signaling and includes sequestering of cytochrome c in 
the cytoplasm preventing binding to APAF-1 and apoptosome formation {Gorman, 
A.M. etal. 2005}. Specifically phosphorylation ofHSPBl sequesters cytochrome-c in 
the cytoplasm preventing apoptosome formation (see figure 1.3). Furthermore HSPB1 
over expression increases expression of Glucose-6-phosphate dehydrogenase causing 
resistance to ROS, and non-phosphorylated and non-oligomerised HSPB1 contribute 
to F-actin stabilization while phosphorylated and oligomerised isoforms do not 
{Concannon, C.G. 2003}.
NHBE and MCF-7 2D-DIGE experiments show the accumulation of phosphorylated 
HSPB1 (see tables 3.1.10, 11, 13 and 14) While in A549 and HMEC HSPB1 
accumulated but was not phosphorylated. The upregulation of phosphorylated HSPB1 
would suggest that HSPB1 sequesters released cytochrome c from the mitochondria. 
The accumulation of non-phosphorylated HSPB1 promotes actin stabilisation and 
seems probable by the data discussed in section 4.1.3. In DLKP HSPB1 was not 
regulated, however HSP70 appears up-regulated and as shown in figure 1.1.3 HSP70 
can sequester APAF-1 and prevent apoptosome formation (Concannon, 2003).
Taking this data in context of 5-FU treatment it seems that cells may inhibit 
apopotosis by three potential mechanisms; (1) sequestering of cytochrome c by 
phophorylated HSPB1 preventing apoptosome formation, (2) sequestering of APAF-1 
by HSP70, again preventing apoptosome formation and (3) HSPB1 promotion of F- 
actin stability.
Very little work to date has investigated the role HSPB1 in 5-FU treatments, and the 
importance of these observations is highlighted by work performed by Miyazaki, T. et 
al. (2005). Who demonstrated that HSPB1 negative expression was a predictor of a 
favourable outcome of patients suffering with oesophageal squamous carcinoma
4.1.5 Inhibition of apoptosis during 5-FU treatments
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treated with 5-FU in combination with other drugs. Thus Miyazaki, et al. (2005) data 
in combination with work here indicates that targeting of HSPB1 anti-apoptopic 
function may be crucial in improving clinical outcome of 5-FU based therapies. 
DLKP did not show alteration in HSPB1 expression.
Cathepsin D (CTSD), a protein involved in proteolytic remodelling of ECM is 
upregulated in HMEC and MCF-7 treated with 5-FU. Its expression does not 
correlate with invasion however CTSD activity is not limited to invasion and plays a 
functional role in ECM architecture (Sis et al., 2004). Thus CTSD increased 
expression may suggest that 5-FU induces altered interactions with the ECM and 
CTSD expression is a component of but not a determinant of phenotypic alterations. 
An alternative role of CTSD is in apoptosis. During pre-induction of apoptosis CTSD 
is up-regulated in the lysosome and released from the lysosome into the cytosol 
where it stimulates the release of cytochrome c from the mitochondria (Zuzarte-luis 
et al., 2006). 5-FU has been shown previously to induce cytochrome c release 
(Emert-Sedlak et al., 2005). Cytochrome c participates in the formation of the 
apoptosome (Gorman, et al. 2005}. However, proliferation data demonstrated that 
MCF-7 survives treatment with 5-FU in this experiment. If CTSD is stimulating the 
release of cytochrome c from the mitochondria in to the cytosol in these cell lines the 
increased expression of HSPB 1 would inhibit its role in apoptosis. Thus this data 
would further suggest that HSPB1 expression is crucial in inhibiting apoptosis and 
promoting cell survival during 5-FU treatment.
The apoptosis related protein Programmed Cell Death 6 Interacting Protein, 
(PDCD6IP also known as ALIX, HP95 and AIP1; should not be confused with WDR- 
1 also caused AIP1) was identified up regulated in both A549 and DLKP treated with 
5-FU. PDCD6IP has been linked to promoting detachment-induced apoptosis 
(anoikis), inhibited detachment of viable cells from substratum and reduced 
tumorigenicity. PDCD6IP overexpression promoted flat cell morphology and 
decreased cell proliferation, whereas PDCD6IP down regulation had opposite effects. 
This data suggests that mammalian PDCD6IP is a positive regulator in apoptotic 
signalling and a negative regulator in cell transformation. They also suggest that 
PDCD6IP has roles in regulating cell adhesion and morphology (Wu et al. 2002). 
These findings are consistent with observed alterations in morphology and may
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indicate that 5-FU promotes cell survival in an attachment dependent manner. 
However, DLKP and A549 adherence and invasion profiles suggest different 
interactions with ECM and may indicate that PDCD6 IP influenced interactions with 
ECM may ultimately be decided by an additional factor. PDCD6 IP expression is 
required for maintaining typical fibroblast morphology, associates with F-actin and F- 
actin based structures in lamellipodia and stress fibers. PDCD6 IP binds CTTN, an 
activator of the ARP2/3 complex-mediated initiation of actin polymerization. 
PDCD6 IP is required for lamellipodial localization of CTTN (CTTN expression is 
discussed in section 4.1.3). The C-terminal half of the middle region of PDCD6 IP 
interacts with a-actinin, a key factor that bundles F-actin in stress fibers (Pan S. et al., 
2006).
In addition to this the integrin subunit Pi was commonly found up regulated in A549 
and DLKP in response to 5-FU treatment. Its binding partners (X2 and a 5 integrin were 
up regulated in A549 and DLKP, respectively, and syndecan-2 was up-regulated in 
A549 and down-regulated in DLKP. P1CI5 integrin and sdc-2 form a complex in focal 
contacts and promote adherence to fibronectin (Kusuno et al., 2004) and there 
expression profiles would explain the adherence assays profiles in A549. DLKP 
showed decreased expression of sdc-2 , and decreased expression has been shown to 
correlate with increased invasion rates and Pia.5 integrin was shown to correlate with 
increased invasion and signalling from this integrin complex was shown to stimulate 
MMP-9 expression - a potent collagenase -  through PKC signalling (Hans et al., 
2006). This data indicates alteration in cell matrix interactions in both cell lines and is 
supported by invasion and adherence assays.
The upregulation of as and Pi integrin subunits in both A549 and DLKP may indicate 
its expression is crucial in cell survival during 5-FU treatment. Work performed by 
Stoeltzing, et a l, (2003) showed that the use of the 0C5 Pi antagonist, ATN-161, when 
used in combination with 5-FU infusion reduced liver metastases formation and 
improved survival in this colon cancer model when compared to 5-FU alone.
These data suggests an important role for integrin dimer in cell survival and 
Syndecan-2-asPi integrin trimer in invasion during 5-FU treatment.
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Data presented in tables 1.1.4,710,13,16 show the regulation of numerous proteins 
involved in nucleoside, nucleotide and nucleobase regulation and are discussed in the 
following sections.
4.1.6.1 HSPA5 and HNRPK and p53 and HNRPK in translation and 
transcription regulation
HNRPK and p53 interact with each other stabilize the promoter/p53/HNRPK complex 
and facilitating additional steps of transcription-complex assembly together with 
transcriptional initiation itself. Several factors that interact with p53 and stimulate its 
DNA binding ability have also been reported to bind HNRPK; these include HMBG1, 
YB-1, and TBP (Moumen A., et al. 2005; Dinthilak et a l, 2002). HNRPK is down 
regulated in DLKP and A549. Further more in NHBE p53 does not accumulate and 
HNRPK accumulates. The HNRPK regulated isoforms are non-phosphorylated. 
Phosphorylation of HNRPK by c-Src drives translational activation of silenced 
mRNA’s. HNRPK specifically binds and activates c-Src. c-Src mediates tyrosine 
phosphorylation of HNRPK and inhibition of its DICE (mRNA sequence) binding 
activity and translation repression. c-Src kinase specifically regulates HNRPK 
function as a translational silencer in vivo (Ostareck lederer et al., 2002). This may 
indicate that during stress were p53 accumulates HNRPK suppression of silenced 
mRNAs is reduced. The role of phosphorylated HNRPK in its interaction with p53 
has not been investigated. However in light of this data it may be speculated that 
phosphorylation of HNRPK leads to activation of translationally repressed mRNA’s 
that may be involved in stress response. The phosphorylation of HNRPK would free it 
from mRNA silencing complex and this may allow it to participate with p53 in 
transcription.
Interestingly HNRPK and the Endoplasmic Reticulum protein HSPA5 show 
accumulation in NHBE while in A549 and DLKP it decreases. Also the genotoxic 
stress related protein p53 shows accumulation in DLKP and A549 and not in NHBE.
4.1.6 Regulation of mRNA metabolism during 5-FU treatments
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This data suggests a regulatory link. In deed there is, HSPA5 accumulation has been 
linked to ER stress and under such conditions GSK03 phosphorylates nuclear p53 
causing it to be relocalised to the cytoplasm for degradation. However, p53 
accumulation, nuclear localisation and nuclear deportation, and degradation rates have 
not been investigated and are worth further investigation in light of this data. Research 
on HNRPK has implicated it in processes including chromatin remodelling and 
transcription as well as mRNA splicing, export, and translation {Moumen, A. 2005}. 
Endoplasmic Reticulum resident chaperone HSPA5 shows down regulation in both 
DLKP and A549, and in NHBE it is upregulated as previously stated. HSPA5 
upregulation indicates ER stress and suggests that NHBE cells are not responding to 
5-FIJ exposure in a similar manner to the lung cancer cell lines. As DLKP and A549 
show p53 accumulation and this indicates genotoxic response. This is not an entirely 
novel observation as 5-FU treatment of luminal cells was found to induce the 
expression of XBP1, a gene involved in activation of the ER stress response (Troester 
et al. 2005). Taking this together with the observed accumulation of HSPA5 (ER 
protein that is upregulated during the ER stress response) show that 5-FU can induce 
either ER-stress or genotoxic response. Cells experiencing ER stress have been shown 
to inhibit the genotoxic stress by GSK(33 phosphorylation of p53 causing p53 
relocalisation to the cytoplasm and degradation preventing genotoxic stress response. 
It has been suggested that this mechanism may inhibit the induction of p53-mediated 
apoptosis thus promoting cell survival.
In MCF-7 treated with 5-FU HSPA5 accumulates, non phosphorylated HNRPK 
accumulates and p53 accumulates and this would contradict the above argument. The 
expression of HNRPK seems to follow HSPA5 trends alone and suggests a link 
between there expression. HNRPK plays a role in stabilising transcription with 
HMBG1 (Moumen, et al., 2005; Dinthilak et al., 2002) and HMGB1 shows an 
upregulation in MCF-7 treated with 5-FU.
Further investigation is warranted to elucidate the role of HNRPK in the regulation of 
translation of these repressed mRNAs.
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4.1.6.2 mRNA splicing during 5-FU treatment
The splicing factor SFRS1 was shown during heat shock in Hela cells to be necessary 
and sufficient for the recruitment of mRNA to nuclear stress bodies and generation of 
splice variants {Chiodi, I. et al., 2004}. SFRS1 is up regulated in DLKP, A549, MCF- 
7 and HMEC in response to 5-FU treatment and may indicate that SFRS1 is regulated 
by p53 accumulation and may be an important component of the stress response. 
Proteomic analysis of the nuclear stress bodies during 5-FU genotoxicity would reveal 
interesting insights into possible regulation of alternative splicing during 5-FU 
treatment.
In combination with data discussed in section 4.1.2 a potential mechanism for the 
regulation of alternative protein products during 5-FU treatment may be evident. This 
further supports a role for further investigation into translation regulation occurring 
during 5-FU treatment.
4.1.6.3 mRNA decay during 5-FU treatments
Phosphorylated Ras-GTPase-activating protein (G3BP) is upregulated in MCF-7 
treated with 5-FU (see table 3.1.13). Barnes et al., 2002 showed that activation of the 
human epidermal growth factor receptor induced increased expression of HER2 in 
breast cell lines and over expression of HER2 induced over expression of G3BP 
(Barnes et al., 2002). Phosphorylation of G3BP leads to binding to RasGAP and 
localisation to the nucleus. There, G3BP mediates mRNA decay of a specific subset 
of mRNAs including c-Myc (Tourriere, et al., 2001). This data may indicate 
alteration in mRNA processing. Further more it may indicate increased expression of 
Her 2 as a result of 5-FU treatment. The translation initiation factor 4A isoform 3, 
DDX48, was found upregulated in both MCF-7 and HMEC after 5-FU exposure. 
DDX48 has been implicated in non-sense mediated mRNA decay a process that 
destroys non-sense RNA {Palacios, et al. 2004}. Incorporation of FUTP into RNA 
would lead to increased levels of fluorinated mRNA. As already discussed 5-FU 
alters a wide variety of mRNA functions (see section 1.1) and it is not surprising that 
increased expression of DDX48 is observed. Thus this data suggests that 5-FU 
treatment of both normal and cancer breast cell lines can lead to increased non-sense
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mediated mRNA decay and may additionally indicate shorter half-lives of mRNA in 
general.
4.I.6.4. Transcription regulation during 5-FU treatment
The transcription factor E-Box binding protein (TCF-12) has been shown to directly 
bind to the transcription factors, inhibitors of DNA binding 1/2/3 (1D1, ID2, and ID3) 
(Langlands, et al., 1997) and these proteins have been established to be regulated by 
5-FU treatment of MCF-7 (Hernandez-Vargas et al., 2006). Data presented in 
McMorrow Ph. D. thesis (2004) predicted the involvement of ID1, ID2 and ID3 in 
transcription during haogenpyrimidine treatment of DLKP and showed the 
upregulation of there transcripts and proteins. This data suggests a potential role for 
the E-box binding protein during 5-FU treatment.
NYF transcription factor complex requires redox potential for their activation 
(Nakshatri et al., 1996). Oxidative stress in MCF-7 cells exposed to 5-FU would thus 
result in the activation of these transcription factors and NYFC was found 2 fold 
upregulated. Oxidative stress induced by 5-FU exposure may result in the activation 
of these transcription factors.
Crabp2 participates in transcription with RARa and releases retinoic acid from this 
receptor during transcription contributing to its stability allowing recruitment of RNA 
polymerase II and initiation of transcription (Despouy, et al., 2003). RARa 
transcription has been shown to be a potent inducer of epithelial differentiation and 
may explain how 5-FU induces the upregulation of Keratin 8 and 18. As epithelial 
cells are often invasive this may implicate RARa transcription activation as an 
important inducer of the epithelial markers in MCF-7 and the invasive characteristics 
observed after 5-FU treatment. If Crabp2 is an important factor in inducing keratin 
expression in MCF-7 it may suggest that inhibition of its activity may enhance 5-FU 
toxicity. All-trans retinoic acid analogues in combination with 5-FU may inhibit 
activity of the transcription complex, prevent keratin accumulation and enhance the 
toxicity of 5-FU.
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RUVBL1 was found to be up-regulated by 2 fold in DLKP treated with 5-FU. 
RUVBL1 plays important roles in essential signalling pathways such as the c-Myc 
and Wnt pathways, in chromatin remodelling, in transcriptional and developmental 
regulation, and in DNA repair and apoptosis (Matias et al., 2006). Thus may indicate 
an additional mechanism of DNA repair activated in DLKP treated with 5-FU.
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4.2 Fluoropyrimidine treatment of DLKP
Treatment of DLKP with various concentrations of the fluoropyrimidines 5-FU, 
52FdU and 55FdU demonstrate that 52FdU is the most toxic of these drugs and 5-FU 
and 55FdU induce similar toxicities (see figures 3.2.1 and 3.2.2). Proteomic analysis 
revealed that 5-FU and 52FdU display 12 similarly regulated proteins 2 oppositely 
regulated proteins (see tables 3.2.2 and 3.2.4).
The commonly regulated proteins include GLOl and STMN1. STMN1 is already 
discussed in the previous section (see section 4.1.1).
Glyoxyase 1 (GLOl) suppresses nucleotide glycation and over expression of GLOl is 
responsible for, in many instances, drug resistance. During oxidative stress many 
products are formed that result in the glycation of DNA and its down regulation 
would lead to sensitisation to oxidising agents {Thomalley, P.J. 2003}. GLOl was 
found up regulated in both 5-FU, 52FdU and 55FdU treatment. This data suggests 
that the fluoropyrimidines induce oxidative damage to DNA in DLKP.
52FdU was found to promote accumulation of EEF1BG, p-CFLl, CCT1 and GSN 
and there potential role in fluoropyrimidine treatments are discussed in section 4.1 
Interestingly EEF2 shows a down regulation by 52FdU treatment while in 5-FU it 
showed an upregulation and the implications of EEF2 regulation are discussed in 
section 4.4.2.
In summary these data clearly indicate that the fluoropyrimidines induce 
disctinct proteomic responces in DLKP as indicated by the poor overlap with 
identified protein from DLKP treated with 5-FU and as such should not be 
considered as the same drug.
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4.3 5-FU resistant variant of DLKP -  DLKP-55 and comparison to 
fluoroyrimidine treatments.
The cell line DLKP-55 was developed by pulse selection with the 5-FU prodrug 
55FdU. As can be seen from the previous section 5-FU and 55FdU effect the 
proteome in distinctly different manners and this may help understand why pulse 
selection with 5-FU failed to generate a 5-FU resistant variant while pulse selection 
with 55FdU did. Analysis of this variant revealed it was resistant to 5-FU, 55FdU, 
Adr but not BrdU or Taxol. Western blots revealed an over expression of TS. 
Analysis of proteome using 2D-DIGE identified 65 differentially regulated proteins 
between DLKP and DLKP-55. Of those regulated proteins 13 were identified by 
MALDI-ToF MS; 7 involved in metabolism, 4 involved in protein metabolism and 1 
involved in signal transduction
The drugs 5-FU, 55FdU and Adr exert their anti-neoplastic effects by inducing DNA 
damage leading to p53 accumulation and generation of reactive oxygen species and 
apoptosis. While Taxol induces apoptosis by inhibiting microtubule depolymerisation 
in dividing cells leading apoptosis (Mollinedo et al., 2004).. A key difference between 
apoptosis induced by Taxol and Adr/5-FU/55FdU is the amount of reactive oxygen 
species produced during induction of apoptosis and thus resistance may be linked with 
resistance to oxidative stress (Chen et al., 2003). Resistance to 5-FU/55FdU may also 
be linked to pyrimidine metabolism. Several component of pyrimidine metabolism 
have been linked to 5-FU resistance (Longley et al., 2003). DLKP-55 showed equal 
tolerance to BrdU as did DLKP. BrdU has not been shown to irreversibly bind to TS 
as does 5-FU (Shwartz et al., 1994) and may indicate resistance is directly linked to 
TS over expression.
Resistance is summarised in figure 4.2.1 and shows that DLKP is ~4 resistant to 5- 
FU, 2 fold resistant to 55FdU and Adriamycin, and shows no resistance to BrdU or 
Taxol.
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Figure 4.2.1: Summary of fold resistance in of DLKP-55 compared to DLKP. Data 
shows DLKP-55 are resistant to 5-FU, 55fdU and Adriamycin. No resistance was 
observed to BrdU or Taxol.
4.3.1 Pyrimidine and Purine metabolism
The nucleoside kinase NME1 was found to be upregulated by 2 fold in DLKP-55 
compared to DLKP. The enzyme NME1 or nucleoside diphosphate kinase is 
responsible for the reversible conversion of dUTP to dUDP. dUDP is two metabolic 
steps from conversion to thymidine monophosphate, the substrate of TS (Gilles et al., 
1991). Higher expression of NME1 may cause increased metabolism of pyrimidines 
and purines and would allow for a generation of a larger pool dUDP or dUTP. As the 
reaction is reversible and equilibrium altered by TS inhibition by 5-FU may force 
increased conversion of FdUDP to FdUTP and may result in higher incorporation 
rates into DNA. Its role in metabolism is inferred from the KEGG database and is 
highlighted in red in figure 4.3.1.
However this may relieve inhibition of TS at a quicker rate and allow for recovery of 
thymidine pool and correct DNA repair. Further more, TS also showed increased 
expression in the resistant variant by western blot. TS is associated with 5-FU 
resistance. 5-FU inhibits TS activity by irreversibly binding to it (Longley et al.,
2003). Thus TS inhibition can be overcome by over expression of TS thus inhibition 
would require higher amounts of 5-FU.
Spermine synthase (SMS) converts Spermidine to Spermine producing 5’- 
Methylthioadenine which is converted to adenine, then to adenosine and then 
adenosine mono-, di- and tri- phosphate derivatives (Wiest et al., 1998). SMS was 
found down-regulated by 2 fold and thus decreases the amount of adenine available 
for synthesis of adenosine triphosphate and thus DNA synthesis. The imbalance in 
purine and pyrimidine metabolism is suggested by increased expression of NME1 and 
TS and decreased expression of SMS may cause adenosine availability to be the rate 
limiting step during DNA synthesis in DLKP-55. Potentially this would alleviate 
pressure on thymidine synthesis and requirements of thymidine for DNA synthesis 
and thus allow cells to tolerate TS inhibition.
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GL01 was down-regulated in the 5-FU resistant variant of DLKP and was specifically 
found to be responsible for the repair of glycated DNA during oxidative stress 
(Sakamoto et al.,2000). Its expression trend would suggest that DLKP-55 would be 
sensitised to oxidative stress. GLOl is upregulated by both 5-FU and 55FdU treatments. 
Thus this data would suggest that GLOl expression is not a determinant factor in 
resistance to 5-FU or 55FdU and that resistance is brought about by prevention of 
oxidative stress.
4.3.2 Oxidative Metabolism
Glucose-6-phosphate dehydrogenase was found to be upregulated by 1.4 fold in the 5- 
FU resistant variant of DLKP, DLKP-55, and it catalyzes the first step in the pentose 
phosphate pathway and provides reductive potential in the form of NADPH. As such it 
provides protection against oxidative stress {Pandolfi, et al. 1995} and as suggested 
above resistance to 5-FU may be a result of prevention of oxidative stress. This would 
be supported by over expression of NADPH.
Increased expression of G6PD would provide increased reserves of NADPH available 
for metabolism and as NADPH is required for pyrimidine synthesis it may result in an 
expanded pool. An end product of the pentose pyrimidine pathway is the production of 
PRPP that is an essential component required for the synthesis of UMP (see figures 
3.2.8 and 3.2.9).
Pyruvate kinase, PKLR, converts phosphoenolpyruvate to pyruvate and is an essential 
substrate for a wide variety of metabolic processes and includes D-alanine metabolism 
amongst others. Alanine metabolism is important in the degradation of 5-FU 
Aldehyde dehydrogenase 1A1 (ALDH1A1) or retinaldehyde is responsible for the 
conversion of all-trans-Retinal to all-trans-retinoate. All-trans retinoate and its derivates 
are subsequently metabolised in the sucrose metabolism. All-trans-retinal is the 
produced by the oxididation of Iodopsin, Porphyropsin and Rhodopsin (see figure 
3.2.11). Sources of oxidation of Iodopsin, Porphyropsin and Rhodopsin include ionising 
radiation, and free radicals produced during oxidative stress. This may indicate that 
DLKP-55 is more efficient at dealing with oxidised retinol derivatives.
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Data presented in section 3.1 and discussed in 4.1 indicate that 5-FU induces oxidative 
stress in DLKP and as DLKP-55 has higher ambient expression of G6PD and 
ALDH1A1 it would facilitate resistance to 5-FU induced oxidative stress.
4.3.3 DLKP and DLKP-55 compared to A549 treated with 5-FU
Comparison between DLKP treated with 5-FU and FLKP-55 revealed very few similar 
trends. DLKP treated with 5-FU becomes sensitised to 5-FU and this may explain why 
so few proteins overlap. Comparison between A549 treated with 5-FU and DLKP v 
DLKP-55 lists revealed an overlap with at least three proteins discussed above.
A parallel can be drawn between A549 treated with 5-FU and DLKP-55/DLKP 
proteomic analysis. Both models show resistance to 5-FU and both show an over 
expression of G6PD, ALDH1A1 and NME1. This data further strengthens the 
possibility that these proteins are involved in resistance to 5-FU.
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4.3.4 Protein metabolism
ERP29 is expressed in most mammalian tissues and was thought to be involved in the 
production of secreted proteins but recent data suggests a role in production of 
endomembrane proteins. However a role in 5-FU resistance is not clear.
The translation elongation factor EEF2 is upregulated in DLKP-55 and would suggest 
higher protein turnover rates. Its role in resistance is not clear but it may provide larger 
pool of proteins and may promote cell survival. Indees the over expression translation 
elongation factor has been linked to oncogenic transformation and thus the increased 
expression of EEF2 may promote oncogenesis in DLKP-55.
CCT3 is involved in turn over of actin and tubulin, however none of these proteins were 
upregulated in DLKP-55 compared to DLKP. The implication of CCT3 in resistance to 
5-FU is not clear.
4.3.5 Possible decrease in motility/invasion in DLKP-55 compared to DLKP
PPP2CB phosphorylates and activates calpains responsible for breaking of actin-focal 
adherence contacts and is reported to promote invasion {Xu, L. et al. 2006}. 
Phosphorylated PPP2CB is down regulated in DLKP- 55 and in contrast to this it is 
upregulated in DLKP treated with 5-FU. This may indicate a decreased invasion rate in 
DLKP-55. Increased expression of NME1 correlates with decreased invasion {Leary, 
J.A. etal. 1995} and is also upregulated in DLKP-55 suggesting decreased invasion.
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4.4 Analysis of DLKP and its clonal subpopulations
As already stated, NSCLC are typically heterogeneous in nature. DLKP is a poorly 
differentiated NSCLC of lung epithelial origin, but lacks markers of epithelial origin. It 
was characterised as being composed of three subpopulation distinguishable by obvious 
morphological differences. And they were named according to there morphological 
characteristics. DLKP-squamous like or DLKP-SQ, DLKP-Mesenchymal like or 
DLKP-M and a third population which the other two populations interconverted with 
referred to DLKP-Intermediate or DLKP-I. Little differences could be determined 
between these subpopulations apart from DLKP-M having a slower growth rate and 
higher adherence rate to fibronectin. No differences in drug resistance were observed 
between the clonal population and parent (McBride, Ph. D. thesis 1995, McBride et a/., 
2000). In order to further characterise these cell lines motility and invasion assays were 
performed in order to accurately determine how these cell lines behaved. The results of 
these assays can be seen in figures 3.4.2 and 3.4.3. the data revealed DLKP-SQ and 
DLKP were poorly invasive while DLKP-I and DLKP-M displayed highly invasive 
phenotype (10-40 times greater than DLKP and DLKP-SQ). Differences in motility 
were found to be less extreme however assays appear saturated and should be repeated 
at a lower incubation time. Proteomic analysis was preformed on the total proteome of 
DLKP and its subpopulations and this data can be found in section 3.4.2. An overview 
of total cell lysate proteome expression trends revealed that DLKP-I and DLKP-M 
appeared equally different to DLKP-SQ. DLKP-I and DLKP-M showed the least 
differences and DLKP-I appeared to be the most similar to the parent cell line (see table 
3 .4.2 and figure 3 .4.3 for images of proteomes). Identification of these proteins resulted 
in a list of 15 proteins. Several isoforms of type III preprocollagen A1 were 
identifedand these were highly abundant iin DLKP-M. this wouold be consistent with it 
observed morphology as Mesenchymal cells are typically associated with 
stromagenesis, the process of ECM generation. In terms of cancer mesenchymal like 
cells are generally more invasive as seem here. Several of the proteins identified were 
found to be highly expressed in DLKP. These include TUBB2A, HDAC1, HYOU1 and 
HSPA1A and these proteins tended to be less abundant in DLKP-SQ than any of the 
other clonal subpopulations (see figure 3.4.4 and table 3.4.2). Amongst the clones 
TUBB2, HDAC1, GANAB, EEF2, and COL3A1, correlated with invasion.
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4.4.1 Analysis of the DLKP and subpopulation total proteome
Only two proteins correlated with enrichment in DLKP-M and these include type 3 
preprocollagen Al (COL3 Al), and eukaryotic elongation factor 2 (EEF2).
Proteomic data indicates that DLKP is more than the sum of its clones. Many proteins
were found more highly expressed in DLKP than in the sub populations and suggest
their accumulation is a result of either cell-cell communication or the presence of an
unidentified fourth population. DLKP-M and DLKP-I to a lesser extent express the
extracellular matric protein COL3A1 and suggest a role in stromagenesis.
Understanding of how stromogenesis effect tumour progression is poorly understood
and this is due to the lack of suitable cellular models (Amatangelo, 2005). Data
presented here may suggest that DLKP and its subpopulations may have the capacity to
address this issue.
The expression of EEF2 was found to 20 times higher in mammary tissue than in liver 
tissue and 50 times higher in mammary tissue than skeletal tissue in bovine models. 
This suggests a role for EEF2 in the production of secreted protein in mammals 
(Christophersen et al. 2002). The production of insulin in pancreatic beta cells is 
regulated by phosphorylation of EEF-2. Phosphorylation inhibits EEF2 activity and 
dephophorylation promotes its activity, and is closely regulated by glucose and insulin 
levels. Thus EEF2 appears to important in the production of secreted proteins (Yan et 
a l 2003).
Glucosidase II (GANAB) was found to be at least 3 times more highly expressed in 
DLKP-I or DLKP-M than DLKP-SQ and suggests a role in the synthesis of collagen. 
GANAB was shown to be important in the production of collagen type I and IV and 
metastasis as its suppression was found to reduce collagen synthesis and metastasis 
(Atsumi et al., 1993). A quality control system for monitoring the folding state of 
glycoproteins is located principally in the ER and is composed of the ER lectins 
calnexin and calreticulin, glucosidase II, UDP-glucose: glycoprotein glucosyltransferase
296
and various chaperones. Improperly folded glycoproteins will be retained in the ER 
prior to further transport by the concerted action of UDP-glucose: glycoprotein 
glucosyltransferase which reglucosylates improperly folded glycoproteins, calnexin and 
calreticulin which interact with the reglucosylated glycoproteins and glucosidase II 
which by glucose removal results in release of calnexin/calreticulin-bound 
glycoproteins. Monoglucosylated oligosaccharides play a key role in the control of 
glycoprotein folding. Since such oligosaccharides represent substrates for binding to 
both calnexin and calreticulin, they will be retarded in the ER through this interaction. 
Calnexin/calreticulin-glycoprotein complexes will be eventually dissociated by the 
action of glucosidase II and this represents an important aspect in the quality control 
performed by glucosidase II (Roth et al., 2003). GANAB is an ER protein important in 
the production glycosylated secreted and membrane proteins. EEF2 is a translation 
elongation factor responsible for production of secreted proteins. Thus the increased 
expression of both these proteins may be important in production of the glycoprotein 
COL3 Al and the maintenance of the DLKP-M population.
GANAB is more highly expressed in DLKP than in the clonal population and suggests 
its expression is regulated by cell-cell communication. It was found to accumulate in 
response to 5-FU treatment. Further more GANAB and EEF2 were found to accumulate 
in DLKP treated with 5-FU. This suggests a potential link with invasion in DLKP 
biology.
Other proteins regulated in this experiment include a2 tubulin (TUB2A) and histone 
deacetylase 1 (HDAC1). Both proteins have a higher expression in DLKP than in any 
of the clonal subpopulations. A protein that is more abundant in DLKP than in any of 
the clones suggest its regulation is a result of cell-cell interaction/communication or its 
abundance is a result of cell-ECM interaction. Due to the small number of proteins 
identified enriched in DLKP it is difficult to determine a regulatory pathway that would 
influence there accumulation. However HDAC1 and TUB2A correlate with invasion in 
the subpopulations. TUB2A is component of the microtubule filaments and is important 
in invasion. The matrix metalloproteinases - MMP-2 and MMP-9 -  are stored in 
vesicles aligned and attached to microtubules. MMP’s vesicles are moved to the cell 
membrane in a micro tubule dependent manner MMP’s are excreted (Schnaeker et al.,
2004). Further more microtubule filaments have also been shown to be important in cell
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migration and are responsible for retraction the tailing end of the cell as it migrates and 
microtubule polymerisation is regulated by stathmin and p27 (Baldassarre et al. 2005). 
The hypoxia-upregulated protein HYOU1 and annexin Al are more highly expressed in 
DLKP-I. However there is no statistically significant difference in expression between 
DLKP-I and DLKP-M for both proteins and they seem to correlate with invasion. 
HYOU1 forms a complex with TRA1, HSPA5, ERp72 in the ER and play an important 
role in the folding and maturation of secreted proteins (Kosnetsov et al., 1997). It is 
likely that DLKP-I secretes different protein than the other populations.
Annexin Al is a calcium dependent binding protein that is bound to the cell membrane. 
Inhibition of Annexin 1 using anti-serum was found to inhibit invasion (Babbin et al., 
2006), and suggests an important role in regulation of invasion. Vinculin (VCL) in a 
complex with talin -  the integrin binding protein -has been shown to attach of F-actin to 
the cell membrane via integrin intercellular domain and F-actin membrane connections 
and is important in cell migration (Fischer et al., 1998; Chen H. et al. 2006) Its 
accumulated expression in DLKP-I and DKP-M over DLKP-SQ suggests vinculin may 
play a role in regulating invasion in the clonal populations. It s increased expression in 
DLKP suggests its upregulation is stimulated by cell-cell interaction or cell-Mitogen 
interactions and its expression accumulated as a result of 5-FU treatment of DLKP 
which again supports a role for vinculin in the promotion of invasion.
HDAC1 is involved ERK activation of invasion. Upon ERK activation (as described in 
Figure 1.4) phosphorylates Sp-1 and recruits HDAC1 to the Reck 1 promoter and 
inhibits it transcription. Reck inhibits the activity of MMP’s thus HDAC1 recruitment to 
the Reck promoter promotes invasion (Hsu et al., 2006). It was also found more 
abundant in DLKP than the clonal populations and was found up-regulated by 5-FU 
treatment of DLKP. Thus this data may indicate that ERK signalling may be important 
in regulating invasion in the clonal population. ERK may inhibit transcription of Reck 
through HDAC1 as stated above thus promoting invasion.
The upregulation of TUBB2A may promote excretion of MMP vesicles and promote 
motility. The increased expression of GANAB and EEF2 may play an important role in 
processing Col3Al and MMP’s thus promoting invasion. The presence of COL3A1 
production in smaller population may drastically alter the proteome of DLKP-SQ when
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in the mixed population and thus this may severly alter expression levels of protein 
involved in integrin signalling.
4.4.2 Analysis of the hydrophobic proteome in DLKP and the subpopulations
DLKP and DLKP-SQ were found to be 10-40 times less invasive than DLKP-M and 
DLKP-I. If the degree of invasion in DLKP was directly proportional to the distribution 
of its subpopulations than the difference in invasion would by about 3-4 fold (as DLKP- 
I and DLKP-M constitute 35% of DLKP). However the difference in 10 fold and this 
suggests the presence of a component that inhibits invasion by 2-3 fold. As DLKP lacks 
cell-cell junctions (McBride et al., 1999) communication between DLKP-SQ and 
DLKP-I and DLKP-M must be regulated by either membrane proteins such as integrins 
or soluble factors such as growth factors. Analysis of conditioned media would help 
identify growth factors that may be regulating invasion in DLKP.
Analysis of the hydrophobic proteome will identify proteins important in the regulation 
of motility/invasion. Initial characterisation of the the trends between the DLKP 
parental population and the subpopulations revealed that DLKP and DLKP-SQ are 
highly similar and DLKP-I and DLKP-M are also highly similar as suggested by 
invasion and motility assays (see table 3.4.5). An estimated 300-500 protein are present 
in this experiment that show a similar expression trend as the invasion trend and due to 
the relevance of the fractionation process it is not surprising. The fractionation process 
was selected to isolate membrane protein and complexes associated with them. This 
would include any microfilaments involved in migration as they must continuously 
make contact and break contact with the cell membrane in order to achieve migration A 
list of identified differentially regulated proteins are present in table 3 .4.6 and proteins 
of interest are highlighted in figure 3 .4.6. In this list there is an over lap of 3 proteins 
with those discussed above and these are TUBB2A, EEF2, ANXA1.
The expression trend of ANXA1 is exactly the same as that in the total proteome as in 
the hydrophobic proteome and may indicate it is only located in the membrane. TUB2A 
shows a similar expression level in DLKP and DLKP-SQ and similarly expressed in 
DLKP-I and DLKP-M. Its expression alters slightly between DLKP and its 
subpopulations in the total proteome and this data highlights the importance of 
fractionation for the identification of proteins involved in various biological functions. 
This suggests that there is protein expressed in DLKP-I/-M that associates tubulin to the
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membrane that is not expressed in DLKP or DLKP-SQ The role of TUB2A and 
TUBA3 in invasion is discussed above. B-actin forms F-actin filaments important in 
cell migration and are discussed in section 1.4.7. The association of F-actin to cell 
membrane would suggest activation of talin, and vinculin and other actin binding 
proteins as discussed previously. ATP5B is a mitochondrial protein responsible for the 
production of ATP (Izquierdo et al, 2006). Its expression has not been shown to 
correlate with invasion, although it inversely correlates with invasion the correlation is 
more than likely an artefact. Inversely correlating data in these experiment are enriched 
in fractionations by lack of the proteins that correlate with invasion and there link with 
invasion while arguable plausible is probably less likely. Stomatin like protein-2 
(HSPC108 or STOML2) is expressed in many tissues but its function is entirely 
unknown (John et al. 2006). This data suggests a functional role for this protein in 
invasion.
The G-protein GNB1 is involved in regulating K+ and Ca+ channels in neurons of the 
heart and brain (Agler et al., 2005). DLKP expresses neuroendocrine markers and the 
expression of neuronal protein is not surprising. The expression trend indicates that in 
DLKP its expression is lowest and it linearly increases from to DLKP-SQ, to DLKP-I 
and finally to DLKP-M its expression does not seem to correlate with invasion.
Finally the G-protein Rablla correlates with invasion. Rablla is not well studied in 
cancer, but has been shown to regulate the recycling of internalized cell surface proteins 
and receptors from the early endosome through the trans-Golgi network. It has been 
shown to modulate Epidermal growth factor receptor and has been shown to decrease 
invasion (Palmieri et al., 2006). Here this data provides coutradictory data on R ablla 
being an inhibitor of invasion and it localisation in a fraction may suggest it exists as a 
complex. Further investigation of these G-proteins are warranted as they will elucidate 
new interactions important in invasion.
Finally, numerous proteins appear to be more highly expressed in DLKP than in any of 
the clonal populations. Three proteins were highlighted in figure 3.4.4 and show there 
expression is almost exclusive to DLKP. This data shows that DLKP is more than the 
sum of the clones. These proteins could only be expressed at a higher level in DLKP 
due to cell-cell communication or the presence of a fourth sub population.
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5.0 Conclusions
> 5-Fluorouracil (5-FU) treatments of both normal and cancer cell lines of 
epithelial origin of the lung and breast were found to alter invasive phenotype of 
these cell lines. This data suggests that 5-FU is capable of inducing a 
differentiation effect. Proteomics investigation of these cell lines treated with 5- 
FU identified a group of proteins involved in actin dynamics to be differentially 
regulated. The most important of these appear to Gelsolin and p-Cofilin which 
play important roles in both migraton/invasion and apoptosis. The data suggests 
5-FU induces increased threadmilling of F-actin in the cell lines DLKP, MCF-7 
and NHBE (three cells which showed an increased invasion post treatment) and 
play a role in cell survival.
> Expression of the 14-3-3 proteins and the simple epithelia marker p-Keratin 18 
expression during 5-FU treatment are hypotosised to play a role in the regulation 
of cofilin phosphorylation and dephosphorylation. Specifically by sequestering 
of slingshot and p-cofilin, thus inhibiting F-actin threadmilling.
> Components of the elongation factor EEF1B were found regulated in all cell 
lines and in the normal cell line were found to accumulate at the higher 
concentration of 5-FU of 30pM and not lOpM. The expression of this did not 
correlate with Stathmin expression suggesting that its expression is not 
specifically linked to cell cycle progression. However its expression appears to 
correlate with p53 expression suggesting it may play a role in genotoxicity or 
apoptosis. The aspartyl tRNA Synthetase (DARS) was found to be up-regulated 
by 5-FU treatment and this may suggest a role in translation control. Specifically 
increased expression of amino acid tRNA synthetases have been shown to 
promote selective translation of protein with higher requirements for the specific 
cognate amino acid of the amino acid tRNA Synthetase up-regulated. This data 
may indicate the preferential translation of proteins with a high occurrence of the 
aspartyl residue.
> Growth inhibition curves by 5-FU treatment reveal that the normal cell lines 
have equal or higher tolerance to cancer cell lines of similar tissue origin. 
Proteomic comparison between normal and tumour cell lines treated with 5-FU
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revealed an increased expression of specific keratins indicative of a more 
differentiated state in the normal cell lines. Keratins play specific roles in 
inhibition of apoptosis and this may suggest a role in the promotion of cell 
survival.
> Analysis of the phosphorylated proteomes of the cancer and normal cell lines 
show that the cancer cell lines express a high level of phosphorylated proteins 
where as the normal cell line NHBE expressed very few phosphorylated 
proteins. Investigation of these phosphorylated protein upregulated in the cancer 
cell lines may reveal signal transduction pathways active in cancer cell lines and 
indicate specific receptor signal kinases active in cancer cell lines.
> The resistant variant DLKP-55 shows specific up-regulation of few proteins 
when compared to DLKP, however data revealed specific up-regulation of 
proteins involved in pyrimidine metabolism and suggests a role in 5-FU 
resistance
> Characterisation of the invasive phenotypes of DLKP and its subpopulations 
reveal that DLKP-I and DLKP-M have a highly invasive phenotype and that 
DLKP-SQ has a low invasive phenotype. DLKP shows a low invasive 
characteristic. Its invasive was lower than the expected degree of invasiveness -  
based purely on its composition of clonal populations. This data suggests that 
DLKP-SQ inhibit invasion through cell-cell communication
> Proteomic analysis of total cell lysates of DLKP and its subpopulations reveal a 
specific higher abundance of protein in DLKP compared to the clonal 
subpopulations. Protein expression values in DLKP would be expected to be an 
average of the subpopulations and thus the higher expression in DLKP suggests 
cell-cell communication.
> DLKP-I and DLKP-M express type III preprocollagen type 1A and increased 
migration/invasion which are characteristics of mesenchymal-like cells. Thus 
this may indicate that DLKP is a novel model for the study of cancer biology
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and may allow for future study of stromatogenesis and cancer stroma 
interactions.
> Analysis of the hydrophobic proteomes of DLKP and its subpopulations found 
300-500 proteins whose expression or inverse expression closely followed 
invasion trends. Identification of some of these proteins found higher abundance 
of actin and tubulin monomers in the hydrophobic proteome which may suggest 
increased association of these cytoskeletal proteins with the cell membrane a 
process important in cell migration/invasion. Thus this suggests this data set is a 
good model for identification of proteins involved in migration/invasion. A 
group of 3 poorly described proteins were identified whose expression follows 
the invasion trend thus suggesting a role in invasion.
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6.0 Future Work
There are many future avenues of research from this work however only the more 
important points are discussed here. These include in regards to 5-FU treatments; actin 
dynamics, translation elongation, phosphorylated proteomes; and in regards to the 
clonal populations of DLKP; investigation of cell-cell interactions, identification of the 
hydrophobic proteome, and functional validation proteins suspected of being involved 
in invasion.
> Future work on these treatments described above would include the 
investigation of actin threadmilling during 5-FU treatment. Data suggests the 
increased formation of actin branching in the cell lines that show a higher 
invasive phenotype post treatment and thus staining of actin filaments by 
immunofluorescence based techniques would allow for confirmation of 
hypotosis. During invasion actin monomers need to be severed from F-actin and 
this is proposed to be accomplished by Gelsolin and cofilin. Thus, their role in 
this process needs to be confirmed. To this end immunofluorescent based 
techniques need to show the localisation of these proteins to the actin filaments. 
Construction of green fluorescent protein tagged plasmid constructs of actin, 
gelsolin and cofilin would allow for the study of actin dynamics over time and 
would allow for observations of actin polymerisation and severing. Alternatively 
microinjection of fluorescently labelled actin monomers, gelsolin and cofilin 
would show if actin polymerisation and severing were increased by 5-FU 
treatment and if these proteins played an important role in invasion progression. 
Confirmation of these proteins roles in actin threadmilling could be confirmed 
using siRNA knockdown. If this work proved promising it could potentially lead 
to the inclusion of F-actin inhibitors in future combinations with 5-FU 
treatments and development of more effective future chemotherapeutic 
therapies.
> The up-regulation of the elongation factors appears to correlate with p53 
accumulation and suggests a role in genotoxicity or apoptosis. Their role in 
apoptosis and genotoxicity require investigation. A role in genotoxic response 
could be determined using siRNA knockout or partial knockdown and
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investigation of induction of apoptosis by various genotoxic agents. If involved 
in DNA repair then genotoxic agents should be capable of inducing apoptosis 
more readily than non-DNA damage agents. If the elongation factors are 
important in triggering apoptosis than knock down of these elongation factors 
would promote cell survival. Again this could lead to the inclusion of translation 
inhibitors, such as a rapamycin, in future 5-FU therapies.
> Proteomic data also suggests the increased production of proteins rich in 
aspartyl. This hypotosis may be investigated by investigation of proteins up- 
regulated in parallel to the DARS protein and the elongation factors during 5-FU 
treatment. If this hypotosis was valid than up-regulated proteins would have a 
higher occurrence of aspartyl in their sequences. The hypotosis can then be 
confirmed by siRNA knockdown of DARS during 5-FU treatments and 
investigation of protein expression during knockdown by western blot of the 
protein DARS and suspected proteins regulated by increased expression of 
DARS. The role of such regulated proteins in terms of induction of cell survival 
or DNA repair need to be determined. If they were found to be inhibitors of 
apoptosis or important in DNA repair then this could lead to the development of 
aspartyl based drugs to be used in combination with 5-FU therapy.
> Investigation of the phosphorylated protein present in carcinoma cell lines and 
not present in normal cells may lead to the identification of signal transduction 
pathways active in carcinoma cell line and not active in normal cell lines. Data 
presented above show that normal cell lines express relatively few 
phosphoproteins while carcinoma cell lines express many phosphorylated 
proteins. This may lead to the identification of receptor signal kinases active in 
cancer cell lines that are not active in normal cell lines. Such signals can 
promote cell survival and thus inhibition of their signalling may promote 
apoptosis. These proteins should be identified using liquid chromatography 
Mass spectrometry/ Mass spectrometry or MALDI-ToF MS/MS which would 
allow for identification specific phosphorylated residues. This would allow for 
identification of a specific list of kinases and phosphorylases potentially active 
in cancer. Expression of such kinases can be determined by western blotting and 
validation of a role in phosphorylation of proteins can be determined by siRNA
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knockout and decreased phosphorylation of target proteins can be confirmaed by 
western blotting thus confirming the role of the kinase in signalling. This should 
potentially lead to identification of a receptor and its expression should be 
examined a selection of cell lines. If it appears to be expressed in many cancer 
cell lines than its expression in clinical samples should be investigated. If it 
appears to be highly expressed in cancer patients than a humanised antibody 
should be developed to inhibit its activity. Thus this may lead to improved future 
therapies.
> DLKP and its subpopulation invasion experiments suggests DLKP-SQ inhibits 
invasion in DLKP-I and DLKP-M. Thus exchanging of conditioned media 
between cell lines during invasion assays may indicate if there is a soluble factor 
responsible for inhibiting invasion secreted by DLKP-SQ. If the conditioned 
media was found to be an inhibitor of invasion than it should be investigated by 
2D-DIGE. Proteins should be identified by MALDI-ToF MS and purified using 
ion exchange columns and High Performance Liquid Chromatography. The role 
of such proteins as inhibitors of invasion should be investigated in by siRNA 
knockout. If these proteins inhibited invasion then they should be screened using 
animal models to determine if they could inhibit the spread of metastasis. If the 
results showed to be interesting than the protein should be developed as a drug 
for the suppression of metastasis.
> Analysis of the hydrophobic proteome in DLKP and its subpopulations revealed 
a list of 300-500 proteins potentially involved in invasion. Identification by 
MALDI-ToF MS and knockout by siRNA could reveal important roles in 
invasion that may lead to the development of future drug combinations that 
target such proteins either by localisation or expression inhibition.
> DLKP-M expressed high levels Col3al and may represent a novel in vitro 
source of the protein. Thus purification of this protein may allow for the 
development of an alternative source of Col3al for research and may have 
commercial value as an alternative source of collagen. Secretion of collagen 
needs to be determined from conditioned media experiments. Cultivation of 
DLKP-M with either DLKP-I or DLKP-SQ and compared to DLKP-I cultured
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with DLKP-SQ may allow for the identification of proteins whose expression is 
altered by interaction with Col3al. This would give insights into tumour 
behaviour and expand the understanding of tumour biology. This work in 
combination with conditioned media from these cell line mixes and the 
conditioned media of each individual population may allow for an understanding 
of how cancer cells communicate. This could lead to identification of signals 
important in promotion of cell survival, migration, invasion, and 
stromatogenesis.
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